PT J
AU Hsieh, CF
   Tsuei, YW
   Liu, CW
   Kao, CC
   Shih, LJ
   Ho, LT
   Wu, LY
   Wu, CP
   Tsai, PH
   Chang, HH
   Ku, HC
   Kao, YH
AF Hsieh, Chi-Fen
   Tsuei, Yi-Wei
   Liu, Chi-Wei
   Kao, Chung-Cheng
   Shih, Li-Jane
   Ho, Low-Tone
   Wu, Liang-Yi
   Wu, Chi-Peng
   Tsai, Pei-Hua
   Chang, Hsin-Huei
   Ku, Hui-Chen
   Kao, Yung-Hsi
TI Green Tea Epigallocatechin Gallate Inhibits Insulin Stimulation of Adipocyte Glucose Uptake via the 67-Kilodalton Laminin Receptor and AMP-Activated Protein Kinase Pathways
SO PLANTA MEDICA
LA English
DT Article
DE green tea; Camellia sinensis; Theaceae; epigallocatechin 3-gallate; insulin; glucose uptake
ID catechin-polyphenols; transporter; egcg; modulation; mechanisms; caffeine; resistin
AB Insulin and (-)-epigallocatechin gallate (EGCG) are reported to regulate obesity and fat accumulation, respectively. This study investigated the pathways involved in EGCG modulation of insulin-stimulated glucose uptake in 3T3-L1 and C3H10T1/2 adipocytes. EGCG inhibited insulin stimulation of adipocyte glucose uptake in a dose- and time-dependent manner. The concentration of EGCG that decreased insulin-stimulated glucose uptake by 50-60% was approximately 5-10 mu M for a period of 2h. At 10 mu M, EGCG and gallic acid were more effective than (-)-epicatechin, (-)-epigallocatechin, and (-)-epicatechin 3-gallate. We identified the EGCG receptor [also known as the 67-kDa laminin receptor (67LR)] in fat cells and extended the findings for this study to clarify whether EGCG-induced changes in insulin-stimulated glucose uptake in adipocytes could be mediated through the 67LR. Pretreatment of adipocytes with a 67LR antibody, but not normal rabbit immunoglobulin, prevented the effects of EGCG on insulin-increased glucose uptake. This suggests that the 67LR mediates the effect of EGCG on insulin-stimulated glucose uptake in adipocytes. Moreover, pretreatment with an AMP-activated protein kinase (AMPK) inhibitor, such as compound C, but not with a glutathione (GSH) activator, such as N-acetyl-L-cysteine (NAC), blocked the antiinsulin effect of EGCG on adipocyte glucose uptake. These data suggest that EGCG exerts its anti-insulin action on adipocyte glucose uptake via the AMPK, but not the GSH, pathway. The results of this study possibly support that EGCG mediates fat content.
C1 [Hsieh, Chi-Fen; Liu, Chi-Wei; Wu, Chi-Peng; Tsai, Pei-Hua; Chang, Hsin-Huei; Ku, Hui-Chen; Kao, Yung-Hsi] Natl Cent Univ, Dept Life Sci, Jhongli 32001, Taoyuan County, Taiwan.
   [Wu, Liang-Yi] Chung Yuan Christian Univ, Dept Biosci Biotechnol, Jhongli, Taiwan.
   [Ho, Low-Tone] Vet Gen Hosp, Dept Internal Med, Taipei, Taiwan.
   [Shih, Li-Jane] Armed Forces Taoyuan Gen Hosp, Dept Joint Lab, Tao Yuan, Taiwan.
   [Tsuei, Yi-Wei; Kao, Chung-Cheng] Armed Forces Taoyuan Gen Hosp, Dept Emergency, Tao Yuan, Taiwan.
C3 National Central University; Chung Yuan Christian University
RP Kao, YH (corresponding author), Natl Cent Univ, Dept Life Sci, 300 Jhongda Rd, Jhongli 32001, Taoyuan County, Taiwan.
EM ykao@cc.ncu.edu.tw
FU National Science Council, Taiwan [NSC98-2311-B-008-001-MY3]; Taoyuan Armed Forces General Hospital; Veterans General Hospital-UST; Tsou's Foundation [VGHUST97-P3-09/VGHUST98-P3-10]; CGH-NCU Joint Research Foundation [CNJRF-98CGH-NCU-B3]
CR Anderson RA, 2002, J AGR FOOD CHEM, V50, P7182, DOI 10.1021/jf020514c
   Ashida H, 2004, BIOFACTORS, V22, P135, DOI 10.1002/biof.5520220126
   Calixto Joao B, 2004, PLANTA MEDICA, V70, P93
   Collins QF, 2007, J BIOL CHEM, V282, P30143, DOI 10.1074/jbc.M702390200
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Fong JC, 2001, CELL SIGNAL, V13, P491, DOI 10.1016/S0898-6568(01)00174-7
   Hwang JT, 2009, NEW BIOTECHNOL, V26, P17, DOI 10.1016/j.nbt.2009.03.005
   Hwang JT, 2005, BIOCHEM BIOPH RES CO, V338, P694, DOI 10.1016/j.bbrc.2005.09.195
   KAO CC, 2009, PLANTA MED, V75, P1
   Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109
   Kobayashi Y, 2000, J AGR FOOD CHEM, V48, P5618, DOI 10.1021/jf0006832
   Koerner A, 2005, BEST PRACT RES CL EN, V19, P525, DOI 10.1016/j.beem.2005.07.008
   Koyama Y, 2004, PLANTA MED, V70, P1100, DOI 10.1055/s-2004-832659
   Ku HC, 2009, AM J PHYSIOL-CELL PH, V297, PC121, DOI 10.1152/ajpcell.00272.2008
   Liao SS, 2001, VITAM HORM, V62, P1, DOI 10.1016/S0083-6729(01)62001-6
   Lin CL, 2008, MOL NUTR FOOD RES, V52, P930, DOI 10.1002/mnfr.200700437
   Lin JK, 2006, MOL NUTR FOOD RES, V50, P211, DOI 10.1002/mnfr.200500138
   Liu F, 2008, ACTA PHARMACOL SIN, V29, P98, DOI 10.1111/j.1745-7254.2008.00709.x
   Mandel S, 2004, J NEUROCHEM, V88, P1555, DOI 10.1046/j.1471-4159.2003.02291.x
   Mochizuki M, 2004, PHYTOTHER RES, V18, P449, DOI 10.1002/ptr.1437
   Naftalin RJ, 2003, BRIT J PHARMACOL, V140, P487, DOI 10.1038/sj.bjp.0705460
   Nomura M, 2008, BIOL PHARM BULL, V31, P1403, DOI 10.1248/bpb.31.1403
   Reiter CEN, 2010, ENDOCRINOLOGY, V151, P103, DOI 10.1210/en.2009-0997
   ROBERTS EAH, 1952, J SCI FOOD AGR, V3, P193, DOI 10.1002/jsfa.2740030501
   Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743
   Ueda M, 2008, BIOCHEM BIOPH RES CO, V377, P286, DOI 10.1016/j.bbrc.2008.09.128
   Wang CT, 2009, MOL NUTR FOOD RES, V53, P349, DOI 10.1002/mnfr.200800013
   WISE LS, 1979, J BIOL CHEM, V254, P273
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   Wolfram S, 2006, J NUTR, V136, P2512, DOI 10.1093/jn/136.10.2512
   YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038
NR 32
TC 26
Z9 28
U1 0
U2 16
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0032-0943
EI 1439-0221
J9 PLANTA MED
JI Planta Med.
PD OCT 15
PY 2010
VL 76
IS 15
BP 1694
EP 1698
DI 10.1055/s-0030-1249877
PG 5
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine
GA 676MY
UT WOS:000283917300011
PM 20455202
DA 2025-04-28
ER

PT J
AU Egger, G
   Dixon, J
AF Egger, G.
   Dixon, J.
TI Inflammatory effects of nutritional stimuli: further support for the need for a big picture approach to tackling obesity and chronic disease
SO OBESITY REVIEWS
LA English
DT Review
DE Environment; inflammation; nutrition; obesity
ID c-reactive protein; fatty-acid-composition; necrosis-factor-alpha; moderate alcohol-consumption; factor-kappa-b; systemic inflammation; coffee consumption; dietary patterns; endothelial dysfunction; cardiovascular-disease
AB The discovery of a form of low-grade systemic inflammation (called 'metaflammation'), and the close evolutionary link between the immune and metabolic systems, poses questions about the supposed antigens (inducers) of such an immune reaction. Initially, this was thought to be mediated through obesity. However, we have identified a number of lifestyle or environmentally related inducers that may cause metaflammation, even in the absence of obesity. In this paper, the third of a series linking obesity with broad environmental and evolutionary factors, we identify nutritional stimuli with evidence of an involvement in metaflammation. From this we propose that components of certain foods and beverages with which humans have not evolved, are more often the inducers of an inflammatory effect in the body than those with which humans have become more familiar, and to which a neutral, or anti-inflammatory response may be expected to have developed. The implications of such a finding are considered in relation to broader aspects of the environment, economic growth, policy change and current global financial issues.
C1 [Egger, G.] So Cross Univ, Lismore, NSW 2480, Australia.
   [Egger, G.] Ctr Hlth Promot & Res, Sydney, NSW, Australia.
   [Dixon, J.] Monash Univ, Dept Primary Hlth Care, Obes Res Unit, Melbourne, Vic 3004, Australia.
C3 Southern Cross University; Monash University
RP Egger, G (corresponding author), POB 313 Fairlight, Fairlight, NSW 2093, Australia.
EM eggergj@ozemail.com.au
CR Ajani UA, 2004, J NUTR, V134, P1181, DOI 10.1093/jn/134.5.1181
   Aljada A, 2004, AM J CLIN NUTR, V79, P682
   ARYA F, 2009, DIFFERENCES AC UNPUB, V0, P0
   Azadbakht L, 2007, DIABETES CARE, V30, P967, DOI 10.2337/dc06-2126
   Baer DJ, 2004, AM J CLIN NUTR, V79, P969
   Beulens JWJ, 2008, DIABETES CARE, V31, P2050, DOI 10.2337/dc08-0814
   BIANCOCOLIO LM, 2000, CIRCULATION, V102, P1020
   Blum S, 2006, ANN NUTR METAB, V50, P20, DOI 10.1159/000089560
   Bogani P, 2007, ATHEROSCLEROSIS, V190, P181, DOI 10.1016/j.atherosclerosis.2006.01.011
   Brand-Miller JC, 2007, AM J CLIN NUTR, V85, P1545, DOI 10.1093/ajcn/85.6.1545
   Buescher ES, 2001, ADV EXP MED BIOL, V501, P207
   Bulló M, 2007, PUBLIC HEALTH NUTR, V10, P1164, DOI 10.1017/S1368980007000663
   Campos H, 2007, NUTR REV, V65, P173, DOI 10.1301/nr.2007.apr.173-179
   Cao Heping, 2007, J INFLAMM (LOND), V4, P1, DOI 10.1186/1476-9255-4-1
   Castilla P, 2006, AM J CLIN NUTR, V84, P252, DOI 10.1093/ajcn/84.1.252
   Cha SH, 2008, P NATL ACAD SCI USA, V105, P16871, DOI 10.1073/pnas.0809255105
   Chacko BK, 2005, AM J PHYSIOL-HEART C, V289, PH908, DOI 10.1152/ajpheart.00781.2004
   Chen L, 2007, MOLECULES, V12, P946, DOI 10.3390/12050946
   Chun OK, 2008, J NUTR, V138, P753
   Cooper KA, 2008, BRIT J NUTR, V99, P1, DOI 10.1017/S0007114507795296
   Cordain L, 2002, EUR J CLIN NUTR, V56, PS42, DOI 10.1038/sj.ejcn.1601353
   Cornelis MC, 2007, CURR OPIN CLIN NUTR, V10, P745, DOI 10.1097/MCO.0b013e3282f05d81
   Dalgard C, 2008, BR J NUTR, V28, P1
   De Bacquer D, 2006, ATHEROSCLEROSIS, V189, P428, DOI 10.1016/j.atherosclerosis.2005.12.028
   de Roos B, 2008, PROTEOMICS, V8, P1965, DOI 10.1002/pmic.200700457
   Delgado-Lista J, 2008, AM J CLIN NUTR, V87, P317, DOI 10.1093/ajcn/87.2.317
   Devaraj S, 2008, METABOLISM, V57, P867, DOI 10.1016/j.metabol.2008.02.016
   Devaraj S, 2006, AM J CLIN NUTR, V84, P756, DOI 10.1093/ajcn/84.4.756
   di Giuseppe R, 2008, J NUTR, V138, P1939, DOI 10.1093/jn/138.10.1939
   Dickinson S, 2008, AM J CLIN NUTR, V87, P1188
   Dixon Andrew F, 2003, AUST FAM PHYSICIAN, V32, P649
   DROKE EA, 2007, J INFLAMM-LOND, V7, P17
   Egger G, 2008, OBES REV, V9, P456, DOI 10.1111/j.1467-789X.2008.00469.x
   Egger G, 2009, OBES REV, V10, P237, DOI 10.1111/j.1467-789X.2008.00542.x
   EGGER G, 2009, NUTR REV, V18, P1
   Egger G, 2009, AM J PREV MED, V37, P78, DOI 10.1016/j.amepre.2009.03.004
   ENGLUND OL, 2006, DIABETES CARE, V29, P908
   Erridge C, 2007, AM J CLIN NUTR, V86, P1286, DOI 10.1093/ajcn/86.5.1286
   Esmaillzadeh A, 2008, AM J CLIN NUTR, V88, P913, DOI 10.1093/ajcn/88.4.913
   Esmaillzadeh A, 2007, J NUTR, V137, P992, DOI 10.1093/jn/137.4.992
   Esposito Katherine, 2007, METABOLIC SYNDROME AND RELATED DISORDERS, V5, P291, DOI 10.1089/met.2007.0018
   Estruch R, 2004, ATHEROSCLEROSIS, V175, P117, DOI 10.1016/j.atherosclerosis.2004.03.006
   Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004
   Fargnoli JL, 2008, AM J CLIN NUTR, V88, P1213, DOI 10.3945/ajcn.2008.26480
   Faridi Z, 2008, AM J CLIN NUTR, V88, P58, DOI 10.1093/ajcn/88.1.58
   Fitó M, 2008, EUR J CLIN NUTR, V62, P570, DOI 10.1038/sj.ejcn.1602724
   Fontana L, 2008, EUR J CARDIOV PREV R, V15, P3, DOI 10.1097/HJR.0b013e3282f17bd4
   FRENK J, 1989, HLTH POLICY PLAN, V41, P29
   Andersen LF, 2006, AM J CLIN NUTR, V83, P1039, DOI 10.1093/ajcn/83.5.1039
   Fung TT, 2001, AM J CLIN NUTR, V73, P61
   Fung TT, 2005, AM J CLIN NUTR, V82, P163
   Galgani J, 2006, NUTR J, V5, P0, DOI 10.1186/1475-2891-5-22
   Gao X, 2004, J NUTR, V134, P913, DOI 10.1093/jn/134.4.913
   Garg ML, 2007, LIPIDS, V42, P583, DOI 10.1007/s11745-007-3042-8
   Greany KA, 2008, EUR J CLIN NUTR, V62, P1419, DOI 10.1038/sj.ejcn.1602885
   HALPEN GM, 2008, INFLAMMOPHARMACOLOGY, V16, P1
   Hamed MS, 2008, SOUTH MED J, V101, P1203, DOI 10.1097/SMJ.0b013e31818859eb
   Han SN, 2002, J LIPID RES, V43, P445
   Harvey KA, 2008, BRIT J NUTR, V99, P723, DOI 10.1017/S0007114507842772
   Havel PJ, 2005, NUTR REV, V63, P133, DOI 10.1111/j.1753-4887.2005.tb00132.x
   Hayes DP, 2008, AM J CLIN NUTR, V88, P578S, DOI 10.1093/ajcn/88.2.578S
   Hickling S, 2008, PREV MED, V47, P71, DOI 10.1016/j.ypmed.2008.02.007
   Higdon JV, 2006, CRIT REV FOOD SCI, V46, P101, DOI 10.1080/10408390500400009
   Hijmering ML, 2007, NETH J MED, V65, P29
   Hodgson JM, 2007, J NUTR, V137, P363, DOI 10.1093/jn/137.2.363
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449
   Hu FB, 2008, CIRCULATION, V118, P1913, DOI 10.1161/CIRCULATIONAHA.108.808493
   Hyun YJ, 2008, OBESITY, V16, P784, DOI 10.1038/oby.2007.127
   Imhof A, 2004, EUR HEART J, V25, P2092, DOI 10.1016/j.ehj.2004.09.032
   Inadera Hidekuni, 2008, INT J MED SCI, V5, P248
   Inoue T, 2008, J CARDIOL, V52, P127, DOI 10.1016/j.jjcc.2008.06.004
   Iqbal R, 2008, CIRCULATION, V118, P1929, DOI 10.1161/CIRCULATIONAHA.107.738716
   Jacob K, 2008, BRIT J NUTR, V99, P137, DOI 10.1017/S0007114507791894
   Jenkins DJA, 2008, EUR J CLIN NUTR, V62, P781, DOI 10.1038/sj.ejcn.1602768
   Jenkins DJA, 2008, J NUTR, V138, P1752S, DOI 10.1093/jn/138.9.1752S
   Jiang R, 2006, AM J EPIDEMIOL, V163, P222, DOI 10.1093/aje/kwj033
   Jimenez-Gomez Yolanda, 2009, ATHEROSCLEROSIS, V204, Pe70, DOI 10.1016/j.atherosclerosis.2008.09.011
   Josse AR, 2007, METABOLISM, V56, P400, DOI 10.1016/j.metabol.2006.10.024
   Kallio P, 2008, AM J CLIN NUTR, V87, P1497, DOI 10.1093/ajcn/87.5.1497
   Kashyap Sangeeta R, 2008, J CARDIOMETAB SYNDR, V3, P141, DOI 10.1111/j.1559-4572.2008.00013.x
   Kechagias S, 2008, GUT, V57, P649, DOI 10.1136/gut.2007.131797
   Kim Jeong-A, 2008, ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, V8, P82, DOI 10.2174/187153008784534349
   King DE, 2008, ANN FAM MED, V6, P100, DOI 10.1370/afm.819
   King DE, 2007, ARCH INTERN MED, V167, P502, DOI 10.1001/archinte.167.5.502
   King DE, 2005, MOL NUTR FOOD RES, V49, P594, DOI 10.1002/mnfr.200400112
   King DE, 2003, AM J CARDIOL, V92, P1335, DOI 10.1016/j.amjcard.2003.08.020
   King JC, 2008, J NUTR, V138, P1734S, DOI 10.1093/jn/138.9.1734S
   Kotani K, 2008, CLIN CHEM LAB MED, V46, P1434, DOI 10.1515/CCLM.2008.286
   Kris-Etherton PN, 2008, J NUTR, V138, P0
   Krishnaswamy K, 2008, ASIA PAC J CLIN NUTR, V17, P265
   Lamon BD, 2008, AM J PATHOL, V173, P1253, DOI 10.2353/ajpath.2008.080442
   Lansky EP, 2007, J ETHNOPHARMACOL, V109, P177, DOI 10.1016/j.jep.2006.09.006
   Laugesen M, 2003, NZ MED J, V116, P1
   Li HL, 2006, FREE RADICAL BIO MED, V40, P1756, DOI 10.1016/j.freeradbiomed.2006.01.005
   Lichtenstein AH, 2006, CIRCULATION, V114, P82, DOI 10.1161/CIRCULATIONAHA.106.176158
   Lopez-Garcia E, 2005, J NUTR, V135, P562, DOI 10.1093/jn/135.3.562
   Lopez-Garcia E, 2006, AM J CLIN NUTR, V84, P888, DOI 10.1093/ajcn/84.4.888
   Luu NT, 2007, J NUTR, V137, P2769, DOI 10.1093/jn/137.12.2769
   Ma YS, 2006, AM J CLIN NUTR, V83, P760, DOI 10.1093/ajcn/83.4.760
   Ma YS, 2008, NUTRITION, V24, P941, DOI 10.1016/j.nut.2008.04.005
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Alvarez JRM, 2009, NUTRITION, V25, P182, DOI 10.1016/j.nut.2008.08.005
   MATSUZAWA Y, 2005, BEST PRACT RES CLIN, V19, P969
   Mayer-Davis EJ, 2008, DIABETES CARE, V31, P470, DOI 10.2337/dc07-1321
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Miller A, 2008, CURR OPIN GASTROEN, V24, P204, DOI 10.1097/MOG.0b013e3282f3f4c4
   Mourente G, 2006, COMP BIOCHEM PHYS B, V145, P389, DOI 10.1016/j.cbpb.2006.08.012
   Mozaffarian D, 2006, NEW ENGL J MED, V354, P1601, DOI 10.1056/NEJMra054035
   Mukamal KJ, 2004, ATHEROSCLEROSIS, V173, P79, DOI 10.1016/j.atherosclerosis.2003.10.011
   Nakamura Y, 2007, METABOLISM, V56, P1060, DOI 10.1016/j.metabol.2007.03.014
   Nanri A, 2008, AM J CLIN NUTR, V87, P1488, DOI 10.1093/ajcn/87.5.1488
   Nasca MM, 2008, AM J CARDIOL, V102, P84, DOI 10.1016/j.amjcard.2008.02.100
   Nettleton JA, 2006, AM J CLIN NUTR, V83, P1369, DOI 10.1093/ajcn/83.6.1369
   OKeefe JH, 2008, J AM COLL CARDIOL, V51, P249, DOI 10.1016/j.jacc.2007.10.016
   OKeefe JH, 2007, J AM COLL CARDIOL, V50, P1009, DOI 10.1016/j.jacc.2007.04.089
   Pai JK, 2006, ATHEROSCLEROSIS, V186, P113, DOI 10.1016/j.atherosclerosis.2005.06.037
   Papoutsi Z, 2008, BRIT J NUTR, V99, P715, DOI 10.1017/S0007114507837421
   Parks EJ, 2008, J NUTR, V138, P1039, DOI 10.1093/jn/138.6.1039
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   Petersson H, 2009, ATHEROSCLEROSIS, V203, P298, DOI 10.1016/j.atherosclerosis.2008.06.020
   Pischon T, 2003, CIRCULATION, V108, P155, DOI 10.1161/01.CIR.0000079224.46084.C2
   Plat J, 2007, J NUTR, V137, P2635, DOI 10.1093/jn/137.12.2635
   Pollan M, 2006, THE OMNIVORES DILEMMA; A HISTORY OF FOUR MEALS, V0, P0
   Poppitt SD, 2008, NUTRITION, V24, P322, DOI 10.1016/j.nut.2007.12.012
   Qi L, 2007, CURR OPIN LIPIDOL, V18, P3, DOI 10.1097/MOL.0b013e328011c6e0
   Ranheim T, 2005, MOL NUTR FOOD RES, V49, P274, DOI 10.1002/mnfr.200400109
   Retterstol L, 2005, ALCOHOL ALCOHOLISM, V40, P102, DOI 10.1093/alcalc/agh132
   Riley JC, 2001, RISING LIFE EXPECTANCY: A GLOBAL HISTORY, V0, P0
   Rimm EB, 2002, CIRCULATION, V105, P2806, DOI 10.1161/01.CIR.0000022344.79651.CC
   Rodrigues C, 2006, HYPERTENS PREGNANCY, V25, P69
   Ros E, 2006, BRIT J NUTR, V96, PS29, DOI 10.1017/BJN20061861
   Rosenblum M, 2005, CHOCOLATE: A BITTERSWEET SAGA OF DARK AND LIGHT, V0, P0
   Rutledge AC, 2007, NUTR REV, V65, PS13, DOI 10.1301/nr.2007.jun.S13-S23
   Sacanella E, 2007, AM J CLIN NUTR, V86, P1463, DOI 10.1093/ajcn/86.5.1463
   Salas-Salvadó J, 2008, ASIA PAC J CLIN NUTR, V17, P333
   Sartorelli DS, 2009, NUTR METAB CARDIOVAS, V19, P77, DOI 10.1016/j.numecd.2008.04.004
   Seierstad SL, 2005, EUR J CLIN INVEST, V35, P52, DOI 10.1111/j.1365-2362.2005.01443.x
   Seimi C, 2008, MOL NUTR FOOD RES, V52, P1340, DOI 10.1002/mnfr.200700435
   Shai I, 2004, DIABETOLOGIA, V47, P1760, DOI 10.1007/s00125-004-1526-0
   Simopoulos AP, 1999, AM J CLIN NUTR, V70, P560S, DOI 10.1093/ajcn/70.3.560s
   Solinas G, 2007, CELL METAB, V6, P386, DOI 10.1016/j.cmet.2007.09.011
   Sorensen LB, 2005, AM J CLIN NUTR, V82, P421, DOI 10.1093/ajcn/82.2.421
   STANHOPE KL, 2008, AM DIAB ANN M SAN FR, V0, P0
   Steptoe A, 2007, ATHEROSCLEROSIS, V193, P277, DOI 10.1016/j.atherosclerosis.2006.08.054
   Surh YJ, 2002, FOOD CHEM TOXICOL, V40, P1091, DOI 10.1016/S0278-6915(02)00037-6
   Swarbrick MM, 2008, BRIT J NUTR, V100, P947, DOI 10.1017/S0007114508968252
   Swinburn B, 2004, BETA CASEIN A1 A2 MI, V0, P0
   Tannahill Reay, 1988, FOOD HIST, V0, P0
   Tapsell LC, 2006, MED J AUSTRALIA, V185, P0
   Togashi N, 2000, J HYPERTENS, V18, P1605, DOI 10.1097/00004872-200018110-00011
   Valtuena S, 2008, AM J CLIN NUTR, V87, P1290, DOI 10.1093/ajcn/87.5.1290
   van der Crabben SN, 2008, J CLIN ENDOCR METAB, V93, P638, DOI 10.1210/jc.2006-2491
   Velayutham P, 2008, CURR MED CHEM, V15, P1840
   Volpato S, 2004, CIRCULATION, V109, P607, DOI 10.1161/01.CIR.0000109503.13955.00
   Vos Miriam B, 2008, MEDSCAPE J MED, V10, P160
   Waldschmidt TJ, 2008, ALCOHOL, V42, P137, DOI 10.1016/j.alcohol.2007.11.003
   Wandler A, 2008, MOL CELL ENDOCRINOL, V296, P26, DOI 10.1016/j.mce.2008.09.006
   Wang JJ, 2008, ACTA CARDIOL, V63, P65, DOI 10.2143/AC.63.1.2025334
   Wannamethee SG, 2006, AM J CLIN NUTR, V83, P567, DOI 10.1093/ajcn.83.3.567
   Warden BA, 2001, J NUTR, V131, P1731, DOI 10.1093/jn/131.6.1731
   Waterhouse AL, 1996, LANCET, V348, P834, DOI 10.1016/S0140-6736(05)65262-2
   Watzl B, 2005, AM J CLIN NUTR, V82, P1052, DOI 10.1093/ajcn/82.5.1052
   White JS, 2008, AM J CLIN NUTR, V88, P1716S, DOI 10.3945/ajcn.2008.25825B
   Willett WC, 2001, EAT DRINK BE HLTH, V0, P0
   Willett WC, 2008, ASIA PAC J CLIN NUTR, V17, P1
   Willett WC, 2007, J CARDIOVASC MED, V8, PS42, DOI 10.2459/01.JCM.0000289275.72556.13
   Wolf A, 2008, OBES REV, V9, P151, DOI 10.1111/j.1467-789X.2007.00389.x
   Yamaguchi K, 2005, HYPERTENS RES, V28, P773, DOI 10.1291/hypres.28.773
   Yoneyama S, 2007, J EPIDEMIOL, V17, P86, DOI 10.2188/jea.17.86
   Yoon JH, 2005, YONSEI MED J, V46, P585, DOI 10.3349/ymj.2005.46.5.585
   Yung LM, 2008, INFLAMMOPHARMACOLOGY, V16, P230, DOI 10.1007/s10787-008-8022-y
   Zampelas A, 2004, AM J CLIN NUTR, V80, P862, DOI 10.1093/ajcn/80.4.862
   Zemel MB, 2008, J NUTR, V138, P1047, DOI 10.1093/jn/138.6.1047
   Zhao GX, 2007, AM J CLIN NUTR, V85, P385, DOI 10.1093/ajcn/85.2.385
   Zielinska-Przyjemska M, 2009, PHYTOTHER RES, V23, P49, DOI 10.1002/ptr.2535
NR 176
TC 39
Z9 42
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1467-7881
EI 1467-789X
J9 OBES REV
JI Obes. Rev.
PD FEB 15
PY 2010
VL 11
IS 2
BP 137
EP 149
DI 10.1111/j.1467-789X.2009.00644.x
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 545LD
UT WOS:000273732700006
PM 19656309
DA 2025-04-28
ER

PT J
AU Smith, AE
   Lockwood, CM
   Moon, JR
   Kendall, KL
   Fukuda, DH
   Tobkin, SE
   Cramer, JT
   Stout, JR
AF Smith, Abbie E.
   Lockwood, Christopher M.
   Moon, Jordan R.
   Kendall, Kristina L.
   Fukuda, David H.
   Tobkin, Sarah E.
   Cramer, Joel T.
   Stout, Jeffrey R.
TI Physiological effects of caffeine, epigallocatechin-3-gallate, and exercise in overweight and obese women
SO APPLIED PHYSIOLOGY NUTRITION AND METABOLISM
LA English
DT Article
ID green tea extract; body-weight loss; energy-expenditure; double-blind; intestinal-absorption; thermogenic drink; fat oxidation; humans; rats; metabolism
AB Cette etude se propose d'analyser les effets combines d'un programme d'exercices de 10 semaines et de la consommation de cafeine additionnee d'epigallocatechine-3-gallate (EGCG) sur la composition corporelle, la condition physique cardiovasculaire et la force chez des femmes presentant un surplus de poids et des femmes obeses. Selon un devis experimental a double insu, des femmes presentant un surpoids et des femmes obeses (n = 27) sont assignees aleatoirement dans 4 groupes : un groupe avec supplementation et exercice (EX-Act), un groupe placebo, soit sans supplementation, mais avec exercice (EX-PL), un groupe avec supplementation, mais sans exercice (NEX-Act) et un autre groupe placebo, soit sans supplementation ni exercice (NEX-PL). Toutes les participantes consomment une boisson par jour durant 10 semaines; les groupes EX-Act et EX-PL participent a un programme combine d'endurance et de force. Les variations de composition corporelle sont evaluees en fonction d'un modele a quatre compartiments. Les variations de la masse musculaire (MM) sont determinees au moyen d'une equation determinant la masse maigre des tissus mous appendiculaires obtenue par DXA. On observe une interaction significative traitement temps en ce qui concerne la MM (p = 0,026) et la concentration totale de cholesterol (TC) (p = 0,047); on observe aussi une interaction significative traitement temps en ce qui concerne le consommation d'oxygene de pointe (p = 0,046) et la force du haut et du bas du corps (p < 0,05). En outre, on observe des differences significatives entre les groupes EX et NEX en ce qui concerne les variations en pourcentage de la MM, du le consommation d'oxygene de pointe et de la force du haut et du bas du corps. Les marqueurs cliniques des fonctions hepatique et renale ne revelent aucun effet indesirable. La TC diminue significativement dans les groupes recevant des supplements (EX-Act, NEX-Act). Cette etude indique que boire un breuvage contenant de la cafeine et du EGCG avant l'exercice dans un programme d'entrainement physique contribue a l'amelioration de la masse musculaire, de la condition physique et du bilan lipidique chez des femmes presentant un surpoids et des femmes obeses.
C1 [Smith, Abbie E.; Lockwood, Christopher M.; Kendall, Kristina L.; Fukuda, David H.; Cramer, Joel T.; Stout, Jeffrey R.] Univ Oklahoma, Dept Hlth & Exercise Sci, Norman, OK 73019 USA.
   [Moon, Jordan R.] United States Sports Acad, Dept Sports Fitness & Hlth, Daphne, AL 36526 USA.
   [Tobkin, Sarah E.] Univ Oklahoma Hlth Sci Ctr, Coll Med, Oklahoma City, OK 73126 USA.
C3 University of Oklahoma System; University of Oklahoma - Norman; University of Oklahoma System; University of Oklahoma Health Sciences Center
RP Stout, JR (corresponding author), Univ Oklahoma, Metab & Body Composit Lab, Norman, OK 73019 USA.
EM jrstout@ou.edu
FU Celsius Inc. (Delray Beach, Fla.)
CR Acheson KJ, 2004, AM J CLIN NUTR, V79, P40
   ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   ASTRUP A, 1991, METABOLISM, V40, P323, DOI 10.1016/0026-0495(91)90117-F
   Beck TW, 2008, J STRENGTH COND RES, V22, P1654, DOI 10.1519/JSC.0b013e318181ff2c
   Belza A, 2007, INT J OBESITY, V31, P121, DOI 10.1038/sj.ijo.0803351
   Benowitz NL, 1995, CLIN PHARMACOL THER, V58, P684, DOI 10.1016/0009-9236(95)90025-X
   Boozer CN, 2001, INT J OBESITY, V25, P316, DOI 10.1038/sj.ijo.0801539
   BORCHARDT RT, 1975, J MED CHEM, V18, P120, DOI 10.1021/jm00235a030
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   Chantre P, 2002, PHYTOMEDICINE, V9, P3, DOI 10.1078/0944-7113-00078
   COSTILL DL, 1978, MED SCI SPORT EXER, V10, P155
   Dalbo VJ, 2008, J INT SOC SPORT NUTR, V5, P0, DOI 10.1186/1550-2783-5-6
   Diepvens K, 2005, BRIT J NUTR, V94, P1026, DOI 10.1079/BJN20051580
   Diepvens K, 2007, AM J PHYSIOL-REG I, V292, PR77, DOI 10.1152/ajpregu.00832.2005
   DULLOO AG, 1994, AM J PHYSIOL-ENDOC M, V267, PE801, DOI 10.1152/ajpendo.1994.267.5.E801
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Dulloo AG, 1998, BRIT J NUTR, V80, P493, DOI 10.1017/S0007114598001573
   Finkelstein EA, 2004, OBES RES, V12, P18, DOI 10.1038/oby.2004.4
   Flegal KM, 2007, JAMA-J AM MED ASSOC, V298, P2028, DOI 10.1001/jama.298.17.2028
   Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014
   Gallagher D, 2000, AM J CLIN NUTR, V72, P694, DOI 10.1093/ajcn/72.3.694
   Hackman RM, 2006, INT J OBESITY, V30, P1545, DOI 10.1038/sj.ijo.0803283
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   Hsu CH, 2008, CLIN NUTR, V27, P363, DOI 10.1016/j.clnu.2008.03.007
   IKEDA I, 1992, BIOCHIM BIOPHYS ACTA, V1127, P141, DOI 10.1016/0005-2760(92)90269-2
   JUNG RT, 1981, CLIN SCI, V60, P527, DOI 10.1042/cs0600527
   Kim J, 2002, AM J CLIN NUTR, V76, P378, DOI 10.1093/ajcn/76.2.378
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Koo SI, 2007, J NUTR BIOCHEM, V18, P179, DOI 10.1016/j.jnutbio.2006.12.005
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   LANDSBERG L, 1984, AM J PHYSIOL, V247, PE181, DOI 10.1152/ajpendo.1984.247.2.E181
   Lockwood CM, 2010, J STRENGTH COND RES, V24, P2227, DOI 10.1519/JSC.0b013e3181aeb0cf
   Moon JR, 2007, J INT SOC SPORT NUTR, V4, P0, DOI 10.1186/1550-2783-4-16
   Moon JR, 2009, EUR J APPL PHYSIOL, V105, P119, DOI 10.1007/s00421-008-0881-9
   MURAMATSU K, 1986, J NUTR SCI VITAMINOL, V32, P613, DOI 10.3177/jnsv.32.613
   Nagao T, 2001, JOURNAL OF OLEO SCIENCE, V50, P717
   Raederstorff DG, 2003, J NUTR BIOCHEM, V14, P326, DOI 10.1016/S0955-2863(03)00054-8
   Roberts MD, 2008, J INT SOC SPORT NUTR, V5, P0, DOI 10.1186/1550-2783-5-19
   Rossiter HB, 2006, J APPL PHYSIOL, V100, P764, DOI 10.1152/japplphysiol.00932.2005
   TSCHIDA T, 2002, PROG MED, V22, P2189
   VANNUCCI SJ, 1989, AM J PHYSIOL, V257, PE871, DOI 10.1152/ajpendo.1989.257.6.E871
   Wang ZM, 1998, INT J OBESITY, V22, P329, DOI 10.1038/sj.ijo.0800590
   Wang ZM, 2002, AM J CLIN NUTR, V76, P968, DOI 10.1093/ajcn/76.5.968
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Wilkins LW, 2010, ACSM GUID EX TEST, V8th, P0
   WONG WW, 1987, AM J CLIN NUTR, V45, P905, DOI 10.1093/ajcn/45.5.905
   YOKO K, 2000, J AGR FOOD CHEM, V48, P5618
NR 48
TC 15
Z9 18
U1 1
U2 48
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 1715-5312
EI 1715-5320
J9 APPL PHYSIOL NUTR ME
JI Appl. Physiol. Nutr. Metab.
PD OCT 15
PY 2010
VL 35
IS 5
BP 607
EP 616
DI 10.1139/H10-056
PG 10
WC Nutrition & Dietetics; Physiology; Sport Sciences
SC Nutrition & Dietetics; Physiology; Sport Sciences
GA 668WD
UT WOS:000283303100005
PM 20962916
DA 2025-04-28
ER

PT J
AU Montenegro-Bethancourt, G
   Vossenaar, M
   Doak, CM
   Solomons, NW
AF Montenegro-Bethancourt, Gabriela
   Vossenaar, Marieke
   Doak, Colleen M.
   Solomons, Noel W.
TI Contribution of beverages to energy, macronutrient and micronutrient intake of third- and fourth-grade schoolchildren in Quetzaltenango, Guatemala
SO MATERNAL AND CHILD NUTRITION
LA English
DT Article
DE water; beverage; juice; milk; energy; micronutrients; schoolchildren; 24-h food record; childhood nutrition; Guatemala
ID discontinuing coffee intake; sugar-sweetened beverages; drinking-water; childhood obesity; consumption; children; weight; foods; growth; association
AB Beverages are selected based on availability, culture, taste preference, health, safety and social context. Beverages may be important to energy and to the macronutrient and micronutrient quality of overall intake. The aim of this study was to determine the contribution of beverages to the dietary energy and estimated macro- and micronutrient intake to the diet of young schoolchildren. We analyzed data from third- and fourth-grade urban Guatemalan school-children aged predominantly 8-10 years old. One-day pictorial registries of all beverages, foods and snacks consumed over a 24-h period were collected from children from private (n = 219) and public (n = 230) schools. Food composition nutrient values were assigned to the items consumed. Eleven main categories of beverages were identified. The contribution of each of the 11 beverage categories to energy, macro- and micronutrients was evaluated. The estimated intake of beverages was 475 300 mL, as reported by the 449 children. As a group, the beverage consumed in the greatest quantity was coffee (126 500 mL), followed by plain water (62 000 mL). Beverages represented a mean energy contribution of 418 +/- 26 kcal (21.5% of total dietary energy). The beverages varied in energy density from 0 (water) to 1.5 kcal mL-1 (thin gruels). Beverages contributed one-third of the dietary carbohydrate. Through the contribution of fortified drinks, beverages were important sources of vitamin A (55%), vitamin C (38%), zinc (21%) and calcium (19%). Milk was an important source for vitamin D (10%). These results show the importance of drinks to nutrition and the balance of concerns of overweight/obesity with micronutrient quality.
C1 [Montenegro-Bethancourt, Gabriela; Vossenaar, Marieke; Solomons, Noel W.] CeSSIAM, Guatemala City 01011, Guatemala.
   [Doak, Colleen M.] Vrije Univ Amsterdam, Inst Hlth Sci, Fac Earth & Life Sci, Amsterdam, Netherlands.
C3 Vrije Universiteit Amsterdam
RP Montenegro-Bethancourt, G (corresponding author), CeSSIAM, 17 Ave 16-89 Interior,Zona 11 Anillo Periferico, Guatemala City 01011, Guatemala.
EM cessiam@guate.net.gt
CR Allen L, 2006, GUIDELINES ON FOOD FORTIFICATION WITH MICRONUTRIENTS, V0, P0
   Avery AA, 1999, ENVIRON HEALTH PERSP, V107, P583, DOI 10.2307/3434401
   Baxter SD, 2006, NUTR RES, V26, P241, DOI 10.1016/j.nutres.2006.05.005
   Benton D, 2004, INT J OBESITY, V28, P858, DOI 10.1038/sj.ijo.0802532
   Blum JW, 2005, J AM COLL NUTR, V24, P93, DOI 10.1080/07315724.2005.10719449
   Cordain L, 1999, WORLD REV NUTR DIET, V84, P19
   CORDAIN L, 2002, STUDIES HLTH DIS, V0, P144
   Cotton PA, 2004, J AM DIET ASSOC, V104, P921, DOI 10.1016/j.jada.2004.03.019
   Dary O, 2002, J NUTR, V132, P2927S, DOI 10.1093/jn/132.9.2927S
   Dehghan M, 2005, NUTR J, V4, P0, DOI 10.1186/1475-2891-4-24
   Dennison BA, 1999, J AM COLL NUTR, V18, P346, DOI 10.1080/07315724.1999.10718874
   Dewey KG, 1997, J NUTR, V127, P306, DOI 10.1093/jn/127.2.306
   Dewey KG, 1997, AM J CLIN NUTR, V66, P168, DOI 10.1093/ajcn/66.1.168
   Dietz WH, 2006, J PEDIATR-US, V148, P152, DOI 10.1016/j.jpeds.2005.12.045
   Dodd KW, 2006, J AM DIET ASSOC, V106, P1640, DOI 10.1016/j.jada.2006.07.011
   Engle PL, 1999, EARLY HUM DEV, V53, P251, DOI 10.1016/S0378-3782(98)00080-2
   Forshee RA, 2006, J AM COLL NUTR, V25, P108, DOI 10.1080/07315724.2006.10719520
   Forshee RA, 2003, INT J FOOD SCI NUTR, V54, P297, DOI 10.1080/09637480120092143
   Fulgoni VL, 2007, J AM COLL NUTR, V26, P588S, DOI 10.1080/07315724.2007.10719663
   GEBHARDT SE, 2004, USDA NUTR DAT STAND, V0, P0
   Gibson S, 2007, INT J FOOD SCI NUTR, V58, P445, DOI 10.1080/09637480701288363
   Gilbert Rachel, 2006, NURS TIMES, V102, P55
   Gill TP, 2006, MED J AUSTRALIA, V184, P263, DOI 10.5694/j.1326-5377.2006.tb00233.x
   Groeneveld IF, 2007, REV PANAM SALUD PUBL, V22, P169, DOI 10.1590/S1020-49892007000800003
   Groeneveld IF, 2007, INT J PEDIATR OBES, V2, P114, DOI 10.1080/17477160601127426
   James J, 2005, INT J OBESITY, V29, PS54, DOI 10.1038/sj.ijo.0803062
   Johnson L, 2007, NUTRITION, V23, P557, DOI 10.1016/j.nut.2007.05.005
   Krause VM, 1998, J NUTR, V128, P860, DOI 10.1093/jn/128.5.860
   Kruawal K, 2005, SCI TOTAL ENVIRON, V340, P57, DOI 10.1016/j.scitotenv.2004.08.008
   Liang Jennifer L, 2006, MORBIDITY AND MORTALITY WEEKLY REPORT, V55, P31
   Livingstone MBE, 2000, P NUTR SOC, V59, P279, DOI 10.1017/S0029665100000318
   Malik VS, 2006, AM J CLIN NUTR, V84, P274
   Menchu MT, 2000, TABLA DE COMPOSICION DE ALIMENTOS DE CENTROAMERICA, V0, P0
   Montenegro-Bethancourt G, 2009, REV PANAM SALUD PUBL, V25, P146, DOI 10.1590/S1020-49892009000200008
   Moore GF, 2007, EUR J CLIN NUTR, V61, P420, DOI 10.1038/sj.ejcn.1602531
   Nawrot P, 2003, FOOD ADDIT CONTAM A, V20, P1, DOI 10.1080/0265203021000007840
   Nielsen SJ, 2004, AM J PREV MED, V27, P205, DOI 10.1016/j.amepre.2004.05.005
   OConnor TM, 2006, PEDIATRICS, V118, PE1010, DOI 10.1542/peds.2005-2348
   Pizarro Fernando, 1999, REVIEWS ON ENVIRONMENTAL HEALTH, V14, P231
   Popkin BM, 2006, AM J CLIN NUTR, V83, P529, DOI 10.1093/ajcn.83.3.529
   Popkin BM, 2005, OBES RES, V13, P2146, DOI 10.1038/oby.2005.266
   Pridmore P, 1995, HEALTH EDUC J, V54, P473, DOI 10.1177/001789699505400410
   Ritz P, 2005, NUTR REV, V63, PS6, DOI 10.1111/j.1753-4887.2005.tb00155.x
   Rivera Juan A, 2008, SALUD PÚBLICA MÉX, V50, P173
   Rolls BJ, 1982, THIRST, V0, P0
   Sanigorski AM, 2007, PUBLIC HEALTH NUTR, V10, P152, DOI 10.1017/S1368980007246634
   Shenkin Jonathan D, 2003, GEN DENT, V51, P30
   SIMOONS FJ, 1978, AM J DIGESTIVE DIS, V23, P363
   Solomons NW, 2009, NUTRITION, V25, P385, DOI 10.1016/j.nut.2008.09.013
   Stookey JD, 2001, EUR J CLIN NUTR, V55, P349, DOI 10.1038/sj.ejcn.1601163
   Storey ML, 2006, J AM DIET ASSOC, V106, P1992, DOI 10.1016/j.jada.2006.09.009
   Striegel-Moore RH, 2006, J PEDIATR-US, V148, P183, DOI 10.1016/j.jpeds.2005.11.025
   VOSSENAAR M, 2008, PUBLIC HEALTH NUTR, V9, P1
NR 53
TC 7
Z9 8
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1740-8695
EI 1740-8709
J9 MATERN CHILD NUTR
JI Matern. Child Nutr.
PD APR 15
PY 2010
VL 6
IS 2
BP 174
EP 189
DI 10.1111/j.1740-8709.2009.00193.x
PG 16
WC Nutrition & Dietetics; Pediatrics
SC Nutrition & Dietetics; Pediatrics
GA 568OK
UT WOS:000275531800006
PM 20624213
DA 2025-04-28
ER

PT J
AU Cho, AS
   Jeon, SM
   Kim, MJ
   Yeo, J
   Seo, KI
   Choi, MS
   Lee, MK
AF Cho, Ae-Sim
   Jeon, Seon-Min
   Kim, Myung-Joo
   Yeo, Jiyoung
   Seo, Kwon-Il
   Choi, Myung-Sook
   Lee, Mi-Kyung
TI Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Chlorogenic acid; Caffeic acid; High-fat diet; Lipid metabolism; Obesity
ID caffeic acid; insulin sensitivity; adipose-tissue; rat-liver; adiponectin; cholesterol; protein; hypoadiponectinemia; carcinogenesis; association
AB This study investigated the efficacy of chlorogenic acid on altering body fat in high-fat diet (37% calories from fat) induced-obese mice compared to caffeic acid. Caffeic acid or chlorogenic acid was supplemented with high-fat diet at 0.02% (wt/wt) dose. Both caffeic acid and chlorogenic acid significantly lowered body weight, visceral fat mass and plasma leptin and insulin levels compared to the high-fat control group. They also lowered triglyceride (in plasma, liver and heart) and cholesterol (in plasma, adipose tissue and heart) concentrations. Triglyceride content in adipose tissue was significantly lowered, whereas the plasma adiponectin level was elevated by chlorogenic acid supplementation compared to the high-fat control group. Body weight was significantly correlated with plasma leptin (r = 0.894. p < 0.01) and insulin (r = 0.496, p < 0.01) levels, respectively. Caffeic acid and chlorogenic acid significantly inhibited fatty acid synthase, 3-hydroxy-3-methylglutaryl CoA reductase and acyl-CoA: cholesterol acyltransferase activities, while they increased fatty acid beta-oxidation activity and peroxisome proliferator-activated receptors alpha expression in the liver compared to the high-fat group. These results suggest that caffeic acid and chlorogenic acid improve body weight, lipid metabolism and obesity-related hormones levels in high-fat fed mice. Chlorogenic acid seemed to be more potent for body weight reduction and regulation of lipid metabolism than caffeic acid. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Jeon, Seon-Min; Choi, Myung-Sook] Kyungpook Natl Univ, Dept Food Sci & Nutr, Taegu 702701, South Korea.
   [Cho, Ae-Sim] Sunchon Natl Univ, Grad Sch Educ, Dept Nutr Educ, Sunchon 540742, South Korea.
   [Kim, Myung-Joo] Daegu Polytech Coll, Dept Food Sci & Nutr, Taegu 706022, South Korea.
   [Yeo, Jiyoung] Pusan Natl Univ, Sch Oriental Med, Pusan 626810, South Korea.
   [Seo, Kwon-Il; Lee, Mi-Kyung] Sunchon Natl Univ, Dept Food & Nutr, Sunchon 540742, South Korea.
C3 Kyungpook National University (KNU); Sunchon National University; Pusan National University; Sunchon National University
RP Choi, MS (corresponding author), Kyungpook Natl Univ, Dept Food Sci & Nutr, 1370 Sankyuk Dong, Taegu 702701, South Korea.
EM mschoi@knu.ac.kr; leemk@sunchon.ac.kr
FU Korea Science and Engineering Foundation (KOSEF) [2009-0063409]
CR Unknown -, 2006, BMC COMPLEM ALTERN M, V0, P0
   Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255
   Azuma K, 2000, J AGR FOOD CHEM, V48, P5496, DOI 10.1021/jf000483q
   Bergeron R, 2006, ENDOCRINOLOGY, V147, P4252, DOI 10.1210/en.2005-1535
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chen XL, 2008, METABOLISM, V57, P1516, DOI 10.1016/j.metabol.2008.06.005
   Clifford MN, 1999, J SCI FOOD AGR, V79, P362, DOI 10.1002/(SICI)1097-0010(19990301)79:3<362::AID-JSFA256>3.0.CO;2-D
   de Sotillo DVR, 2002, J NUTR BIOCHEM, V13, P717, DOI 10.1016/S0955-2863(02)00231-0
   ERICKSON SK, 1980, J LIPID RES, V21, P930
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   GILLIES PJ, 1986, EXP MOL PATHOL, V44, P329, DOI 10.1016/0014-4800(86)90046-8
   Gonthier MP, 2006, BIOMED PHARMACOTHER, V60, P536, DOI 10.1016/j.biopha.2006.07.084
   Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638
   Hemmerle H, 1997, J MED CHEM, V40, P137, DOI 10.1021/jm9607360
   HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381
   Hsu CL, 2006, J AGR FOOD CHEM, V54, P4191, DOI 10.1021/jf0609882
   HULCHER FH, 1973, J LIPID RES, V14, P625
   Jung UJ, 2006, J PHARMACOL EXP THER, V318, P476, DOI 10.1124/jpet.106.105163
   Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005
   Kim H, 2003, DIABETES, V52, P1770, DOI 10.2337/diabetes.52.7.1770
   Kim HK, 2003, CLIN CHIM ACTA, V327, P129, DOI 10.1016/S0009-8981(02)00344-3
   Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50
   Lafontan M, 2008, DIABETES METAB, V34, P317, DOI 10.1016/j.diabet.2008.04.001
   Lazarow P B, 1981, METHODS ENZYMOL, V72, P315
   Lee MK, 2003, J BIOCHEM MOL TOXIC, V17, P255, DOI 10.1002/jbt.10087
   Mathieu P, 2008, INT J BIOCHEM CELL B, V40, P821, DOI 10.1016/j.biocel.2007.12.001
   MORI H, 1986, CANCER LETT, V30, P49, DOI 10.1016/0304-3835(86)90131-X
   NARDINI M, 1995, FREE RADICAL BIO MED, V19, P541, DOI 10.1016/0891-5849(95)00052-Y
   Nepokroeff C M, 1975, METHODS ENZYMOL, V35, P37, DOI 10.1016/0076-6879(75)35136-7
   Ouchi N, 2003, HYPERTENSION, V42, P231, DOI 10.1161/01.HYP.0000083488.67550.B8
   Radtke J, 1998, Z ERNAHRUNGSWISS, V37, P190, DOI 10.1007/s003940050016
   Scalbert A, 2000, J NUTR, V130, P2073S, DOI 10.1093/jn/130.8.2073S
   SHAPIRO DJ, 1974, BIOCHIM BIOPHYS ACTA, V370, P369, DOI 10.1016/0005-2744(74)90098-9
   Slawik M, 2006, AGEING RES REV, V5, P144, DOI 10.1016/j.arr.2006.03.004
   TANAKA T, 1993, CARCINOGENESIS, V14, P1321, DOI 10.1093/carcin/14.7.1321
   Torre-Villalvazo I, 2008, J NUTR, V138, P462, DOI 10.1093/jn/138.3.462
   Trujillo ME, 2005, J INTERN MED, V257, P167, DOI 10.1111/j.1365-2796.2004.01426.x
   Tsuchiya T, 1996, BIOSCI BIOTECH BIOCH, V60, P765, DOI 10.1271/bbb.60.765
   Willson TM, 1997, CURR OPIN CHEM BIOL, V1, P235, DOI 10.1016/S1367-5931(97)80015-4
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
   Bieri JG, 1977, JOURNAL OF NUTRITION, V107, P1394
NR 42
TC 615
Z9 679
U1 9
U2 192
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD MAR 15
PY 2010
VL 48
IS 3
BP 937
EP 943
DI 10.1016/j.fct.2010.01.003
PG 7
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA 573VO
UT WOS:000275943600026
PM 20064576
DA 2025-04-28
ER

PT J
AU Ballard, SL
   Wellborn-Kim, JJ
   Clauson, KA
AF Ballard, Stephanie L.
   Wellborn-Kim, Jennifer J.
   Clauson, Kevin A.
TI Effects of Commercial Energy Drink Consumption on Athletic Performance and Body Composition
SO PHYSICIAN AND SPORTSMEDICINE
LA English
DT Article
DE energy drink; functional food; caffeine; taurine; athletic performance; weight loss
ID acute hormonal response; caffeine ingestion; thermogenic drink; taurine; exercise; supplementation; obesity; safety; risk; men
AB Energy drinks are frequently marketed to individuals interested in athletics and an active lifestyle. From 2001 to 2008, estimates of energy drink use in adolescent to middle-aged populations ranged from 24% to 56%. Most energy drinks feature caffeine and a combination of other components, including taurine, sucrose, guarana, ginseng, niacin, pyridoxine, and cyanocobalamin. This article examines the evidence for 2 commonly purported uses of energy drinks: athletic performance enhancement and weight loss. Observed ergogenic benefits of energy drinks are likely attributable to caffeine and glucose content. There is conflicting evidence regarding the impact of energy drinks on weight loss, although some data suggest that combining energy drink use with exercise may enhance body fat reduction. As with any pharmacologically active substance, energy drinks are associated with adverse effects. Combining energy drinks with alcohol exacerbates safety concerns and is an increasingly common practice contributing to toxic jock identity among college-aged male athletes. Practitioners should monitor identified populations likely to consume these loosely regulated beverages.
C1 [Clauson, Kevin A.] Nova SE Univ, Coll Pharm, Ft Lauderdale, FL 33328 USA.
   [Ballard, Stephanie L.; Wellborn-Kim, Jennifer J.] Nova SE Univ, Coll Pharm, W Palm Beach, FL USA.
C3 Nova Southeastern University; Nova Southeastern University
RP Clauson, KA (corresponding author), Nova SE Univ, Coll Pharm, 3200 S Univ Dr, Ft Lauderdale, FL 33328 USA.
EM clauson@nova.edu
CR Acheson Kevin J, 2005, METABOLIC SYNDROME AND RELATED DISORDERS, V3, P19, DOI 10.1089/met.2005.3.19
   Alford C, 2001, AMINO ACIDS, V21, P139, DOI 10.1007/s007260170021
   ARRIA AM, 2008, 136 ANN M EXP AM PUB, V0, P0
   Bahrke MS, 2009, INT J SPORT NUTR EXE, V19, P298, DOI 10.1123/ijsnem.19.3.298
   Ballistreri MC, 2008, REV LAT-AM ENFERM, V16, P558, DOI 10.1590/S0104-11692008000700009
   Barthel T, 2001, AMINO ACIDS, V20, P63, DOI 10.1007/s007260170066
   Baum M, 2001, AMINO ACIDS, V20, P75, DOI 10.1007/s007260170067
   Berger AJ, 2009, MED J AUSTRALIA, V190, P41, DOI 10.5694/j.1326-5377.2009.tb02263.x
   Brons C, 2004, EUR J CLIN NUTR, V58, P1239, DOI 10.1038/sj.ejcn.1601955
   Burke LM, 2008, APPL PHYSIOL NUTR ME, V33, P1319, DOI 10.1139/H08-130
   Candow DG, 2009, J STRENGTH COND RES, V23, P1271, DOI 10.1519/JSC.0b013e3181a026c2
   Chapman Robert F, 2009, PHYS SPORTSMED, V37, P97, DOI 10.3810/psm.2009.12.1747
   Chelben J, 2008, GEN HOSP PSYCHIAT, V30, P187, DOI 10.1016/j.genhosppsych.2007.10.002
   Clauson KA, 2008, J AM PHARM ASSOC, V48, PE55, DOI 10.1331/JAPhA.2008.07055
   Dalbo VJ, 2008, J INT SOC SPORT NUTR, V5, P0, DOI 10.1186/1550-2783-5-6
   Davis JK, 2009, SPORTS MED, V39, P813, DOI 10.2165/11317770-000000000-00000
   Desbrow B, 2007, INT J SPORT NUTR EXE, V17, P328, DOI 10.1123/ijsnem.17.4.328
   Desbrow B, 2006, INT J SPORT NUTR EXE, V16, P545, DOI 10.1123/ijsnem.16.5.545
   Dhingra R, 2007, CIRCULATION, V116, P480, DOI 10.1161/CIRCULATIONAHA.107.689935
   Diepvens K, 2007, AM J PHYSIOL-REG I, V292, PR77, DOI 10.1152/ajpregu.00832.2005
   Doherty M, 2005, SCAND J MED SCI SPOR, V15, P69, DOI 10.1111/j.1600-0838.2005.00445.x
   Ellender L, 2005, PRIMARY CARE, V32, P277, DOI 10.1016/j.pop.2004.11.008
   *EUR COMM HLTH CON, 2003, OP SCI COMM FOOD FUR, V0, P0
   Finnegan D, 2003, NUTRITION BULLETIN, V28, P147, DOI 10.1046/j.1467-3010.2003.00345.x
   Forbes SC, 2007, INT J SPORT NUTR EXE, V17, P433, DOI 10.1123/ijsnem.17.5.433
   Ganio MS, 2009, J STRENGTH COND RES, V23, P315, DOI 10.1519/JSC.0b013e31818b979a
   GEISS KR, 1994, AMINO ACIDS, V7, P45, DOI 10.1007/BF00808445
   Hasani-Ranjbar S, 2009, WORLD J GASTROENTERO, V15, P3073, DOI 10.3748/wjg.15.3073
   Health Canada, 2009, CANADIAN ADVERSE REA, V19, P4
   Hoffman JR, 2008, J STRENGTH COND RES, V22, P874, DOI 10.1519/JSC.0b013e31816d5db6
   Ivy JL, 2009, INT J SPORT NUTR EXE, V19, P61, DOI 10.1123/ijsnem.19.1.61
   Iyadurai SJP, 2007, EPILEPSY BEHAV, V10, P504, DOI 10.1016/j.yebeh.2007.01.009
   Lee S, 2005, DIABETES CARE, V28, P566, DOI 10.2337/diacare.28.3.566
   Lopez-Garcia E, 2006, AM J CLIN NUTR, V83, P674, DOI 10.1093/ajcn.83.3.674
   Machado-Vieira R, 2001, CAN J PSYCHIAT, V46, P454, DOI 10.1177/070674370104600524
   Malek MH, 2006, J STRENGTH COND RES, V20, P751
   Malinauskas BM, 2007, NUTR J, V6, P0, DOI 10.1186/1475-2891-6-35
   Masuda K, 2009, CLIN EXP DERMATOL, V34, Pe263, DOI 10.1111/j.1365-2230.2008.03173.x
   Miller KE, 2008, J ADOLESCENT HEALTH, V43, P490, DOI 10.1016/j.jadohealth.2008.03.003
   Miller KE, 2008, J AM COLL HEALTH, V56, P481, DOI 10.3200/JACH.56.5.481-490
   Nagajothi N, 2008, AM J MED, V121, PE3, DOI 10.1016/j.amjmed.2007.12.003
   OBrien MC, 2008, ACAD EMERG MED, V15, P453, DOI 10.1111/j.1553-2712.2008.00085.x
   ODea JA, 2003, HEALTH EDUC RES, V18, P98, DOI 10.1093/her/18.1.98
   Oteri A, 2007, ALCOHOL CLIN EXP RES, V31, P1677, DOI 10.1111/j.1530-0277.2007.00464.x
   Petrie HJ, 2004, AM J CLIN NUTR, V80, P22
   Petróczi A, 2007, J INT SOC SPORT NUTR, V4, P0, DOI 10.1186/1550-2783-4-19
   Ratamess NA, 2007, INT J SPORT NUTR EXE, V17, P608, DOI 10.1123/ijsnem.17.6.608
   Reissig CJ, 2009, DRUG ALCOHOL DEPEN, V99, P1, DOI 10.1016/j.drugalcdep.2008.08.001
   Roberts MD, 2008, J INT SOC SPORT NUTR, V5, P0, DOI 10.1186/1550-2783-5-19
   Röggla G, 2007, LANCET, V370, P220, DOI 10.1016/S0140-6736(07)61121-0
   Rush E, 2006, ASIA PAC J CLIN NUTR, V15, P242
   Schneiker KT, 2006, MED SCI SPORT EXER, V38, P578, DOI 10.1249/01.mss.0000188449.18968.62
   SEXSON B, 2009, NATL J CRIMINAL JUST, V4, P14
   SHERMAN WM, 1995, AM J CLIN NUTR, V62, P228S, DOI 10.1093/ajcn/62.1.228S
   Slater G, 2003, INT J SPORT NUTR EXE, V13, P320, DOI 10.1123/ijsnem.13.3.320
   SMITH N, 2007, EVID-BASED COMPL ALT, V0, P1
   SOTANIEMI EA, 1995, DIABETES CARE, V18, P1373, DOI 10.2337/diacare.18.10.1373
   Steinke L, 2009, ANN PHARMACOTHER, V43, P596, DOI 10.1345/aph.1L614
   Stimulant Drinks Committee, 2002, REV HLTH EFF STIM DR, V0, P0
   Suliman ME, 2002, NEPHROL DIAL TRANSPL, V17, P528, DOI 10.1093/ndt/17.3.528
   Terlizzi R, 2008, CLIN AUTON RES, V18, P221, DOI 10.1007/s10286-008-0483-y
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   Vuksan V, 2000, DIABETES CARE, V23, P1221, DOI 10.2337/diacare.23.9.1221
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   WOLINSKY I, 1998, NUTR EXERCISE SPORTS, V0, P183
   Woojae K, 2003, NUTRITION BYTES, V9, P1
   Worrall BB, 2005, NEUROLOGY, V65, P1137, DOI 10.1212/01.wnl.0000178985.35765.e0
   Zhang M, 2004, AMINO ACIDS, V26, P203, DOI 10.1007/s00726-003-0002-3
NR 83
TC 52
Z9 66
U1 2
U2 140
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0091-3847
EI 2326-3660
J9 PHYSICIAN SPORTSMED
JI Physician Sportsmed.
PD APR 15
PY 2010
VL 38
IS 1
BP 107
EP 117
DI 10.3810/psm.2010.04.1768
PG 11
WC Primary Health Care; Orthopedics; Sport Sciences
SC General & Internal Medicine; Orthopedics; Sport Sciences
GA 766SO
UT WOS:000290807000012
PM 20424408
DA 2025-04-28
ER

PT J
AU Kim, SY
   Kim, SM
AF Kim, Seok-Young
   Kim, Se Min
TI Energy intake and snack choice by the meal patterns of employed people
SO NUTRITION RESEARCH AND PRACTICE
LA English
DT Article
DE Snack; meal; energy intake; meal pattern
ID eating patterns; nutrient intake; dietary-intake; food choices; frequency; time; obesity; weight; adults; women
AB The aim of this study was to provide descriptive information on meal and snack patterns and to investigate snacks in relation to energy intake and food choice according to the meal patterns of employed people in Korea. 683 employed people (292 males, 391 females) were interviewed to collect one day dietary data by using 24-h dietary recall. A recorded day was divided into 3 meal and 3 snack periods by the respondent's criteria and the time of consumption. To analyze the eating pattern participants were divided as the more frequent snack eaters (MFSE) and the less frequent snack eaters (LFSE). They were also categorized into 6 groups according to the frequency of all eating occasions. The common meal pattern in nearly half of the subjects (47.6%) was composed of three meals plus one or two snacks per day. A trend of an increasing the number of snacks in between main meals emerges, although the conventional meal pattern is still retained in most employed Korean adults. Women, aged 30-39, and urban residents, had a higher number of being MFSE than LFSE. Increasing eating occasions was associated with higher energy, protein, and carbohydrate intakes, with the exception of fat intakes. 16.8% of the total daily energy intake came from snack consumption, while the 3 main meals contributed 83.2%. Energy and macronutrient intakes from snacks in the MFSE were significantly higher than the LFSE. Instant coffee was the most popular snack in the morning and afternoon, whereas heavy snacks and alcohol were more frequently consumed by both of the meal skipper groups (<= 2M+2,3S and <= 2M+0,1S) in the evening. In conclusion, meal pattern is changing to reflect an increase of more snacks between the three main meals. Meal and snack patterns may be markers for the energy and macronutrient intakes of employed people in Korea.
C1 [Kim, Seok-Young] Gyeoungsang Natl Univ, Dept Food & Nutr, Jinju 660701, Gyeongnam, South Korea.
   [Kim, Se Min] Gyeoungsang Natl Univ, Grad Sch Educ, Jinju 660701, Gyeongnam, South Korea.
C3 Gyeongsang National University; Gyeongsang National University
RP Kim, SY (corresponding author), Gyeoungsang Natl Univ, Dept Food & Nutr, 900 Gajwa Dong, Jinju 660701, Gyeongnam, South Korea.
EM sykim@gnu.ac.kr
CR Andersson J, 2003, APPETITE, V41, P149, DOI 10.1016/S0195-6663(03)00052-7
   BASDEVANT A, 1993, APPETITE, V21, P17, DOI 10.1006/appe.1993.1033
   Bellisle F, 2003, PHYSIOL BEHAV, V79, P183, DOI 10.1016/S0031-9384(03)00088-X
   Bellisle F, 1999, APPETITE, V32, P46, DOI 10.1006/appe.1998.0195
   Berg C, 2009, APPETITE, V52, P21, DOI 10.1016/j.appet.2008.07.008
   Bertéus-Forslund H, 2005, INT J OBESITY, V29, P711, DOI 10.1038/sj.ijo.0802950
   Carlson O, 2007, METABOLISM, V56, P1729, DOI 10.1016/j.metabol.2007.07.018
   de Castro JM, 2004, J NUTR, V134, P104, DOI 10.1093/jn/134.1.104
   De Castro JM, 2007, BRIT J NUTR, V98, P1077, DOI 10.1017/S0007114507754296
   de Graaf C, 2006, APPETITE, V47, P18, DOI 10.1016/j.appet.2006.02.007
   Dubois L, 2009, PUBLIC HEALTH NUTR, V12, P19, DOI 10.1017/S1368980008001894
   Forslund HB, 2002, EUR J CLIN NUTR, V56, P740, DOI 10.1038/sj.ejcn.1601387
   Gatenby SJ, 1997, BRIT J NUTR, V77, PS7, DOI 10.1079/BJN19970100
   Giskes K, 2006, PUBLIC HEALTH NUTR, V9, P75, DOI 10.1079/PHN2005758
   최미경, 2003, JOURNAL OF THE KOREAN SOCIETY OF FOOD CULTURE 한국식생활문화학회지, V18, P45
   Haveman-Nies A, 1998, J AM DIET ASSOC, V98, P1297, DOI 10.1016/S0002-8223(98)00290-9
   Jabs J, 2006, APPETITE, V47, P196, DOI 10.1016/j.appet.2006.02.014
   Kerver JM, 2006, J AM DIET ASSOC, V106, P46, DOI 10.1016/j.jada.2005.09.045
   Mazlan N, 2006, PHYSIOL BEHAV, V87, P679, DOI 10.1016/j.physbeh.2006.01.032
   Neuhouser ML, 2000, J AM DIET ASSOC, V100, P576, DOI 10.1016/S0002-8223(00)00176-0
   Nicklas TA, 1998, AM J CLIN NUTR, V67, P757S, DOI 10.1093/ajcn/67.4.757S
   Ovaskainen ML, 2006, EUR J CLIN NUTR, V60, P494, DOI 10.1038/sj.ejcn.1602343
   Roos E, 1997, APPETITE, V29, P11, DOI 10.1006/appe.1996.0095
   SCHLETTWEINGSELD, 1996, EUROPEAN J CLIN N S2, V50, P56
   Sjöberg A, 2003, EUR J CLIN NUTR, V57, P1569, DOI 10.1038/sj.ejcn.1601726
   SUMMERBELL CD, 1995, EUR J CLIN NUTR, V49, P33
   Wahlqvist ML, 1999, APPETITE, V32, P23, DOI 10.1006/appe.1998.0192
   Wang ZH, 2008, ASIA PAC J CLIN NUTR, V17, P123
   Zizza C, 2001, PREV MED, V32, P303, DOI 10.1006/pmed.2000.0817
   Zizza CA, 2007, J AM DIET ASSOC, V107, P800, DOI 10.1016/j.jada.2007.02.002
NR 31
TC 13
Z9 14
U1 0
U2 10
PU KOREAN NUTRITION SOC
PI SEOUL
PA 804 KST CTR, 635-4 YEOGSAM-SONG KANGNAM-KU, SEOUL, 135-703, SOUTH KOREA
SN 1976-1457
EI 2005-6168
J9 NUTR RES PRACT
JI Nutr. Res. Pract.
PD FEB 15
PY 2010
VL 4
IS 1
BP 43
EP 50
DI 10.4162/nrp.2010.4.1.43
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 562BS
UT WOS:000275024700007
PM 20198208
DA 2025-04-28
ER

PT J
AU Buscemi, S
   Verga, S
   Batsis, JA
   Donatelli, M
   Tranchina, MR
   Belmonte, S
   Mattina, A
   Re, A
   Cerasola, G
AF Buscemi, S.
   Verga, S.
   Batsis, J. A.
   Donatelli, M.
   Tranchina, M. R.
   Belmonte, S.
   Mattina, A.
   Re, A.
   Cerasola, G.
TI Acute effects of coffee on endothelial function in healthy subjects
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE coffee; endothelial function; FMD; insulin
ID coronary-artery-disease; flow-mediated vasodilation; cardiovascular events; tea consumption; myocardial-infarction; mediterranean diet; insulin-resistance; carbohydrate diet; chlorogenic acid; blood-pressure
AB Background/Objectives: Coffee is the most widely consumed beverage in the world, but its effect on the cardiovascular system has not been fully understood. Coffee contains caffeine and antioxidants, which may influence endothelial function, both of which have not yet been investigated. The objective of this study was to investigate the acute effects of coffee on endothelial function measured by brachial artery flow-mediated dilation (FMD). Subjects/Methods: A total of 20 (10 males and 10 females) healthy non-obese subjects underwent a double-blind, crossover study. Subjects ingested one cup of caffeinated (CC) and one cup of decaffeinated (DC) Italian espresso coffee in random order at 5- to 7-day intervals. Results: Following CC ingestion, FMD decreased progressively and significantly (mean +/- s.e.m.: 0 min, 7.7 +/- 0.6; 30 min, 6.3 +/- 0.7; 60 min, 6.0 +/- 0.8%; ANOVA (analysis of variance), P<0.05), but it did not significantly increase after DC ingestion (0 min, 6.9 +/- 0.6; 30 min, 8.1 +/- 0.9; 60 min, 8.5 +/- 0.9%; P = 0.115). Similarly, CC significantly increased both systolic and diastolic blood pressure; this effect was not observed after DC ingestion. Blood glucose concentrations remained unchanged after ingestion of both CC and DC, but insulin (0 min, 15.8 +/- 0.9; 60 min, 15.0 +/- 0.8 mu U/ml; P<0.05) and C-peptide (0 min, 1.25 +/- 0.09; 60 min, 1.18 +/- 0.09 ng/ml; P<0.01) blood concentrations decreased significantly only after CC ingestion. Conclusions: CC acutely induced unfavorable cardiovascular effects, especially on endothelial function. In the fasting state, insulin secretion is also likely reduced after CC ingestion. Future studies will determine whether CC has detrimental clinically relevant effects, especially in unhealthy subjects. European Journal of Clinical Nutrition (2010) 64, 483-489; doi:10.1038/ejcn.2010.9; published online 3 February 2010
C1 [Buscemi, S.] Univ Palermo, Dipartimento Med Interna Malattie Cardiovasc & Ne, Fac Med, Policlin P Giaccone, I-90127 Palermo, Italy.
   [Batsis, J. A.] Dartmouth Hitchcock Med Ctr, Gen Internal Med Sect, Lebanon, NH 03766 USA.
   [Donatelli, M.] Univ Palermo, Fac Med, Dipartimento Biomed Med Interna & Specialist, I-90127 Palermo, Italy.
C3 University of Palermo; Dartmouth College; University of Palermo
RP Buscemi, S (corresponding author), Univ Palermo, Dipartimento Med Interna Malattie Cardiovasc & Ne, Fac Med, Policlin P Giaccone, Via Vespro 129, I-90127 Palermo, Italy.
EM silbus@tin.it
FU Italian Ministry of Education; Associazione Onlus Nutrizione e Salute, Italy
CR Alexopoulos N, 2008, EUR J CARDIOV PREV R, V15, P300, DOI 10.1097/HJR.0b013e3282f4832f
   Barac A, 2007, HYPERTENSION, V49, P748, DOI 10.1161/01.HYP.0000259601.38807.a6
   Bonita JS, 2007, PHARMACOL RES, V55, P187, DOI 10.1016/j.phrs.2007.01.006
   Buscemi S, 2009, EUR J CLIN NUTR, V63, P1200, DOI 10.1038/ejcn.2009.51
   Buscemi S, 2009, EUR J CLIN INVEST, V39, P339, DOI 10.1111/j.1365-2362.2009.02091.x
   Buus NH, 2007, BLOOD PRESSURE, V16, P106, DOI 10.1080/08037050701343688
   CASIGLIA E, 1991, J INTERN MED, V229, P501, DOI 10.1111/j.1365-2796.1991.tb00385.x
   Cornelis MC, 2006, JAMA-J AM MED ASSOC, V295, P1135, DOI 10.1001/jama.295.10.1135
   Corretti MC, 2002, J AM COLL CARDIOL, V39, P257, DOI 10.1016/S0735-1097(01)01746-6
   Corti R, 2002, CIRCULATION, V106, P2935, DOI 10.1161/01.CIR.0000046228.97025.3A
   Daglia M, 2000, J AGR FOOD CHEM, V48, P1449, DOI 10.1021/jf990510g
   Deanfield JE, 2007, CIRCULATION, V115, P1285, DOI 10.1161/CIRCULATIONAHA.106.652859
   Duffy SJ, 2001, CIRCULATION, V104, P151, DOI 10.1161/01.CIR.104.2.151
   Esposito K, 2003, AM J CLIN NUTR, V77, P139, DOI 10.1093/ajcn/77.1.139
   Frary CD, 2005, J AM DIET ASSOC, V105, P110, DOI 10.1016/j.jada.2004.10.027
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Fujioka K, 2008, FOOD CHEM, V106, P217, DOI 10.1016/j.foodchem.2007.05.091
   FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0
   Gokce N, 2002, CIRCULATION, V105, P1567, DOI 10.1161/01.CIR.0000012543.55874.47
   Grassi D, 2008, J NUTR, V138, P1671, DOI 10.1093/jn/138.9.1671
   Greenberg JA, 2006, AM J CLIN NUTR, V84, P682, DOI 10.1093/ajcn/84.4.682
   Hamdy O, 2003, DIABETES CARE, V26, P2119, DOI 10.2337/diacare.26.7.2119
   Keogh JB, 2005, ARTERIOSCL THROM VAS, V25, P1274, DOI 10.1161/01.ATV.0000163185.28245.a1
   Kitta Y, 2009, J AM COLL CARDIOL, V53, P323, DOI 10.1016/j.jacc.2008.08.074
   Klatsky AL, 2008, AM J CARDIOL, V101, P825, DOI 10.1016/j.amjcard.2007.11.022
   Lane JD, 2008, DIABETES CARE, V31, P221, DOI 10.2337/dc07-1112
   Larsson SC, 2008, STROKE, V39, P1681, DOI 10.1161/STROKEAHA.107.504183
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Lopez-Garcia E, 2006, AM J CLIN NUTR, V84, P888, DOI 10.1093/ajcn/84.4.888
   Mäki-Petäjä KM, 2007, J AM COLL CARDIOL, V50, P852, DOI 10.1016/j.jacc.2007.04.076
   Mahmud A, 2001, HYPERTENSION, V38, P227, DOI 10.1161/01.HYP.38.2.227
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Moens AL, 2005, CHEST, V127, P2254, DOI 10.1378/chest.127.6.2254
   Moisey LL, 2008, AM J CLIN NUTR, V87, P1254, DOI 10.1093/ajcn/87.5.1254
   Nurminen ML, 1999, EUR J CLIN NUTR, V53, P831, DOI 10.1038/sj.ejcn.1600899
   Odegaard AO, 2008, AM J CLIN NUTR, V88, P979, DOI 10.1093/ajcn/88.4.979
   Papamichael CM, 2005, CLIN SCI, V109, P55, DOI 10.1042/CS20040358
   Riksen NP, 2009, PHARMACOL THERAPEUT, V121, P185, DOI 10.1016/j.pharmthera.2008.10.006
   Rossi R, 2008, J AM COLL CARDIOL, V51, P997, DOI 10.1016/j.jacc.2007.11.044
   Shimabukuro M, 2007, AM J CLIN NUTR, V86, P923, DOI 10.1093/ajcn/86.4.923
   Silletta MG, 2007, CIRCULATION, V116, P2944, DOI 10.1161/CIRCULATIONAHA.107.712976
   Suzuki A, 2006, J HYPERTENS, V24, P1065, DOI 10.1097/01.hjh.0000226196.67052.c0
   van Woudenbergh GJ, 2008, ARTERIOSCL THROM VAS, V28, P1018, DOI 10.1161/ATVBAHA.107.160457
   VANDAM RM, 2008, JAMA-J AM MED ASSOC, V294, P97
   VERGA S, 1994, ACTA DIABETOL, V31, P47, DOI 10.1007/BF00580761
   Vogel RA, 2000, J AM COLL CARDIOL, V36, P1455, DOI 10.1016/S0735-1097(00)00896-2
   WHITSETT TL, 1984, AM J CARDIOL, V53, P918, DOI 10.1016/0002-9149(84)90525-3
   Widlansky ME, 2003, J AM COLL CARDIOL, V42, P1149, DOI 10.1016/S0735-1097(03)00994-X
   Wu GY, 2002, ANNU REV NUTR, V22, P61, DOI 10.1146/annurev.nutr.22.110901.145329
   Yeboah J, 2007, CIRCULATION, V115, P2390, DOI 10.1161/CIRCULATIONAHA.106.678276
   Zampelas A, 2004, AM J CLIN NUTR, V80, P862, DOI 10.1093/ajcn/80.4.862
NR 51
TC 82
Z9 87
U1 0
U2 19
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
EI 1476-5640
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD MAY 15
PY 2010
VL 64
IS 5
BP 483
EP 489
DI 10.1038/ejcn.2010.9
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 591VJ
UT WOS:000277332800007
PM 20125186
DA 2025-04-28
ER

PT J
AU Wang, HQ
   Wen, YB
   Du, YP
   Yan, XY
   Guo, HW
   Rycroft, JA
   Boon, N
   Kovacs, EMR
   Mela, DJ
AF Wang, Hongqiang
   Wen, Yibo
   Du, Yaping
   Yan, Xiuyuan
   Guo, Hongwei
   Rycroft, Jane A.
   Boon, Niels
   Kovacs, Eva M. R.
   Mela, David J.
TI Effects of Catechin Enriched Green Tea on Body Composition
SO OBESITY
LA English
DT Article
ID diet-induced obesity; fat oxidation; energy-expenditure; weight maintenance; blood-pressure; abdominal fat; extract; caffeine; exercise; reduction
AB Obesity is a major health problem in the developed and developing world. Many "functional" foods and ingredients are advocated for their effects on body composition but few have consistent scientific support for their efficacy. However, an increasing amount of mechanistic and clinical evidence is building for green tea (GT). This experiment was therefore undertaken to study the effects of a high-catechin GT on body composition in a moderately overweight Chinese population. In a randomized placebo-controlled trial, 182 moderately overweight Chinese subjects, consumed either two servings of a control drink (C; 30 mg catechins, 10 mg caffeine/day), one serving of the control drink and one serving of an extra high-catechin GT1 (458 mg catechins, 104 mg caffeine/day), two servings of a high-catechin GT2 (468 mg catechins, 126 mg caffeine/day) or two servings of the extra high-catechin GT3 (886 mg catechins, 198 mg caffeine/day) for 90 days. Data were collected at 0, 30, 60, and 90 days. We observed a decrease in estimated intra-abdominal fat (IAF) area of 5.6 cm(2) in the GT3 group. In addition, we found decreases of 1.9 cm in waist circumference and 1.2 kg body weight in the GT3 group vs. C (P < 0.05). We also observed reductions in total body fat (GT2, 0.7 kg, P < 0.05) and body fat % (GT1, 0.6%, P < 0.05). We conclude that consumption of two servings of an extra high-catechin GT leads to improvements in body composition and reduces abdominal fatness in moderately overweight Chinese subjects.
C1 [Boon, Niels; Kovacs, Eva M. R.; Mela, David J.] Unilever Res Labs, Vlaardingen, Netherlands.
   [Wang, Hongqiang; Wen, Yibo; Du, Yaping; Yan, Xiuyuan] Unilever R&D, Shanghai, Peoples R China.
   [Guo, Hongwei] Fudan Univ, Shanghai Med Sch, Shanghai 200433, Peoples R China.
   [Rycroft, Jane A.] Lipton Inst Tea, Sharnbrook, Beds, England.
C3 Unilever; Unilever; Fudan University
RP Boon, N (corresponding author), Unilever Res Labs, Vlaardingen, Netherlands.
EM niels.boon@unilever.com
FU Lipton Institute of Tea
CR Astill C, 2001, J AGR FOOD CHEM, V49, P5340, DOI 10.1021/jf010759+
   Auvichayapat P, 2008, PHYSIOL BEHAV, V93, P486, DOI 10.1016/j.physbeh.2007.10.009
   Cabrera C, 2006, J AM COLL NUTR, V25, P79, DOI 10.1080/07315724.2006.10719518
   Després JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488
   Diepvens K, 2006, PHYSIOL BEHAV, V87, P185, DOI 10.1016/j.physbeh.2005.09.013
   Diepvens K, 2007, AM J PHYSIOL-REG I, V292, PR77, DOI 10.1152/ajpregu.00832.2005
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   Harada U, 2005, J HEALTH SCI, V51, P248, DOI 10.1248/jhs.51.248
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   Hill AM, 2007, J AM COLL NUTR, V26, P396S, DOI 10.1080/07315724.2007.10719628
   Hodgson JM, 2006, CLIN EXP PHARMACOL P, V33, P838, DOI 10.1111/j.1440-1681.2006.04450.x
   Hsu CH, 2008, CLIN NUTR, V27, P363, DOI 10.1016/j.clnu.2008.03.007
   Hsu TF, 2006, EUR J CLIN NUTR, V60, P1330, DOI 10.1038/sj.ejcn.1602464
   Ikeda I, 2005, J NUTR, V135, P155, DOI 10.1093/jn/135.2.155
   Kajimoto O, 2005, J HEALTH SCI, V51, P161, DOI 10.1248/jhs.51.161
   Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109
   Kataoka K, 2004, PROGRESS IN MEDICINE, V24, P3358
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   Kovacs EMR, 2006, OBES REV, V7, P59, DOI 10.1111/j.1467-789X.2006.00203.x
   LIVINGSTONE MBE, 1995, BRIT J BIOMED SCI, V52, P58
   Maki KC, 2009, J NUTR, V139, P264, DOI 10.3945/jn.108.098293
   Manach C, 2005, AM J CLIN NUTR, V81, P230S, DOI 10.1093/ajcn/81.1.230S
   Matsuyama T, 2008, OBESITY, V16, P1338, DOI 10.1038/oby.2008.60
   Murase T, 2006, AM J PHYSIOL-REG I, V290, PR1550, DOI 10.1152/ajpregu.00752.2005
   Murase T, 2006, INT J OBESITY, V30, P561, DOI 10.1038/sj.ijo.0803135
   Murase T, 2005, AM J PHYSIOL-REG I, V288, PR708, DOI 10.1152/ajpregu.00693.2004
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nagao T, 2001, JOURNAL OF OLEO SCIENCE, V50, P717
   Nagao T, 2007, OBESITY, V15, P1473, DOI 10.1038/oby.2007.176
   Noakes M, 2008, ASIA PAC J CLIN NUTR, V17, P169
   Ota N, 2005, J HEALTH SCI, V51, P233, DOI 10.1248/jhs.51.233
   Raederstorff DG, 2003, J NUTR BIOCHEM, V14, P326, DOI 10.1016/S0955-2863(03)00054-8
   Rudelle S, 2007, OBESITY, V15, P349, DOI 10.1038/oby.2007.529
   SARIS WHM, 1995, INT J OBESITY, V19, P0
   Shimotoyodome A, 2005, MED SCI SPORT EXER, V37, P1884, DOI 10.1249/01.mss.0000178062.66981.a8
   Takashima S, 2004, PROGRESS IN MEDICINE, V24, P3371
   TREUTH MS, 1995, AM J CLIN NUTR, V62, P527, DOI 10.1093/ajcn/62.3.527
   TSUCHIDA T, 2002, PROGR MED, V22, P2189
   Van Amelsvoort JMM, 2001, XENOBIOTICA, V31, P891, DOI 10.1080/00498250110079149
   Venables MC, 2008, AM J CLIN NUTR, V87, P778, DOI 10.1093/ajcn/87.3.778
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   World Health Organization-Regional Office for the Western Pacific, 2000, THE ASIA-PACIFIC PERSPECTIVE: REDEFINING OBESITY AND ITS TREATMENT, V0, P0
NR 46
TC 134
Z9 146
U1 2
U2 61
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD APR 15
PY 2010
VL 18
IS 4
BP 773
EP 779
DI 10.1038/oby.2009.256
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 583HR
UT WOS:000276665200021
PM 19680234
DA 2025-04-28
ER

PT J
AU Marques-Vidal, P
   Bochud, M
   Paccaud, F
   Mooser, V
   Waeber, G
   Vollenweider, P
AF Marques-Vidal, Pedro
   Bochud, Murielle
   Paccaud, Fred
   Mooser, Vincent
   Waeber, Gerard
   Vollenweider, Peter
TI Distribution of plasma levels of adiponectin and leptin in an adult Caucasian population
SO CLINICAL ENDOCRINOLOGY
LA English
DT Article
ID cardiovascular risk-factors; body-fat; cigarette-smoking; life-style; insulin sensitivity; dietary factors; normal-weight; association; women; obesity
AB P>Objectives Little is known regarding the distribution and the determinants of leptin and adiponectin levels in the general population. Design Cross-sectional study. Patients Women (3004) and men (2552) aged 35-74 living in Lausanne, Switzerland. Measurements Plasma levels of leptin and adiponectin (ELISA measurement). Results Women had higher leptin and adiponectin levels than men. In both genders, leptin and adiponectin levels increased with age. After adjusting for fat mass, leptin levels were significantly and negatively associated with age in women: 18 center dot 1 +/- 0 center dot 3, 17 center dot 1 +/- 0 center dot 3, 16 center dot 7 +/- 0 center dot 3 and 15 center dot 5 +/- 0 center dot 4 ng/ml (adjusted mean +/- SE) for age groups [35-44], [45-54], [55-64] and [65-75], respectively, P < 0 center dot 001. A similar but nonsignificant trend was also found in men. Conversely, the age-related increase of adiponectin was unrelated to body fat in both genders. Post-menopausal women had higher leptin and adiponectin levels than premenopausal women, independently of hormone replacement therapy. Although body fat mass was associated with leptin and adiponectin, the associations were stronger with body mass index (BMI), waist and hip in both genders. Finally, after adjusting for age and anthropometry, no relationships were found between leptin or adiponectin levels with alcohol, caffeine consumption and physical activity, whereas smoking and diabetes decreased leptin and adiponectin levels in women only. Conclusions The age-related increase in leptin levels is attributable to changes in fat mass in women and probably also in men. Leptin and adiponectin levels are more related to BMI than to body fat mass. The effects of smoking and diabetes appear to be gender-specific.
C1 [Marques-Vidal, Pedro] Univ Lausanne, Ctr Cardiovasc & Metab Res Cardiomet, CH-1015 Lausanne, Switzerland.
   [Marques-Vidal, Pedro; Bochud, Murielle; Paccaud, Fred] Univ Lausanne, Inst Social & Prevent Med IUMSP, CH-1015 Lausanne, Switzerland.
   [Mooser, Vincent] GlaxoSmithKline, Div Genet, Philadelphia, PA USA.
   [Waeber, Gerard; Vollenweider, Peter] CHU Vaudois, Dept Med, CH-1005 Lausanne, Switzerland.
C3 University of Lausanne; University of Lausanne; GlaxoSmithKline; Glaxosmithkline USA; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)
RP Marques-Vidal, P (corresponding author), CHU Vaudois, Inst Social & Prevent Med IUMSP, Bugnon 17, CH-1005 Lausanne, Switzerland.
EM Pedro-Manuel.Marques-Vidal@chuv.ch
FU GlaxoSmithKline; Faculty of Biology and Medicine of Lausanne, Switzerland; Fonds National Suisse de la recherche [33CSCO-122661]; Swiss National Foundation for Science [111362/1, 11361/1]
CR Chiesa C, 2008, CLIN CHEM, V54, P550, DOI 10.1373/clinchem.2007.095299
   Chu NF, 2001, INT J OBESITY, V25, P106, DOI 10.1038/sj.ijo.0801468
   Cnop M, 2003, DIABETOLOGIA, V46, P459, DOI 10.1007/s00125-003-1074-z
   Donahue RP, 1999, ANN EPIDEMIOL, V9, P108, DOI 10.1016/S1047-2797(98)00037-4
   Dufour MC, 1999, ALCOHOL RES HEALTH, V23, P5
   Firmann M, 2008, BMC CARDIOVASC DISOR, V8, P0, DOI 10.1186/1471-2261-8-6
   Fruehwald-Schultes B, 2002, METABOLISM, V51, P531, DOI 10.1053/meta.2002.31332
   Gable DR, 2007, ANN HUM GENET, V71, P453, DOI 10.1111/j.1469-1809.2006.00340.x
   Galea S, 2007, ANN EPIDEMIOL, V17, P643, DOI 10.1016/j.annepidem.2007.03.013
   Hart CL, 1999, BMJ-BRIT MED J, V318, P1725, DOI 10.1136/bmj.318.7200.1725
   Hughes VA, 2004, AM J CLIN NUTR, V80, P475, DOI 10.1093/ajcn/80.2.475
   Im JA, 2006, MATURITAS, V54, P65, DOI 10.1016/j.maturitas.2005.08.008
   Isidori AM, 2000, J CLIN ENDOCR METAB, V85, P1954, DOI 10.1210/jc.85.5.1954
   Iwashima Y, 2005, HYPERTENSION, V45, P1094, DOI 10.1161/01.HYP.0000169444.05588.4c
   Kennedy A, 1997, J CLIN ENDOCR METAB, V82, P1293, DOI 10.1210/jc.82.4.1293
   Kim OY, 2006, CLIN CHIM ACTA, V370, P63, DOI 10.1016/j.cca.2006.01.021
   Koh SJ, 2008, CLIN CHIM ACTA, V389, P45, DOI 10.1016/j.cca.2007.11.017
   Kotani K, 2007, ARCH MED RES, V38, P887, DOI 10.1016/j.arcmed.2007.06.008
   Kutner MH, 2004, APPLIED LINEAR REGRESSION MODELS, V4, P0
   Kwon K, 2005, INT J CARDIOL, V101, P385, DOI 10.1016/j.ijcard.2004.03.050
   Lagiou P, 1999, ANN NUTR METAB, V43, P23, DOI 10.1159/000012763
   LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158
   Lee HJ, 2006, NEUROSCI LETT, V409, P47, DOI 10.1016/j.neulet.2006.09.013
   Manigrasso MR, 2005, J CLIN ENDOCR METAB, V90, P5876, DOI 10.1210/jc.2005-0281
   Marques-Vidal P, 2001, ATHEROSCLEROSIS, V157, P431, DOI 10.1016/S0021-9150(00)00734-6
   Marshall JA, 2000, OBES RES, V8, P543, DOI 10.1038/oby.2000.70
   Martin LJ, 2003, INT J OBESITY, V27, P334, DOI 10.1038/sj.ijo.0802232
   Miller GD, 2001, NUTRITION, V17, P105, DOI 10.1016/S0899-9007(00)00511-6
   Miyata G, 2000, NUTRITION, V16, P141, DOI 10.1016/S0899-9007(99)00223-3
   Morton GJ, 2007, J PHYSIOL-LONDON, V583, P437, DOI 10.1113/jphysiol.2007.135590
   Panarotto D, 2000, METABOLISM, V49, P1055, DOI 10.1053/meta.2000.7745
   Pischon T, 2005, AM J CLIN NUTR, V81, P780, DOI 10.1093/ajcn/81.4.780
   Reseland JE, 2005, PROSTAG LEUKOTR ESS, V73, P43, DOI 10.1016/j.plefa.2005.04.006
   Rokling-Andersen MH, 2007, AM J CLIN NUTR, V86, P1293, DOI 10.1093/ajcn/86.5.1293
   Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424
   Ruhl CE, 2001, AM J CLIN NUTR, V74, P295
   Salas-Salvadó J, 2007, METABOLISM, V56, P1486, DOI 10.1016/j.metabol.2007.06.014
   Sandhu MS, 2008, LANCET, V371, P483, DOI 10.1016/S0140-6736(08)60208-1
   Santos JL, 2006, EUR J NUTR, V45, P454, DOI 10.1007/s00394-006-0619-6
   Sieminska L, 2005, METABOLISM, V54, P1610, DOI 10.1016/j.metabol.2005.06.008
   Soares MJ, 2000, INT J OBESITY, V24, P1592, DOI 10.1038/sj.ijo.0801450
   Sowers MR, 2008, MATURITAS, V59, P149, DOI 10.1016/j.maturitas.2007.12.006
   Wang ZH, 2007, ENDOCRINOLOGY, V148, P2845, DOI 10.1210/en.2006-1313
   WARWICK PM, 1993, EUR J CLIN NUTR, V47, P600
   Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930
   Williams CJ, 2008, DIABETES CARE, V31, P504, DOI 10.2337/dc07-1952
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984
NR 47
TC 39
Z9 40
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-0664
EI 1365-2265
J9 CLIN ENDOCRINOL
JI Clin. Endocrinol.
PD JAN 15
PY 2010
VL 72
IS 1
BP 38
EP 46
DI 10.1111/j.1365-2265.2009.03628.x
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 532SX
UT WOS:000272771200008
PM 19473178
DA 2025-04-28
ER

PT J
AU Bouchard, DR
   Ross, R
   Janssen, I
AF Bouchard, Danielle R.
   Ross, Robert
   Janssen, Ian
TI Coffee, Tea and Their Additives: Association with BMI and Waist Circumference
SO OBESITY FACTS
LA English
DT Article
DE Obesity; Caffeine; Whitener; Sweetener
ID weight-loss; metabolic syndrome; life-style; long-term; body-fat; consumption; health; caffeine; risk; consequences
AB Objective: The purposes of this study were to perform a detailed analysis how: i) the frequency of coffee/tea consumption and ii) the use of additives in coffee/tea is associated with measures of total and abdominal obesity. Method: 3,823 participants of the 2003-2004 National Health and Nutrition Examination Survey were examined. Obesity was assessed by BMI and waist circumference (WC). Coffee and tea consumption and use of additives were assessed by questionnaire. Results: Coffee consumption was not related to BMI or WC in either gender. However, men who drank >= 2 cups of tea per day had lower BMI (25.9 vs. 28.0 kg/m(2)) and WC (95.2 vs. 101.32 cm) values than men who never drank drink tea (p <= 0.05). The associations between tea consumption and BMI or WC were no longer significant after adjustment for additive use. Coffee/tea drinkers who used artificial sweeteners had larger (p <= 0.05) BMIs than coffee/tea drinkers who did not use sweeteners (28.2 vs. 27.1 kg/m(2) in men, 28.4 vs. 27.1 kg/m(2) in women). Conclusion: Frequency of coffee/tea consumption was not associated with measures of obesity because additive use explained the association between tea consumption and obesity in men. Artificial sweetener use within coffee/tea was associated with higher BMI.
C1 [Bouchard, Danielle R.; Ross, Robert; Janssen, Ian] Queens Univ, Sch Kinesiol & Hlth Studies, Kingston, ON, Canada.
   [Janssen, Ian] Queens Univ, Dept Community Hlth Epidemiol, Kingston, ON, Canada.
C3 Queens University - Canada; Queens University - Canada
RP Bouchard, DR (corresponding author), Ctr Rech Etienne Lebel CHUS, 3001,12E Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.
EM Danielle.Bouchard@usherbrooke.ca
CR ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   Unknown -, 2008, USDA NAT NUTR DAT ST, V0, P0
   Balk L, 2009, EUR J EPIDEMIOL, V24, P203, DOI 10.1007/s10654-009-9323-1
   Barone JJ, 1996, FOOD CHEM TOXICOL, V34, P119, DOI 10.1016/0278-6915(95)00093-3
   BEERBORST S, 1995, Z ERNAHRUNGSWISS, V34, P183, DOI 10.1007/BF01623156
   Bellisle F, 2007, EUR J CLIN NUTR, V61, P691, DOI 10.1038/sj.ejcn.1602649
   Bellisle F, 2001, J HUM NUTR DIET, V14, P191, DOI 10.1046/j.1365-277X.2001.00289.x
   Bleich SN, 2009, AM J CLIN NUTR, V89, P372, DOI 10.3945/ajcn.2008.26883
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   Cameron AJ, 2009, MED J AUSTRALIA, V191, P202, DOI 10.5694/j.1326-5377.2009.tb02753.x
   Dellalibera O, 2006, PHYTOTHERAPIE (PARIS), V4, P194, DOI 10.1007/s10298-006-0181-7
   Egger G, 1999, MED J AUSTRALIA, V171, P604, DOI 10.5694/j.1326-5377.1999.tb123817.x
   Greenberg JA, 2005, INT J OBESITY, V29, P1121, DOI 10.1038/sj.ijo.0802999
   GREGERSEN NT, 2009, BR J NUTR, V0, P1
   GYNTELBERG F, 2009, INT J FOOD SCI NUTR, V0, P1
   Han LK, 1999, INT J OBESITY, V23, P98, DOI 10.1038/sj.ijo.0800766
   He RR, 2009, CHIN J INTEGR MED, V15, P34, DOI 10.1007/s11655-009-0034-8
   Higdon JV, 2006, CRIT REV FOOD SCI, V46, P101, DOI 10.1080/10408390500400009
   Hino A, 2007, DIABETES RES CLIN PR, V76, P383, DOI 10.1016/j.diabres.2006.09.033
   Ito Y, 2008, BIOMED RES-TOKYO, V29, P27, DOI 10.2220/biomedres.29.27
   Lee BL, 2000, J CHROMATOGR A, V881, P439, DOI 10.1016/S0021-9673(00)00215-6
   MONTERROSA AE, 1995, DIABETES CARE, V18, P448, DOI 10.2337/diacare.18.4.448
   Rosengren A, 2004, J INTERN MED, V255, P89, DOI 10.1046/j.1365-2796.2003.01260.x
   ROSS CE, 1994, J HEALTH SOC BEHAV, V35, P161, DOI 10.2307/2137363
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   Schneider C, 2009, AM FAM PHYSICIAN, V79, P591
   Serafini M, 2003, NATURE, V424, P1013, DOI 10.1038/4241013a
   Shields DH, 2004, J AM DIET ASSOC, V104, P650, DOI 10.1016/j.jada.2004.01.015
   Soriguer F, 2004, ANN INTERN MED, V141, P321, DOI 10.7326/0003-4819-141-4-200408170-00017
   Swithers SE, 2010, PHYSIOL BEHAV, V100, P55, DOI 10.1016/j.physbeh.2009.12.021
   Thom E, 2007, J INT MED RES, V35, P900, DOI 10.1177/147323000703500620
   Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   Westerterp-Plantenga M, 2006, PHYSIOL BEHAV, V89, P85, DOI 10.1016/j.physbeh.2006.01.027
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Wu CH, 2003, OBES RES, V11, P1088, DOI 10.1038/oby.2003.149
   Yang YC, 2004, ARCH INTERN MED, V164, P1534, DOI 10.1001/archinte.164.14.1534
NR 42
TC 53
Z9 56
U1 0
U2 42
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1662-4025
EI 1662-4033
J9 OBESITY FACTS
JI Obes. Facts
PD JUN 15
PY 2010
VL 3
IS 6
BP 345
EP 352
DI 10.1159/000322915
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 698HS
UT WOS:000285585500004
PM 21196787
DA 2025-04-28
ER

PT J
AU Al-Obaidi, H
   Afzal, M
AF Al-Obaidi, Hetham
   Afzal, Mohammad
TI Methylxanthine content in hot drinks consumed in the State of Kuwait
SO JOURNAL OF FOOD AGRICULTURE & ENVIRONMENT
LA English
DT Article
DE Tea; coffee; methylxanthine; caffeine; theophylline; theobromine; HPLC
ID green tea; kidney-stones; beverage use; black tea; caffeine; theobromine; obesity; risk; theophylline; adenosine
AB Apart from four major catechins present in Camellia sinensis (tea), four major methylxanthines are also present in tea aqueous extract. Caffeine with its structural similarity to uric acid is the predominant methylxanthine in tea and it is known to contribute to hypertension and obesity leading to diabetes. Caffeine intake from tea, soft drinks and candies may be contributing to high level of obesity and diabetes prevalent in Kuwait. There are a variety of hot drinks that are traditional to the culture of Kuwait and their caffeine content has not been established. In this study we have undertaken to establish caffeine content in traditional hot drinks used in Kuwait and have found that Arabic Gahwa, a very popular hot drink in Kuwait, has one of the lowest caffeine content among coffee drinks but its high frequency of consumption may have an additive effect on caffeine intake. Caffeine content of commercial brands and herbal teas used in Kuwait has also been established and found that Rabea black tea had the highest caffeine and theobromine content, while Red label black tea has the lowest caffeine. Reverse phase high performance liquid chromatography (HPLC) was used to establish methylxanthine content in different tea aqueous extracts. A comparison of caffeine content in various hot drinks is presented.
C1 [Afzal, Mohammad] Kuwait Univ, Fac Sci, Dept Biol Sci, Safat 13060, Kuwait.
   [Al-Obaidi, Hetham] Publ Author Appl Educ &Training, Coll Technol Studies, Dept Lab Technol Appl Sci, Kuwait, Kuwait.
C3 Kuwait University; Public Authority for Applied Education & Training (PAAET) - Kuwait
RP Afzal, M (corresponding author), Kuwait Univ, Fac Sci, Dept Biol Sci, POB 5969, Safat 13060, Kuwait.
EM afzalq8@gmail.com
CR ABERNETHY DR, 1985, BRIT J CLIN PHARMACO, V20, P61, DOI 10.1111/j.1365-2125.1985.tb02799.x
   Ahmad N, 1999, NUTR REV, V57, P78, DOI 10.1111/j.1753-4887.1999.tb06927.x
   Al-Kandari YY, 2006, OBES REV, V7, P147, DOI 10.1111/j.1467-789X.2006.00231.x
   ALAWADI F, 1989, J ROY SOC HEALTH, V109, P175, DOI 10.1177/146642408910900508
   Anderson RA, 2002, J AGR FOOD CHEM, V50, P7182, DOI 10.1021/jf020514c
   Bispo MS, 2002, J CHROMATOGR SCI, V40, P45, DOI 10.1093/chromsci/40.1.45
   BRENNER M, 1988, CLIN ALLERGY, V18, P143, DOI 10.1111/j.1365-2222.1988.tb02853.x
   BUTCHER RW, 1962, J BIOL CHEM, V237, P1244
   Cao J, 1996, FUND APPL TOXICOL, V29, P244, DOI 10.1006/faat.1996.0028
   Curhan GC, 1996, AM J EPIDEMIOL, V143, P240, DOI 10.1093/oxfordjournals.aje.a008734
   Curhan GC, 1998, ANN INTERN MED, V128, P534, DOI 10.7326/0003-4819-128-7-199804010-00003
   Fredholm BB, 2005, ANNU REV PHARMACOL, V45, P385, DOI 10.1146/annurev.pharmtox.45.120403.095731
   GENNARO MC, 1992, FRESEN J ANAL CHEM, V343, P523, DOI 10.1007/BF00322162
   GRYGIEL JJ, 1981, CLIN PHARMACOL THER, V30, P491, DOI 10.1038/clpt.1981.193
   Itoh Y, 2005, J UROLOGY, V173, P271, DOI 10.1097/01.ju.0000141311.51003.87
   JOAN L, 2006, J FOOD SCI, V48, P745
   KAMIMIRO GH, 1987, EUR J CLIN PHARMACOL, V31, P595, DOI 10.1007/BF00606637
   Khanchi AR, 2007, FOOD CHEM, V103, P1062, DOI 10.1016/j.foodchem.2006.07.035
   KIM RO, 2008, J NUTR, V38, P2111
   Miyagawa C, 1997, BIOSCI BIOTECH BIOCH, V61, P1901, DOI 10.1271/bbb.61.1901
   Pharn-Huy LAN, 2008, J FOOD AGRIC ENVIRON, V6, P6
   RAUCH G, 1986, METHOD FIND EXP CLIN, V8, P147
   Sai K, 1998, FOOD CHEM TOXICOL, V36, P1043, DOI 10.1016/S0278-6915(98)00073-8
   SCOTT LND, 1999, ALTERN MED REV, V4, P178
   SLATTERY ML, 1993, CANCER CAUSE CONTROL, V4, P559, DOI 10.1007/BF00052432
   SNYDER SH, 1981, P NATL ACAD SCI-BIOL, V78, P3260, DOI 10.1073/pnas.78.5.3260
   STUHLINGER W, 1980, SCHWEIZ MED WOCHENSC, V110, P380
   SUZUKI T, 1975, BIOCHEM J, V146, P87, DOI 10.1042/bj1460087
   TAHA TH, 1983, DIABETOLOGIA, V25, P306, DOI 10.1007/BF00253190
   Tiwari RP, 2005, INDIAN J MED RES, V122, P80
   van het Hof KH, 1998, EUR J CLIN NUTR, V52, P356, DOI 10.1038/sj.ejcn.1600568
   VASIL AV, 2004, PHARM CHEM J, V23, P776
   Vinson JA, 1998, FEBS LETT, V433, P44, DOI 10.1016/S0014-5793(98)00880-1
   Vinson JA, 2005, J AGR FOOD CHEM, V53, P3710, DOI 10.1021/jf048052l
   Winkelmayer WC, 2005, JAMA-J AM MED ASSOC, V294, P2330, DOI 10.1001/jama.294.18.2330
NR 35
TC 1
Z9 1
U1 0
U2 4
PU WFL PUBL
PI HELSINKI
PA MERI-RASTILANTIE 3 C, HELSINKI, FI-00980, FINLAND
SN 1459-0255
EI 1459-0263
J9 J FOOD AGRIC ENVIRON
JI J. Food Agric. Environ.
PD JAN 15
PY 2010
VL 8
IS 1
BP 41
EP 43
DI 
PG 3
WC Food Science & Technology
SC Food Science & Technology
GA 545JC
UT WOS:000273727300009
DA 2025-04-28
ER

PT J
AU Celec, P
   Behuliak, M
AF Celec, P.
   Behuliak, M.
TI Behavioural and endocrine effects of chronic cola intake
SO JOURNAL OF PSYCHOPHARMACOLOGY
LA English
DT Article
DE Coca cola; Kofola; oxidative stress; Pepsi cola; steroids
ID forced swimming test; exploratory-behavior; oxidative stress; caffeine; mice; beverages; rats; anxiety
AB Consumption of cola beverages is very high worldwide. The health effects of cola intake are not clear, although epidemiological studies point toward associations with obesity, kidney diseases and osteoporosis. Experimental studies are surprisingly rare. In this study, we substituted drinking water of adult male Wistar rats with three different cola beverages for 3 months. Behavioural phenotyping, measurement of sex steroids in plasma and oxidative stress in testes were performed at the end of the study. A light-dark box showed increased locomotor activity and anxiety in all groups with cola intake. A subtle anti-depressive effect was seen in the forced swim test. Chronic cola intake increased both oestradiol and testosterone levels suggesting an additional mechanism of action beyond the known effects of caffeine on adenosine receptors.
C1 [Celec, P.] Comenius Univ, Dept Mol Biol, Inst Mol Biomed, Bratislava 81108, Slovakia.
   [Celec, P.; Behuliak, M.] Comenius Univ, Inst Pathophysiol, Bratislava 81108, Slovakia.
C3 Comenius University Bratislava; Comenius University Bratislava
RP Celec, P (corresponding author), Comenius Univ, Dept Mol Biol, Inst Mol Biomed, Sasinkova 4, Bratislava 81108, Slovakia.
EM petercelec@gmail.com
CR Abrams JK, 2005, NEUROSCIENCE, V133, P983, DOI 10.1016/j.neuroscience.2005.03.025
   Aikey JL, 2002, HORM BEHAV, V42, P448, DOI 10.1006/hbeh.2002.1838
   Chou KH, 2007, J FOOD SCI, V72, PC337, DOI 10.1111/j.1750-3841.2007.00414.x
   CRAWLEY JN, 1985, NEUROSCI BIOBEHAV R, V9, P37, DOI 10.1016/0149-7634(85)90030-2
   El-Seweidy MM, 2008, J PHARM PHARMACOL, V60, P1237, DOI 10.1211/jpp.60.9.0017
   Enríquez-Castillo A, 2008, PHYSIOL BEHAV, V94, P501, DOI 10.1016/j.physbeh.2008.03.004
   Ettarh RR, 2000, PHARM BIOL, V38, P281, DOI 10.1076/1388-0209(200009)3841-AFT281
   Ferrini RL, 1996, AM J EPIDEMIOL, V144, P642, DOI 10.1093/oxfordjournals.aje.a008975
   Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965
   Hascoët M, 1998, PHARMACOL BIOCHEM BE, V60, P645, DOI 10.1016/S0091-3057(98)00031-8
   Iivonen S, 2006, NEUROSCIENCE, V137, P1143, DOI 10.1016/j.neuroscience.2005.10.023
   Kaur P, 2004, J BIOMED SCI, V11, P391, DOI 10.1159/000077108
   Malik VS, 2006, AM J CLIN NUTR, V84, P274
   NEHLIG A, 1992, BRAIN RES REV, V17, P139, DOI 10.1016/0165-0173(92)90012-B
   Pena A, 2005, FOOD ADDIT CONTAM, V22, P91, DOI 10.1080/02652030500037886
   POLLARD I, 1988, J ENDOCRINOL, V119, P275, DOI 10.1677/joe.0.1190275
   PORSOLT RD, 1978, EUR J PHARMACOL, V47, P379, DOI 10.1016/0014-2999(78)90118-8
   Vieira C, 2008, NEUROSCI LETT, V445, P170, DOI 10.1016/j.neulet.2008.09.001
NR 18
TC 15
Z9 18
U1 0
U2 30
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-8811
EI 
J9 J PSYCHOPHARMACOL
JI J. Psychopharmacol.
PD OCT 15
PY 2010
VL 24
IS 10
BP 1569
EP 1572
DI 10.1177/0269881109105401
PG 4
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 662PA
UT WOS:000282822500018
PM 19423611
DA 2025-04-28
ER

PT J
AU Bustanji, Y
   Issa, A
   Mohammad, M
   Hudaib, M
   Tawah, K
   Alkhatib, H
   Almasri, I
   Al-Khalidi, B
AF Bustanji, Yasser
   Issa, Ala
   Mohammad, Mohammad
   Hudaib, Mohammad
   Tawah, Khalid
   Alkhatib, Hatim
   Almasri, Ihab
   Al-Khalidi, Bashar
TI Inhibition of hormone sensitive lipase and pancreatic lipase by Rosmarinus officinalis extract and selected phenolic constituents
SO JOURNAL OF MEDICINAL PLANTS RESEARCH
LA English
DT Article
DE Rosmarinus officinalis; Rosemary; obesity; diabetes mellitus; pancreatic lipase; hormone sensitive lipase; phenolic compounds; rosmarinic acid
ID antioxidant activity; fat-cells; in-vitro; rosemary; acid; discovery; lipolysis; therapy; obesity; assays
AB Rosmarinus officinalis L. (Rosemary) has been long claimed to have hypogylcemic-hypolipidemic dual effects in folkloric medicine. In an effort to explain rosemary's claimed benefits, numerous published studies have investigated an array of pharmacologic activities of the plant including anti-inflammatory, anticarcinogenic and metabolic effects. The question remained, however, as how rosemary would target both plasma lipids and glucose levels simultaneously. A newer mechanism has been suggested, in which targeting the hormone sensitive lipase (HSL) would be the common link between the two metabolic effects. In fact, HSL has been extensively studied for its effects on the metabolic switch between glucose and free fatty acids (FFAs) as an energy source. The current manuscript summarizes a significant amount of work that was undertaken to identify plant species native to Jordan with potential HSL and pancreatic lipase (PL) inhibitory activities. Our results demonstrated in vitro inhibitory effects of R. officnalis on both HSL and PL in a dose dependent manner. Interestingly, the rosemary extract had an IC50 for PL that was several fold lower than the IC50 for HSL, indicating a higher affinity to the former enzyme (13.8 and 95.2 mu g/mL for PL and HSL, respectively). In addition, we have compared the inhibitory activities of purified constituents found in rosemary to the parent plant [ rosmarinic acid (RA), chlorogenic acid (CA), caffeic acid (CaA) and gallic acid (GA)]. Our results showed that all the tested compounds (RA, CA, CaA, and GA) were able to inhibit the PL and HSL activities in a dose dependent manner, but with different potencies. PL and HSL IC50 values were calculated for each compound and GA was found to be the most potent (IC50 10.1 and 14.5 for PL and HSL, respectively). Further work is necessary to determine whether our in vitro findings would correlate with the in vivo effects. Nonetheless, our results are a first step in fully understanding the long claimed hypoglycemic-hypolipidemic dual effects of rosemary. Simultaneous targeting of both HSL and PL is likely to open the door for a new era in our continuous battle against DM type 2 and its cardiovascular complications. Currently we are working on identifying the most active constituents of the plant to evaluate a structure-activity relationship which would pave the road for future therapeutic use.
C1 [Bustanji, Yasser; Issa, Ala; Mohammad, Mohammad; Hudaib, Mohammad; Tawah, Khalid; Alkhatib, Hatim; Al-Khalidi, Bashar] Univ Jordan, Dept Clin Pharm & Biopharmaceut, Fac Pharm, Amman 11942, Jordan.
   [Almasri, Ihab] Al Azhar Univ, Fac Pharm, Gaza, Gaza Strip, Israel.
C3 University of Jordan; Al Azhar University Gaza
RP Bustanji, Y (corresponding author), Univ Jordan, Dept Clin Pharm & Biopharmaceut, Fac Pharm, Amman 11942, Jordan.
EM bustanji@ju.edu.jo
FU Deanship of Scientific Research at the University of Jordan
CR Al-Sereiti MR, 1999, INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, V37, P124
   Anthonsen MW, 1999, PROG OBES R, V0, P89
   Bai NS, 2010, J AGR FOOD CHEM, V58, P5363, DOI 10.1021/jf100332w
   Bakirel T, 2008, J ETHNOPHARMACOL, V116, P64, DOI 10.1016/j.jep.2007.10.039
   BASSANI V, 1990, INT J PHARMACEUT, V63, P57, DOI 10.1016/0378-5173(90)90101-9
   Bergman RN, 2000, TRENDS ENDOCRIN MET, V11, P351, DOI 10.1016/S1043-2760(00)00323-4
   Birari RB, 2007, DRUG DISCOV TODAY, V12, P879, DOI 10.1016/j.drudis.2007.07.024
   BUSTANJI Y, 2010, JORDAN J PH IN PRESS, V0, P0
   Bustanji Y, 2010, J MED PLANT IN PRESS, V0, P0
   Cicero AFG, 2004, ACTA DIABETOL, V41, P91, DOI 10.1007/s00592-004-0150-2
   Dearlove RP, 2008, J MED FOOD, V11, P275, DOI 10.1089/jmf.2007.536
   Dipiro JT, 2007, PHARMACOTHERAPY PATH, V0, P0
   Dubois M, 2008, J MED CHEM, V51, P2575, DOI 10.1021/jm7011134
   El Deeb KS, 1993, B FAC PHARM, V31, P237
   Erenmemisoglu A, 1997, PHARMAZIE, V52, P645
   Erion DM, 2010, NAT MED, V16, P400, DOI 10.1038/nm0410-400
   Fabio A, 2007, PHYTOTHER RES, V21, P374, DOI 10.1002/ptr.1968
   Fazio G, 2010, CURR PHARM DESIGN, V16, P463, DOI 10.2174/138161210790232167
   Flex M, 2008, BIOCHEM SOC T, V36, P885, DOI 10.1042/BST0360885
   Furtado RA, 2010, J APPL TOXICOL, V30, P254, DOI 10.1002/jat.1491
   Gutiérrez R, 2010, PHYTOTHER RES, V24, P595, DOI 10.1002/ptr.2997
   Hadafi A, 1998, RIV ITAL EPPOS, V0, P325
   Harach T, 2010, PLANTA MED, V76, P566, DOI 10.1055/s-0029-1240612
   Hasani-Ranjbar Shirin, 2009, INFLAMMATION & ALLERGY DRUG TARGETS, V8, P2
   Herrero M, 2010, J CHROMATOGR A, V1217, P2512, DOI 10.1016/j.chroma.2009.11.032
   HOLM C, 1994, PROTEIN ENG, V7, P537, DOI 10.1093/protein/7.4.537
   Koga K, 2006, J FOOD SCI, V71, PS507, DOI 10.1111/j.1750-3841.2006.00125.x
   Lean MEJ, 2004, J DRUG EVAL, V2, P179
   LEE YP, 1993, BIOCHIM BIOPHYS ACTA, V1169, P156
   LOWE ME, 1989, J BIOL CHEM, V264, P20042
   McCue PP, 2004, ASIA PAC J CLIN NUTR, V13, P101
   Mohammad M, 2010, JORDAN JOURNAL OF PHARMACEUTICAL SCIENCES, V3, P69
   Mohammad MK, 2010, PHARM BIOL IN PRESS, V0, P0
   Moon DO, 2010, CANCER LETT, V288, P183, DOI 10.1016/j.canlet.2009.06.033
   Morimoto C, 1999, J BIOCHEM-TOKYO, V125, P976, DOI 10.1093/oxfordjournals.jbchem.a022377
   Nabekura T, 2010, PHARMACOL RES, V61, P259, DOI 10.1016/j.phrs.2009.11.010
   Nawroth PP, 2010, EXP CLIN ENDOCR DIAB, V118, P1, DOI 10.1055/s-0029-1246117
   Osterlund T, 2001, EUR J BIOCHEM, V268, P1899, DOI 10.1046/j.1432-1327.2001.02097.x
   Park SU, 2008, AFR J BIOTECHNOL, V7, P4959
   Petry S, 2005, J LIPID RES, V46, P603, DOI 10.1194/jlr.D400021-JLR200
   Pfeiffer AFH, 2007, HORM METAB RES, V39, P734, DOI 10.1055/s-2007-990271
   Rababah TM, 2004, J AGR FOOD CHEM, V52, P5183, DOI 10.1021/jf049645z
   Roberts DL, 2010, ANNU REV MED, V61, P301, DOI 10.1146/annurev.med.080708.082713
   RODBELL M, 1964, J BIOL CHEM, V239, P375
   Sanjust E, 2008, NAT PROD RES, V22, P689, DOI 10.1080/14786410801997125
   Scarpati M, 1958, RIC. SCI, V28, P2329
   Shetty K, 2007, FOOD SCIENCE AND TECHNOLOGY, V0, P187
   Sjöström L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4
   Slanc P, 2009, PHYTOTHER RES, V23, P874, DOI 10.1002/ptr.2718
   Smith GM, 1996, FEBS LETT, V396, P90, DOI 10.1016/0014-5793(96)01076-9
   Sotelo-Félix JI, 2002, EUR J GASTROEN HEPAT, V14, P1001, DOI 10.1097/00042737-200209000-00011
   Taha MO, 2008, J MED CHEM, V51, P6478, DOI 10.1021/jm800718k
   Takaki I, 2008, J MED FOOD, V11, P741, DOI 10.1089/jmf.2007.0524
   Vanithadevi B, 2008, INT J DIABETES METAB, V16, P35, DOI 10.1159/000497651
   Verger R, 1997, TRENDS BIOTECHNOL, V15, P32, DOI 10.1016/S0167-7799(96)10064-0
   Wang HF, 2004, FOOD CHEM, V87, P307, DOI 10.1016/j.foodchem.2003.12.029
   Wheatley D, 2004, HDB EXP PHARM, V157, P325
   Yamamoto H, 2005, LIPASE INHIBITOR CON, V0, P10
NR 58
TC 94
Z9 99
U1 1
U2 23
PU ACADEMIC JOURNALS
PI VICTORIA ISLAND
PA P O BOX 5170-00200 NAIROBI, VICTORIA ISLAND, LAGOS 73023, NIGERIA
SN 1996-0875
EI 
J9 J MED PLANTS RES
JI J. Med. Plants Res.
PD NOV 4
PY 2010
VL 4
IS 21
BP 2235
EP 2242
DI 
PG 8
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 699UY
UT WOS:000285689600011
DA 2025-04-28
ER

PT J
AU Almoosawi, S
   Fyfe, L
   Ho, C
   Al-Dujaili, E
AF Almoosawi, Suzana
   Fyfe, Lorna
   Ho, Clement
   Al-Dujaili, Emad
TI The effect of polyphenol-rich dark chocolate on fasting capillary whole blood glucose, total cholesterol, blood pressure and glucocorticoids in healthy overweight and obese subjects
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Dark chocolate; Glucose; Blood pressure; Cholesterol; Glucocorticoids; Obesity
ID body-mass index; urinary free cortisol; metabolic-syndrome; chlorogenic acid; 11-beta-hydroxysteroid dehydrogenase; insulin sensitivity; nitric-oxide; intermediate phenotype; dependent vasodilation; essential-hypertension
AB Numerous studies indicate that polyphenol-rich chocolate reduces fasting blood glucose, blood pressure (BP) and total cholesterol in healthy individuals and hypertensives with or without glucose intolerance. The aim of the present study was to investigate the effect of two doses of polyphenol-rich dark chocolate (DC) on fasting capillary whole blood glucose, total cholesterol and BP and to examine whether improvements in these parameters are associated with changes in adrenocorticoid excretion in overweight and obese individuals. The study used a randomised, single-blind, cross-over design where fourteen overweight and obese subjects were randomised to either take 20 g DC with 500 mg polyphenols then 20 g DC with 1000 mg polyphenols or vice-versa. Participants followed each diet for 2 weeks separated by a 1-week washout period. It was observed that the 500 mg polyphenol dose was equally effective in reducing fasting blood glucose levels, systolic BP (SBP) and diastolic BP (DBP) as the 1000 mg polyphenol dose suggesting that a saturation effect might occur with increasing dose of polyphenols. There was also a trend towards a reduction in urinary free cortisone levels with both groups although it did not reach statistical significance. No changes in anthropometrical measurements were seen. We suggest that more research is required to investigate the mechanism(s) by which polyphenol-rich foods influence health.
C1 [Almoosawi, Suzana; Fyfe, Lorna; Al-Dujaili, Emad] Queen Margaret Univ, Dept Dietet Nutr & Biol Sci, Musselburgh EH21 6UU, Scotland.
   [Ho, Clement] Royal Infirm Edinburgh NHS Trust, Dept Clin Biochem, Edinburgh EH16 4SA, Midlothian, Scotland.
C3 Queen Margaret University; University of Edinburgh; Royal Infirmary of Edinburgh
RP Al-Dujaili, E (corresponding author), Queen Margaret Univ, Dept Dietet Nutr & Biol Sci, Queen Margaret Dr, Musselburgh EH21 6UU, Scotland.
EM ealdujaili@qmu.ac.uk
CR Al-Dujaili EAS, 2006, CLIN CHIM ACTA, V364, P172, DOI 10.1016/j.cccn.2005.06.019
   Alberti L, 2007, INT J OBESITY, V31, P1826, DOI 10.1038/sj.ijo.0803677
   ALDUJAILI EAS, 2005, END ABSTR, V10, P75
   Unknown -, 2000, WHO TECHN REP SER, V0, P0
   Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874
   Balzer J, 2008, J AM COLL CARDIOL, V51, P2141, DOI 10.1016/j.jacc.2008.01.059
   Bayard Vicente, 2007, INT J MED SCI, V4, P53
   Bjelakovic G, 2007, J BASIC CLIN PHYSIOL PHARMACOL, V18, P115
   BOUCHARD C, 1983, AM J CLIN NUTR, V37, P461, DOI 10.1093/ajcn/37.3.461
   Buijsse B, 2006, ARCH INTERN MED, V166, P411, DOI 10.1001/.411
   Chamarthi B, 2007, J CLIN ENDOCR METAB, V92, P1340, DOI 10.1210/jc.2006-2093
   Counet C, 2004, J AGR FOOD CHEM, V52, P6243, DOI 10.1021/jf040105b
   Davison K, 2008, INT J OBESITY, V32, P1289, DOI 10.1038/ijo.2008.66
   Ding EL, 2006, NUTR METAB, V3, P0, DOI 10.1186/1743-7075-3-2
   Duclos M, 2005, OBES RES, V13, P1157, DOI 10.1038/oby.2005.137
   Faridi Z, 2008, AM J CLIN NUTR, V88, P58, DOI 10.1093/ajcn/88.1.58
   Farin HMF, 2006, AM J CLIN NUTR, V83, P47
   Fisher NDL, 2003, J HYPERTENS, V21, P2281, DOI 10.1097/00004872-200312000-00016
   Ford ES, 2007, OBESITY, V15, P1139, DOI 10.1038/oby.2007.628
   Fraga Cesar G, 2005, CLIN DEV IMMUNOL, V12, P11, DOI 10.1080/10446670410001722159
   Fraser R, 1999, HYPERTENSION, V33, P1364, DOI 10.1161/01.HYP.33.6.1364
   Fuchs FD, 2005, OBES RES, V13, P1515, DOI 10.1038/oby.2005.184
   Grahame-Smith DG, 2002, OXFORD TXB CLIN PHAR, V0, P0
   Grassi D, 2005, HYPERTENSION, V46, P398, DOI 10.1161/01.HYP.0000174990.46027.70
   Grassi D, 2005, AM J CLIN NUTR, V81, P611
   Grassi D, 2008, J NUTR, V138, P1671, DOI 10.1093/jn/138.9.1671
   Guo J, 1998, J LAB CLIN MED, V132, P32, DOI 10.1016/S0022-2143(98)90022-1
   Hemmerle H, 1997, J MED CHEM, V40, P137, DOI 10.1021/jm9607360
   Hollenberg NK, 2006, J CARDIOVASC PHARM, V47, PS119, DOI 10.1097/00005344-200606001-00005
   Iuchi T, 2003, CIRC RES, V92, P81, DOI 10.1161/01.RES.0000050588.35034.3C
   Karim M, 2000, J NUTR, V130, P2105S, DOI 10.1093/jn/130.8.2105S
   KERSTENS MN, 2001, J CLIN ENDOCR METAB, V88, P4180
   Kidambi S, 2007, HYPERTENSION, V49, P704, DOI 10.1161/01.HYP.0000253258.36141.c7
   Lamuela-Raventós RM, 2001, J NUTR, V131, P834, DOI 10.1093/jn/131.3.834
   Lee KW, 2003, J AGR FOOD CHEM, V51, P7292, DOI 10.1021/jf0344385
   Lee YS, 1996, CLIN PHARMACOL THER, V59, P62, DOI 10.1016/S0009-9236(96)90025-9
   LINDROOS AK, 1993, EUR J CLIN NUTR, V47, P461
   Litchfield WR, 1998, HYPERTENSION, V31, P569, DOI 10.1161/01.HYP.31.2.569
   Liu Y, 2009, CARDIOVASC RES, V81, P140, DOI 10.1093/cvr/cvn231
   Lovallo WR, 2006, INT J PSYCHOPHYSIOL, V59, P195, DOI 10.1016/j.ijpsycho.2005.10.007
   Luna F, 2002, J AGR FOOD CHEM, V50, P3527, DOI 10.1021/jf0116597
   McDougall GJ, 2005, J AGR FOOD CHEM, V53, P2760, DOI 10.1021/jf0489926
   McKeown NM, 2008, EUR J NUTR, V47, P210, DOI 10.1007/s00394-008-0715-x
   Meisel P, 2005, HYPERTENSION, V46, PE17, DOI 10.1161/01.HYP.0000188406.38247.fd
   Morton NM, 2001, J BIOL CHEM, V276, P41293, DOI 10.1074/jbc.M103676200
   Nelson M, 2002, PHOTOGRAPHIC ATLAS F, V0, P0
   Newton R, 2000, THORAX, V55, P603, DOI 10.1136/thorax.55.7.603
   Olson TP, 2006, AM J PREV MED, V30, P487, DOI 10.1016/j.amepre.2006.02.006
   Olthof MR, 2003, J NUTR, V133, P1806, DOI 10.1093/jn/133.6.1806
   Olthof MR, 2001, AM J CLIN NUTR, V73, P532
   Olthof MR, 2001, J NUTR, V131, P66, DOI 10.1093/jn/131.1.66
   Palermo M, 1996, CLIN ENDOCRINOL, V45, P605, DOI 10.1046/j.1365-2265.1996.00853.x
   Pereira MA, 2006, ARCH INTERN MED, V166, P1311, DOI 10.1001/archinte.166.12.1311
   Quesada C, 1996, J FOOD PROTECT, V59, P185, DOI 10.4315/0362-028X-59.2.185
   Richelle M, 2001, J AGR FOOD CHEM, V49, P3438, DOI 10.1021/jf0101410
   Rios LY, 2003, AM J CLIN NUTR, V77, P912, DOI 10.1093/ajcn/77.4.912
   Rohleder N, 2006, INT J PSYCHOPHYSIOL, V59, P236, DOI 10.1016/j.ijpsycho.2005.10.012
   Roura E, 2006, CLIN CHEM, V52, P749, DOI 10.1373/clinchem.2005.063628
   Sardi Alberto, 2002, ANN ITAL MED INT, V17, P126
   Song CH, 2007, EUR J CLIN NUTR, V61, P682, DOI 10.1038/sj.ejcn.1602568
   SONG DJ, 1992, J LAB CLIN MED, V120, P792
   Song YQ, 2005, DIABETES CARE, V28, P1438, DOI 10.2337/diacare.28.6.1438
   Stimson RH, 2007, J CLIN ENDOCR METAB, V92, P4480, DOI 10.1210/jc.2007-0692
   STOTE KS, 2007, FASEB J, V21, P84717
   Taubert D, 2003, JAMA-J AM MED ASSOC, V290, P1029, DOI 10.1001/jama.290.8.1029
   Taubert D, 2007, JAMA-J AM MED ASSOC, V298, P49, DOI 10.1001/jama.298.1.49
   Tomaru M, 2007, NUTRITION, V23, P351, DOI 10.1016/j.nut.2007.01.007
   Verdecchia P, 2004, BLOOD PRESS MONIT, V9, P225, DOI 10.1097/00126097-200408000-00008
   Vicennati V, 2000, J CLIN ENDOCR METAB, V85, P4093, DOI 10.1210/jc.85.11.4093
NR 69
TC 70
Z9 79
U1 0
U2 48
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD MAR 28
PY 2010
VL 103
IS 6
BP 842
EP 850
DI 10.1017/S0007114509992431
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 577NQ
UT WOS:000276230900008
PM 19825207
DA 2025-04-28
ER

PT J
AU Higgins, JP
   Tuttle, TD
   Higgins, CL
AF Higgins, John P.
   Tuttle, Troy D.
   Higgins, Christopher L.
TI Energy Beverages: Content and Safety
SO MAYO CLINIC PROCEEDINGS
LA English
DT Review
ID drink consumption; l-carnitine; caffeine; performance; metabolism; nutrition; fluid; supplementation; carbohydrate; association
AB Exercise is making a resurgence in many countries, given its benefits for fitness as well as prevention of obesity This trend has spawned many supplements that purport to aid performance, muscle growth, and recovery initially, sports drinks were developed to provide electrolyte and carbohydrate replacement Subsequently, energy beverages (EBs) containing stimulants and additives have appeared in most gyms and grocery stores and are being used in creasingly by "weekend warriors" and those seeking an edge In an endurance event Long term exposure to the various components of EBs may result in significant alterations in the cardiovascular system, and the safety of EBs has not been fully established For this review, we searched the MEDLINE and EMBASE databases from 1976 through May 2010, using the following keywords energy beverage, energy drink, power drink, exercise, caffeine, red bull, bitter orange, glucose, ginseng, guarana, and taurine Evidence regarding the effects of EBs is summarized, and practical recommendations are made to help in answering the patient who asks, "Is it safe for me to drink an energy beverage when I exercise?"
C1 [Higgins, John P.] Univ Texas Med Sch Houston, Lyndon B Johnson Gen Hosp, Div Cardiol, Houston, TX 77026 USA.
   [Higgins, John P.] Univ Texas Med Sch Houston, Mem Hermann Sports Med Inst, Houston, TX 77026 USA.
   [Tuttle, Troy D.] Univ Texas Hlth Sci Ctr, Noninvas Cardiovasc Lab, Houston, TX USA.
   [Higgins, Christopher L.] Univ Queensland, Sch Human Movements Studies, St Lucia, Qld, Australia.
C3 University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Queensland
RP Higgins, JP (corresponding author), Univ Texas Med Sch Houston, Lyndon B Johnson Gen Hosp, Div Cardiol, 5656 Kelley St,UT Annex Room 104, Houston, TX 77026 USA.
CR Armstrong LE, 2005, INT J SPORT NUTR EXE, V15, P252, DOI 10.1123/ijsnem.15.3.252
   Bâ A, 2008, CELL MOL NEUROBIOL, V28, P923, DOI 10.1007/s10571-008-9297-7
   Bahrke MS, 2009, INT J SPORT NUTR EXE, V19, P298, DOI 10.1123/ijsnem.19.3.298
   Bain MA, 2006, J CLIN PHARMACOL, V46, P1163, DOI 10.1177/0091270006292851
   Balla T, 2009, CELL CALCIUM, V45, P527, DOI 10.1016/j.ceca.2009.03.013
   Ballard SL, 2010, PHYSICIAN SPORTSMED, V38, P107, DOI 10.3810/psm.2010.04.1768
   Baum M, 2001, AMINO ACIDS, V20, P75, DOI 10.1007/s007260170067
   Berger AJ, 2009, MED J AUSTRALIA, V190, P41, DOI 10.5694/j.1326-5377.2009.tb02263.x
   BERTHOLD BN, 1997, ANN NUTR METAB, V41, P29
   BLANCHARD J, 1983, EUR J CLIN PHARMACOL, V24, P93, DOI 10.1007/BF00613933
   Bryce DJ, 2007, HARVARD BUS REV, V85, P84
   Burke LM, 2007, J SPORT SCI, V25, PS29, DOI 10.1080/02640410701607239
   Calamaro CJ, 2009, PEDIATRICS, V123, PE1005, DOI 10.1542/peds.2008-3641
   Candow DG, 2009, J STRENGTH COND RES, V23, P1271, DOI 10.1519/JSC.0b013e3181a026c2
   CBCNEWS RED, 2003, HEART DA, V5, P253
   Clarkson PM, 1996, SPORTS MED, V21, P393, DOI 10.2165/00007256-199621060-00001
   Clauson KA, 2008, J AM PHARM ASSOC, V48, PE55, DOI 10.1331/JAPhA.2008.07055
   Curry K, 2009, HUM PSYCHOPHARM CLIN, V24, P473, DOI 10.1002/hup.1045
   DAVIS JM, 1988, EUR J APPL PHYSIOL, V57, P563, DOI 10.1007/BF00418463
   Depeint F, 2006, CHEM-BIOL INTERACT, V163, P94, DOI 10.1016/j.cbi.2006.04.014
   ElSayed MS, 1997, COMP BIOCHEM PHYS A, V118, P789, DOI 10.1016/S0300-9629(97)00064-9
   FISHER SM, 1986, INT J SPORTS MED, V7, P276, DOI 10.1055/s-2008-1025774
   Frishman William H, 2003, HEART DIS, V5, P253, DOI 10.1097/01.hdx.0000080713.09303.a6
   Ganio MS, 2009, J STRENGTH COND RES, V23, P315, DOI 10.1519/JSC.0b013e31818b979a
   GAULL GE, 1989, PEDIATRICS, V83, P433
   Hew-Butler T, 2006, CLIN J SPORT MED, V16, P283, DOI 10.1097/00042752-200607000-00001
   Howarth KR, 2009, J APPL PHYSIOL, V106, P1394, DOI 10.1152/japplphysiol.90333.2008
   Ivy JL, 2009, INT J SPORT NUTR EXE, V19, P61, DOI 10.1123/ijsnem.19.1.61
   Jeukendrup AE, 2005, SPORTS MED, V35, P163, DOI 10.2165/00007256-200535020-00005
   JONES B, 2009, US TODAY 0708, V0, P0
   Jones G, 2008, ESSAYS BIOCHEM, V44, P109, DOI 10.1042/BSE0440109
   Karlic H, 2004, NUTRITION, V20, P709, DOI 10.1016/j.nut.2004.04.003
   Lakshmi AV, 1998, INDIAN J MED RES, V108, P182
   Laurent D, 2000, J CLIN ENDOCR METAB, V85, P2170, DOI 10.1210/jc.85.6.2170
   Lourenco R, 2002, NUTR HOSP, V17, P262
   Mahmud A, 2001, HYPERTENSION, V38, P227, DOI 10.1161/01.HYP.38.2.227
   Margaritis I, 2008, NUTR RES REV, V21, P3, DOI 10.1017/S0954422408018076
   Masuda K, 2009, CLIN EXP DERMATOL, V34, Pe263, DOI 10.1111/j.1365-2230.2008.03173.x
   Maughan RJ, 2003, J HUM NUTR DIET, V16, P411, DOI 10.1046/j.1365-277X.2003.00477.x
   Miller KE, 2008, J ADOLESCENT HEALTH, V43, P490, DOI 10.1016/j.jadohealth.2008.03.003
   Miranda VD, 2009, J ALTERN COMPLEM MED, V15, P431, DOI 10.1089/acm.2008.0324
   Nagajothi N, 2008, AM J MED, V121, PE3, DOI 10.1016/j.amjmed.2007.12.003
   Nicolaï SPA, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006888.pub2
   Oteri A, 2007, ALCOHOL CLIN EXP RES, V31, P1677, DOI 10.1111/j.1530-0277.2007.00464.x
   Peake JM, 2007, J NUTR BIOCHEM, V18, P357, DOI 10.1016/j.jnutbio.2006.10.005
   Piirainen H, 2011, BBA-BIOMEMBRANES, V1808, P1233, DOI 10.1016/j.bbamem.2010.05.021
   Ragsdale FR, 2010, AMINO ACIDS, V38, P1193, DOI 10.1007/s00726-009-0330-z
   Rashti SL, 2009, LIPIDS HEALTH DIS, V8, P0, DOI 10.1186/1476-511X-8-57
   Reissig CJ, 2009, DRUG ALCOHOL DEPEN, V99, P1, DOI 10.1016/j.drugalcdep.2008.08.001
   Riesenhuber A, 2006, AMINO ACIDS, V31, P81, DOI 10.1007/s00726-006-0363-5
   ROBERTSON D, 1981, J CLIN INVEST, V67, P1111, DOI 10.1172/JCI110124
   Sato S, 2003, FOODS FOOD INGREDIENTS JOURNAL OF JAPAN, V208, P133
   SATTARI MG, 2010, J AMINO ACIDS, V0, P10
   Sauve AA, 2008, J PHARMACOL EXP THER, V324, P883, DOI 10.1124/jpet.107.120758
   Smith N, 2010, EVID-BASED COMPL ALT, V7, P279, DOI 10.1093/ecam/nem162
   Sökmen B, 2008, J STRENGTH COND RES, V22, P978, DOI 10.1519/JSC.0b013e3181660cec
   Spinneker A, 2007, NUTR HOSP, V22, P7
   Steinke L, 2009, ANN PHARMACOTHER, V43, P596, DOI 10.1345/aph.1L614
   Sudano Isabella, 2005, PROG CARDIOVASC NURS, V20, P65, DOI 10.1111/j.0889-7204.2005.02477.x
   Tappy L, 2010, NUTRITION, V26, P1044, DOI 10.1016/j.nut.2010.02.014
   Terlizzi R, 2008, CLIN AUTON RES, V18, P221, DOI 10.1007/s10286-008-0483-y
   Thombs DL, 2010, ADDICT BEHAV, V35, P325, DOI 10.1016/j.addbeh.2009.11.004
   WEISE E, 2008, US TODAY 1022, V0, P0
   Wiklund U, 2009, CLIN PHYSIOL FUNCT I, V29, P74, DOI 10.1111/j.1475-097X.2008.00837.x
   Williams SL, 2006, NUTR REV, V64, P93, DOI 10.1111/j.1753-4887.2006.tb00193.x
   Zhou W, 2004, CARDIOVASC DRUG REV, V22, P309
   Zóltaszek R, 2008, POSTEP HIG MED DOSW, V62, P451
NR 70
TC 259
Z9 284
U1 0
U2 118
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD NOV 15
PY 2010
VL 85
IS 11
BP 1033
EP 1041
DI 10.4065/mcp.2010.0381
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 680AN
UT WOS:000284202500009
PM 21037046
DA 2025-04-28
ER

PT J
AU Vijayagopal, P
   Figueroa, JE
   Prasad, C
AF Vijayagopal, Parakat
   Figueroa, Julio E.
   Prasad, Chandan
TI EFFECT OF A COMBINATION OF GRAPE SEED EXTRACT, CAPSAICIN, GENISTEIN, AND CAFFEINE ON BODY WEIGHT IN OBESE ZUCKER RATS
SO CURRENT TOPICS IN NUTRACEUTICAL RESEARCH
LA English
DT Article
DE Body Weight; Caffeine; Capsaicin; Genistein; Grape Seed Extract; Obesity
ID insulin sensitivity; 3t3-l1 adipocytes; metabolic-rate; adiponectin; lipolysis; expression; resistance; hormone; humans; trial
AB The incidence of obesity is increasing rapidly worldwide. Identification of compounds that may decrease fat cell burden will be beneficial in the control of obesity. In the present study we investigated the effect of a combination of grape seed extarct, caffeine, genistein, and capsaicin (GCGC) in reducing body weight in obese male zucker rats. Rats were pair-fed on a high fat diet or high fat diet + GCGC for 5-weeks. GCGC caused a significant weight loss due to the depletion of fat depots. GCGC also improved insulin response, reduced plasma glucose and free fatty acids, and increased plasma adiponectin. Adipocytes from rats fed GCGC were more responsive to the various stimulators of lipolysis than the control adipocytes. These results show that a combination of plant-derived products is very effective in reducing body weight and improving insulin sensitivity and glucose response in obese zucker rats. This may have implications in the treatment of overweight and obesity in humans.
C1 [Vijayagopal, Parakat; Prasad, Chandan] Texas Womans Univ, Dept Nutr & Food Sci, Denton, TX 76204 USA.
   [Figueroa, Julio E.] Louisiana State Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70112 USA.
C3 Texas Womans University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans
RP Vijayagopal, P (corresponding author), Texas Womans Univ, Dept Nutr & Food Sci, POB 425888, Denton, TX 76204 USA.
CR ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   Boozer CN, 2002, INT J OBESITY, V26, P593, DOI 10.1038/sj.ijo.0802023
   Chandran M, 2003, DIABETES CARE, V26, P2442, DOI 10.2337/diacare.26.8.2442
   Chen M D, 1994, ZHONGHUA YI XUE ZA ZHI (TAIPEI), V53, P257
   Combs TP, 2004, ENDOCRINOLOGY, V145, P367, DOI 10.1210/en.2003-1068
   Décorde K, 2009, MOL NUTR FOOD RES, V53, P659, DOI 10.1002/mnfr.200800165
   Díez JJ, 2003, EUR J ENDOCRINOL, V148, P293, DOI 10.1530/eje.0.1480293
   Fasshauer M, 2002, BIOCHEM BIOPH RES CO, V290, P1084, DOI 10.1006/bbrc.2001.6307
   Figueroa JE, 2002, BIOCHEM BIOPH RES CO, V293, P847, DOI 10.1016/S0006-291X(02)00300-5
   Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356
   Goodman-Gruen D, 2003, MENOPAUSE, V10, P427, DOI 10.1097/01.GME.0000058866.35869.B4
   Harmon AW, 2001, AM J PHYSIOL-CELL PH, V280, PC807, DOI 10.1152/ajpcell.2001.280.4.C807
   HENRY CJK, 1986, HUM NUTR-CLIN NUTR, V40C, P165
   JUNG RT, 1981, CLIN SCI, V60, P527, DOI 10.1042/cs0600527
   Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200
   MAEDA N, 2002, NAT MED, V1, P1155
   Mokdad AH, 2000, JAMA-J AM MED ASSOC, V284, P1650, DOI 10.1001/jama.284.13.1650
   Moreno DA, 2003, NUTRITION, V19, P876, DOI 10.1016/S0899-9007(03)00167-9
   NOBLE R, 1988, DRUG INTEL CLIN PHAR, V22, P296, DOI 10.1177/106002808802200403
   Park Su-Hui, 2008, NUTR RES PRACT, V2, P227, DOI 10.4162/nrp.2008.2.4.227
   RANDLE PJ, 1963, LANCET, V1, P785
   Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742
   Ruan H, 2002, DIABETES, V51, P1319, DOI 10.2337/diabetes.51.5.1319
   Szkudelska K, 2000, J STEROID BIOCHEM, V75, P265, DOI 10.1016/S0960-0760(00)00172-2
   WATANABE T, 1994, LIFE SCI, V54, P369, DOI 10.1016/0024-3205(94)00793-4
   *WHO, 2000, TECH REP SER WHO, V894, P0
   Wulster-Radcliffe MC, 2004, BIOCHEM BIOPH RES CO, V316, P924, DOI 10.1016/j.bbrc.2004.02.130
NR 27
TC 1
Z9 1
U1 0
U2 10
PU NEW CENTURY HEALTH PUBLISHERS, LLC
PI COPPELL
PA PO BOX 175, COPPELL, TX 75019 USA
SN 1540-7535
EI 
J9 CURR TOP NUTRACEUT R
JI Curr. Top. Nutraceutical Res.
PD AUG 15
PY 2010
VL 8
IS 2-3
BP 59
EP 64
DI 
PG 6
WC Nutrition & Dietetics; Pharmacology & Pharmacy
SC Nutrition & Dietetics; Pharmacology & Pharmacy
GA 645VJ
UT WOS:000281494000001
DA 2025-04-28
ER

PT J
AU Törrönen, R
   Sarkkinen, E
   Tapola, N
   Hautaniemi, E
   Kilpi, K
   Niskanen, L
AF Torronen, Riitta
   Sarkkinen, Essi
   Tapola, Niina
   Hautaniemi, Elina
   Kilpi, Kyllikki
   Niskanen, Leo
TI Berries modify the postprandial plasma glucose response to sucrose in healthy subjects
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Berries; Polyphenols; Sucrose; Glucose response
ID border-membrane-vesicles; gastrointestinal hormone-secretion; emarginata dc. fruit; alpha-glucosidase; phenolic-compounds; inhibitory-activity; chlorogenic acid; oat gum; polyphenols; insulin
AB Sucrose increases postprandial blood glucose concentrations, and diets with a high glycaemic response may be associated with increased risk of obesity, type 2 diabetes and CVD. Previous studies have suggested that polyphenols may influence carbohydrate digestion and absorption and thereby postprandial glycaemia. Berries are rich sources of various polyphenols and berry products are typically consumed with sucrose. We investigated the glycaemic effect of a berry puree made of bilberries, blackcurrants, cranberries and strawberries, and sweetened with sucrose, in comparison to sucrose with adjustment of available carbohydrates. A total of twelve healthy subjects (eleven women and one man, aged 25-69 years) with normal fasting plasma glucose ingested 150 g of the berry puree with 35 g sucrose or a control sucrose load in a randomised, controlled cross-over design. After consumption of the berry meal, the plasma glucose concentrations were significantly lower at 15 and 30 min (P<0.05, P<0.01, respectively) and significantly higher at 150 min (P<0.05) compared with the control meal. The peak glucose concentration was reached at 45 min after the berry meal and at 30 min after the control meal. The peak increase from the baseline was 1.0 mmol/l smaller (P=0.002) after ingestion of the berry meal. There was no statistically significant difference in the 3 h area under the glucose response curve. These results show that berries rich in polyphenols decrease the postprandial glucose response of sucrose in healthy subjects. The delayed and attenuated glycaemic response indicates reduced digestion and/or absorption of sucrose from the berry meal.
C1 [Torronen, Riitta] Univ Kuopio, Food & Hlth Res Ctr, Dept Clin Nutr, FI-70211 Kuopio, Finland.
   [Sarkkinen, Essi; Tapola, Niina; Hautaniemi, Elina] Foodfiles Ltd, Kuopio, Finland.
   [Kilpi, Kyllikki] Finnsugar Ltd, Kantvik, Finland.
   [Niskanen, Leo] Kuopio Univ Hosp, Inst Med, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland Hospital
RP Törrönen, R (corresponding author), Univ Kuopio, Food & Hlth Res Ctr, Dept Clin Nutr, POB 1627, FI-70211 Kuopio, Finland.
EM riitta.torronen@uku.fi
FU Finnsugar Ltd.
CR Adisakwattana S, 2004, J ENZYM INHIB MED CH, V19, P313, DOI 10.1080/14756360409162443
   Adisakwattana S, 2009, J ENZYM INHIB MED CH, V24, P65, DOI 10.1080/14756360801906947
   BRAATEN JT, 1991, AM J CLIN NUTR, V53, P1425, DOI 10.1093/ajcn/53.6.1425
   Buchert J, 2005, J SCI FOOD AGR, V85, P2548, DOI 10.1002/jsfa.2284
   Cermak R, 2004, BRIT J NUTR, V91, P849, DOI 10.1079/BJN20041128
   Fineli, 2004, FINN FOOD COMP DAT, V0, P0
   Hanamura T, 2005, BIOSCI BIOTECH BIOCH, V69, P280, DOI 10.1271/bbb.69.280
   Hanamura T, 2006, BIOSCI BIOTECH BIOCH, V70, P1813, DOI 10.1271/bbb.50592
   Iwai K, 2006, J AGR FOOD CHEM, V54, P4588, DOI 10.1021/jf0606353
   Johnston K, 2005, FEBS LETT, V579, P1653, DOI 10.1016/j.febslet.2004.12.099
   Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728
   Johnston KL, 2002, J SCI FOOD AGR, V82, P1800, DOI 10.1002/jsfa.1264
   Kobayashi Y, 2000, J AGR FOOD CHEM, V48, P5618, DOI 10.1021/jf0006832
   Koponen JM, 2007, J AGR FOOD CHEM, V55, P1612, DOI 10.1021/jf062897a
   LEVIN RJ, 1994, AM J CLIN NUTR, V59, P690S, DOI 10.1093/ajcn/59.3.690S
   Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414
   Määttä-Riihinen KR, 2004, J AGR FOOD CHEM, V52, P4477, DOI 10.1021/jf049595y
   Määttä-Riihinen KR, 2004, J AGR FOOD CHEM, V52, P6178, DOI 10.1021/jf049450r
   Matsiu T, 2002, J AGR FOOD CHEM, V50, P7244, DOI 10.1021/jf025913m
   Matsui T, 2001, J AGR FOOD CHEM, V49, P1952, DOI 10.1021/jf0012502
   Matsui T, 2007, J AGR FOOD CHEM, V55, P99, DOI 10.1021/jf0627672
   Mattila P, 2006, J AGR FOOD CHEM, V54, P7193, DOI 10.1021/jf0615247
   McDougall GJ, 2005, J AGR FOOD CHEM, V53, P2760, DOI 10.1021/jf0489926
   Ovaskainen ML, 2008, J NUTR, V138, P562
   Pinto MDS, 2008, J AGR FOOD CHEM, V56, P4386, DOI 10.1021/jf0732758
   Schäfer A, 2007, DIABETES RES CLIN PR, V77, P41, DOI 10.1016/j.diabres.2006.10.011
   Song J, 2002, J BIOL CHEM, V277, P15252, DOI 10.1074/jbc.M110496200
   Tadera K, 2006, J NUTR SCI VITAMINOL, V52, P149, DOI 10.3177/jnsv.52.149
   Tappy L, 1996, DIABETES CARE, V19, P831, DOI 10.2337/diacare.19.8.831
   Thom E, 2007, J INT MED RES, V35, P900, DOI 10.1177/147323000703500620
   WELSCH CA, 1989, J NUTR, V119, P1737, DOI 10.1093/jn/119.11.1737
   WELSCH CA, 1989, J NUTR, V119, P1698, DOI 10.1093/jn/119.11.1698
   Wilson T, 2008, J MED FOOD, V11, P46, DOI 10.1089/jmf.2007.531
   Wood PJ, 2007, J CEREAL SCI, V46, P230, DOI 10.1016/j.jcs.2007.06.012
   WOOD PJ, 1994, BRIT J NUTR, V72, P731, DOI 10.1079/BJN19940075
NR 35
TC 126
Z9 138
U1 4
U2 53
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 
J9 BRIT J NUTR
JI Br. J. Nutr.
PD APR 28
PY 2010
VL 103
IS 8
BP 1094
EP 1097
DI 10.1017/S0007114509992868
PG 4
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 590ST
UT WOS:000277248800002
PM 19930765
DA 2025-04-28
ER

PT J
AU Greenberg, JA
   Owen, DR
   Geliebter, A
AF Greenberg, James A.
   Owen, David R.
   Geliebter, Allan
TI Decaffeinated Coffee and Glucose Metabolism in Young Men
SO DIABETES CARE
LA English
DT Article
ID type-2 diabetes-mellitus; chlorogenic acid; blood-glucose; caffeine; consumption; tolerance; obese; risk
AB OBJECTIVE - The epidemiological association between coffee drinking and decreased risk Of type 2 diabetes is strong. However, caffeinated coffee acutely impairs glucose metabolism. We assessed acute effects of decaffeinated coffee on glucose and insulin levels. RESEARCH DESIGN AND METHODS - This was a randomized, cross-over, placebo-controlled trial of the effects of decaffeinated coffee, caffeinated coffee, and caffeine on glucose, insulin, and glucose-de pendent insulinotropic poly-peptide (GIP) levels during a 2-h Oral glucose tolerance test (OGTT) in 11 young men. RESULTS - Within the first hour Of the CGTT, glucose and insulin were higher for decaffeinated coffee than for placebo (P < 0.05). During the whole OGTT, decaffeinated coffee yielded higher insulin than placebo and lower glucose and a higher insulin sensitivity index than caffeine. Changes in GIP could not explain any beverage effects on glucose and insulin. CONCLUSIONS - Some types of decaffeinated coffee may acutely impair glucose metabolism but less than caffeine.
C1 [Greenberg, James A.] NYU, Brooklyn Coll City, Dept Hlth & Nutr Sci, New York, NY 10003 USA.
   [Owen, David R.] NYU, Brooklyn Coll City, Dept Psychol, New York, NY USA.
   [Geliebter, Allan] St Lukes Roosevelt Hosp, New York Obes Res Ctr, New York, NY USA.
   [Geliebter, Allan] Columbia Univ, Dept Psychol, New York, NY 10027 USA.
C3 New York University; New York University; Mount Sinai West; Mount Sinai St. Luke's; Columbia University
RP Greenberg, JA (corresponding author), NYU, Brooklyn Coll City, Dept Hlth & Nutr Sci, New York, NY 10003 USA.
EM jamesg@brooklyn.cuny.edu
FU Professional Staff Congress; City University of New York Research Award Program
CR Battram DS, 2006, J NUTR, V136, P1276, DOI 10.1093/jn/136.5.1276
   Belfiore F, 2001, METABOLISM, V50, P573, DOI 10.1053/meta.2001.22518
   Gautier JF, 2008, DIABETES METAB, V34, PS65, DOI 10.1016/S1262-3636(08)73397-4
   Greenberg JA, 2006, AM J CLIN NUTR, V84, P682, DOI 10.1093/ajcn/84.4.682
   Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728
   Lane JD, 2008, DIABETES CARE, V31, P221, DOI 10.2337/dc07-1112
   McCusker RR, 2006, J ANAL TOXICOL, V30, P611, DOI 10.1093/jat/30.8.611
   Moisey LL, 2008, AM J CLIN NUTR, V87, P1254, DOI 10.1093/ajcn/87.5.1254
   Paynter NP, 2006, AM J EPIDEMIOL, V164, P1075, DOI 10.1093/aje/kwj323
   Pereira MA, 2006, ARCH INTERN MED, V166, P1311, DOI 10.1001/archinte.166.12.1311
   Thom E, 2007, J INT MED RES, V35, P900, DOI 10.1177/147323000703500620
   van Dijk AE, 2009, DIABETES CARE, V32, P1023, DOI 10.2337/dc09-0207
NR 12
TC 39
Z9 42
U1 0
U2 17
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 
J9 DIABETES CARE
JI Diabetes Care
PD FEB 15
PY 2010
VL 33
IS 2
BP 278
EP 280
DI 10.2337/dc09-1539
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 563PA
UT WOS:000275143700011
PM 19918017
DA 2025-04-28
ER

PT J
AU Hursel, R
   Westerterp-Plantenga, MS
AF Hursel, R.
   Westerterp-Plantenga, M. S.
TI Thermogenic ingredients and body weight regulation
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Review
DE body weight; thermogenic; fat oxidation; energy expenditure; energy intake
ID green tea extract; catechol-o-methyltransferase; diet-induced obesity; energy-expenditure; fat oxidation; red-pepper; substrate utilization; double-blind; white tea; caffeine consumption
AB The global prevalence of obesity has increased considerably in the last decade. Tools for obesity management, including consumption of caffeine, capsaicin and different teas such as green, white and oolong tea, have been proposed as strategies for weight loss and weight maintenance, as they may increase energy expenditure (4-5%), fat oxidation (10-16%) and have been proposed to counteract the decrease in metabolic rate that is present during weight loss. Daily increases in thermogenesis of approximately 300-400 kJ can eventually lead to substantial weight loss. However, it becomes clearer that certain conditions have to be met before thermogenic ingredients yield an effect, as intra-variability with respect to body weight regulation has been shown between subjects. Furthermore, the sympathetic nervous system is involved in the regulation of lipolysis, and the sympathetic innervation of white adipose tissue may have an important role in the regulation of total body fat in general. Taken together, these functional ingredients have the potential to produce significant effects on metabolic targets such as satiety, thermogenesis and fat oxidation. A significant clinical outcome may sometimes appear straightforward and may also depend very strongly on full compliance of subjects. Nevertheless, thermogenic ingredients may be considered as functional agents that could help in preventing a positive energy balance and obesity. International Journal of Obesity (2010) 34, 659-669; doi: 10.1038/ijo.2009.299; published online 9 February 2010
C1 [Hursel, R.; Westerterp-Plantenga, M. S.] Maastricht Univ, Fac Hlth Med & Life Sci, Dept Human Biol, Maastricht, Netherlands.
C3 Maastricht University
RP Westerterp-Plantenga, MS (corresponding author), Maastricht Univ, Fac Hlth Med & Life Sci, Dept Human Biol, Maastricht, Netherlands.
EM m.westerterp@hb.unimaas.nl
CR Acheson KJ, 2004, AM J CLIN NUTR, V79, P40
   ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   Alcazar A, 2007, J AGR FOOD CHEM, V55, P5960, DOI 10.1021/jf070601a
   ARCIERO PJ, 1995, AM J PHYSIOL-ENDOC M, V268, PE1192, DOI 10.1152/ajpendo.1995.268.6.E1192
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Auvichayapat P, 2008, PHYSIOL BEHAV, V93, P486, DOI 10.1016/j.physbeh.2007.10.009
   Belza A, 2007, INT J OBESITY, V31, P121, DOI 10.1038/sj.ijo.0803351
   Belza A, 2009, EUR J CLIN NUTR, V63, P57, DOI 10.1038/sj.ejcn.1602901
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   BORCHARDT RT, 1975, J MED CHEM, V18, P120, DOI 10.1021/jm00235a030
   Boschmann M, 2007, J AM COLL NUTR, V26, P389S, DOI 10.1080/07315724.2007.10719627
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   BROWN PJ, 1963, J CHROMATOGR, V11, P504, DOI 10.1016/S0021-9673(01)80953-5
   Chan CCW, 2006, J SOC GYNECOL INVEST, V13, P63, DOI 10.1016/j.jsgi.2005.10.006
   Chantre P, 2002, PHYTOMEDICINE, V9, P3, DOI 10.1078/0944-7113-00078
   Chen W, 1998, JPN J CLIN NUTR, V20, P83
   Cornelis MC, 2007, AM J CLIN NUTR, V86, P240, DOI 10.1093/ajcn/86.1.240
   CURATOLO PW, 1983, ANN INTERN MED, V98, P641, DOI 10.7326/0003-4819-98-5-641
   Diepvens K, 2005, BRIT J NUTR, V94, P1026, DOI 10.1079/BJN20051580
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   Faraut B, 2007, AM J PHYSIOL-ENDOC M, V292, PE1474, DOI 10.1152/ajpendo.00292.2006
   Galgani JE, 2010, BRIT J NUTR, V103, P38, DOI 10.1017/S0007114509991358
   GRAHAM HN, 1992, PREV MED, V21, P334, DOI 10.1016/0091-7435(92)90041-F
   Gregersen NT, 2009, BRIT J NUTR, V102, P1187, DOI 10.1017/S0007114509371779
   Harada U, 2005, J HEALTH SCI, V51, P248, DOI 10.1248/jhs.51.248
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   He RR, 2009, CHIN J INTEGR MED, V15, P34, DOI 10.1007/s11655-009-0034-8
   Hertog MGL, 1997, AM J CLIN NUTR, V65, P1489, DOI 10.1093/ajcn/65.5.1489
   Hilal Y, 2007, J VERBRAUCH LEBENSM, V2, P414, DOI 10.1007/s00003-007-0250-3
   Hodgson JM, 2006, BRIT J NUTR, V95, P14, DOI 10.1079/BJN20051621
   HOLLANDS MA, 1981, AM J CLIN NUTR, V34, P2291, DOI 10.1093/ajcn/34.10.2291
   Hsu CH, 2008, CLIN NUTR, V27, P363, DOI 10.1016/j.clnu.2008.03.007
   Hursel R, 2009, INT J OBESITY, V33, P956, DOI 10.1038/ijo.2009.135
   Hursel R, 2009, AM J CLIN NUTR, V89, P822, DOI 10.3945/ajcn.2008.27043
   Jöbstl E, 2006, J AGR FOOD CHEM, V54, P4077, DOI 10.1021/jf053259f
   Kajimoto O, 2005, J HEALTH SCI, V51, P161, DOI 10.1248/jhs.51.161
   Kao Y, 2000, AM J CLIN NUTR, V72, P1232
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Komatsu Tatsushi, 2003, JOURNAL OF MEDICAL INVESTIGATION, V50, P170
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   Lejeune MPGM, 2003, BRIT J NUTR, V90, P651, DOI 10.1079/BJN2003938
   Lopez-Garcia E, 2006, AM J CLIN NUTR, V83, P674, DOI 10.1093/ajcn.83.3.674
   Lorenz M, 2007, EUR HEART J, V28, P219, DOI 10.1093/eurheartj/ehl442
   Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527
   Masuda Y, 2003, J APPL PHYSIOL, V95, P2408, DOI 10.1152/japplphysiol.00828.2002
   Matsuyama T, 2008, OBESITY, V16, P1338, DOI 10.1038/oby.2008.60
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nagao T, 2001, JOURNAL OF OLEO SCIENCE, V50, P717
   Nagao T, 2007, OBESITY, V15, P1473, DOI 10.1038/oby.2007.176
   Obesity, 2000, WORLD HEALTH ORGAN TECH REP SER, V894, P1, DOI 10.1016/J.BBI.2016.02.019
   Ohnuki K, 2001, BIOSCI BIOTECH BIOCH, V65, P2033, DOI 10.1271/bbb.65.2033
   Otsuka K, 2002, JAPANESE J NUTR ASSE, V19, P365
   Palmatier MA, 1999, BIOL PSYCHIAT, V46, P557, DOI 10.1016/S0006-3223(99)00098-0
   Pasman WJ, 1997, INT J OBESITY, V21, P1143, DOI 10.1038/sj.ijo.0800528
   Pasman WJ, 1999, METABOLISM, V48, P15, DOI 10.1016/S0026-0495(99)90004-5
   Reinbach HC, 2009, CLIN NUTR, V28, P260, DOI 10.1016/j.clnu.2009.01.010
   ROBERTSON D, 1978, NEW ENGL J MED, V298, P181, DOI 10.1056/NEJM197801262980403
   ROBERTSON D, 1981, J CLIN INVEST, V67, P1111, DOI 10.1172/JCI110124
   Rudelle S, 2007, OBESITY, V15, P349, DOI 10.1038/oby.2007.529
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   Santana-Rios G, 2001, MUTAT RES-GEN TOX EN, V495, P61, DOI 10.1016/S1383-5718(01)00200-5
   Serafini M, 1996, EUR J CLIN NUTR, V50, P28
   Shixian Q, 2006, J MED FOOD, V9, P451, DOI 10.1089/jmf.2006.9.451
   Smeets AJ, 2009, EUR J NUTR, V48, P229, DOI 10.1007/s00394-009-0006-1
   Snitker S, 2009, AM J CLIN NUTR, V89, P45, DOI 10.3945/ajcn.2008.26561
   Söhle J, 2009, NUTR METAB, V6, P0, DOI 10.1186/1743-7075-6-20
   Stunkard AJ, 1996, AM J MED, V100, P230, DOI 10.1016/S0002-9343(97)89464-8
   TREMBLAY A, 1988, NUTR RES, V8, P553, DOI 10.1016/S0271-5317(88)80077-0
   TSUCHIDA T, 2002, PROGR MED, V22, P2189
   WADDEN TA, 1988, J CONSULT CLIN PSYCH, V56, P925, DOI 10.1037/0022-006X.56.6.925
   Wang H, 2009, OBESITY SILVER SPRIN, V0, P0
   Weisburger JH, 1997, CANCER LETT, V114, P315, DOI 10.1016/S0304-3835(97)04691-0
   Westerterp-Plantenga MS, 2005, INT J OBESITY, V29, P682, DOI 10.1038/sj.ijo.0802862
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Yang FJ, 2001, MOL PHARMACOL, V60, P528
   Yoshioka M, 1995, J NUTR SCI VITAMINOL, V41, P647, DOI 10.3177/jnsv.41.647
   Yoshioka M, 1999, BRIT J NUTR, V82, P115, DOI 10.1017/S0007114599001269
   Yoshioka M, 1998, BRIT J NUTR, V80, P503, DOI 10.1017/S0007114598001597
   Yoshioka M, 2001, BRIT J NUTR, V85, P203, DOI 10.1079/BJN2000224
NR 85
TC 101
Z9 112
U1 0
U2 41
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD APR 15
PY 2010
VL 34
IS 4
BP 659
EP 669
DI 10.1038/ijo.2009.299
PG 11
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 580WQ
UT WOS:000276481700009
PM 20142827
DA 2025-04-28
ER

PT J
AU Gondoin, A
   Grussu, D
   Stewart, D
   McDougall, GJ
AF Gondoin, Anais
   Grussu, Dominic
   Stewart, Derek
   McDougall, Gordon J.
TI White and green tea polyphenols inhibit pancreatic lipase in vitro
SO FOOD RESEARCH INTERNATIONAL
LA English
DT Article
DE Tea; Polyphenols; Lipase; Fat digestion; Obesity; Health; Tannins
ID epigallocatechin gallate; intestinal-absorption; purine alkaloids; gallic acid; catechins; extract; caffeine; identification; chromatography; cholesterol
AB Green, white and black teas were assayed for inhibition of pancreatic lipase activity in vitro. White tea proved to be more effective than green tea with black tea showing little inhibition even at 200 mu g GAE/ml. The EC50 values for inhibition were 22 mu g/ml for white tea and 35 mu g/ml for green tea: both easily achievable from normal infusions of tea. Liquid chromatography-mass spectroscopy analysis showed that white and green teas had essentially equal amounts of flavan-3-ols but green tea had higher levels of flavonols. White tea had higher levels of 5-galloyl quinic acid, digalloyl glucose, trigalloyl glucose and the tannin, strictinin. After chromatography on Sephadex LH-20, the main inhibitory fraction was enriched in strictinin and fractions enriched in other components were ineffective. This suggests that strictinin content may be crucial for inhibition of pancreatic lipase. However, the possibility of synergies between the polyphenols cannot be disregarded. Crown Copyright (C) 2010 Published by Elsevier Ltd. All rights reserved.
C1 [Gondoin, Anais; Grussu, Dominic; Stewart, Derek; McDougall, Gordon J.] Scottish Crop Res Inst Mylnefield, Plant Prod & Food Qual Programme, Dundee DD2 5DA, Scotland.
C3 James Hutton Institute
RP McDougall, GJ (corresponding author), Scottish Crop Res Inst Mylnefield, Plant Prod & Food Qual Programme, Dundee DD2 5DA, Scotland.
EM Gordon.mcdougall@scri.ac.uk
FU Rural and Environment Research and Analysis Directorate, Scottish Government
CR Unknown -, 2003, OBESITY OVERWEIGHT F, V0, P0
   BALENTINE DA, 1992, ACS SYM SER, V506, P102
   Birari RB, 2007, DRUG DISCOV TODAY, V12, P879, DOI 10.1016/j.drudis.2007.07.024
   de Mejia EG, 2009, BRAIN BEHAV IMMUN, V23, P721, DOI 10.1016/j.bbi.2009.02.013
   Deighton N, 2000, J SCI FOOD AGR, V80, P1307, DOI 10.1002/1097-0010(200007)80:9<1307::AID-JSFA638>3.0.CO;2-P
   Del Rio D, 2004, J AGR FOOD CHEM, V52, P2807, DOI 10.1021/jf0354848
   Dou J, 2008, PHYTOCHEM ANALYSIS, V19, P251, DOI 10.1002/pca.1044
   Engelhardt UH, 2004, ACS SYM SER, V871, P254
   FINGER A, 1992, J CHROMATOGR, V624, P293, DOI 10.1016/0021-9673(92)85685-M
   Frazier RA, 2010, J PHARMACEUT BIOMED, V51, P490, DOI 10.1016/j.jpba.2009.05.035
   Friedman M, 2006, J FOOD SCI, V71, PC328, DOI 10.1111/j.1750-3841.2006.00090.x
   Grassi D, 2008, J NUTR, V138, P1554
   Henning SA, 2005, J NUTR BIOCHEM, V16, P610, DOI 10.1016/j.jnutbio.2005.03.003
   Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464
   Hilal Y, 2007, J VERBRAUCH LEBENSM, V2, P414, DOI 10.1007/s00003-007-0250-3
   Hsu CL, 2008, MOL NUTR FOOD RES, V52, P53, DOI 10.1002/mnfr.200890019
   IKEDA I, 1992, BIOCHIM BIOPHYS ACTA, V1127, P141, DOI 10.1016/0005-2760(92)90269-2
   Ikeda I, 2003, J AGR FOOD CHEM, V51, P7303, DOI 10.1021/jf034728l
   Juhel C, 2000, J NUTR BIOCHEM, V11, P45, DOI 10.1016/S0955-2863(99)00070-4
   Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109
   Kim HJ, 2009, PHYTOTHER RES, V23, P467, DOI 10.1002/ptr.2647
   Komes D, 2010, FOOD RES INT, V43, P167, DOI 10.1016/j.foodres.2009.09.022
   Koo SI, 2007, J NUTR BIOCHEM, V18, P179, DOI 10.1016/j.jnutbio.2006.12.005
   Koo SI, 2008, FASEB J, V22, P0
   Lin YS, 2003, J AGR FOOD CHEM, V51, P1864, DOI 10.1021/jf021066b
   Mämmelä P, 2000, J CHROMATOGR A, V891, P75, DOI 10.1016/S0021-9673(00)00624-5
   McDougall GJ, 2005, J AGR FOOD CHEM, V53, P2760, DOI 10.1021/jf0489926
   McDougall GJ, 2009, FOOD CHEM, V115, P193, DOI 10.1016/j.foodchem.2008.11.093
   Mizukami Y, 2007, J AGR FOOD CHEM, V55, P4957, DOI 10.1021/jf070323f
   Nakai M, 2005, J AGR FOOD CHEM, V53, P4593, DOI 10.1021/jf047814+
   Price KR, 1998, J AGR FOOD CHEM, V46, P2517, DOI 10.1021/jf9800211
   Record IR, 2001, FOOD CHEM, V73, P481, DOI 10.1016/S0308-8146(01)00131-5
   ROBERTS HR, 1983, FOOD TECHNOL-CHICAGO, V37, P32
   Rusak G, 2008, FOOD CHEM, V110, P852, DOI 10.1016/j.foodchem.2008.02.072
   Serafini M, 1996, EUR J CLIN NUTR, V50, P28
   Seto R, 1997, BIOSCI BIOTECH BIOCH, V61, P1434, DOI 10.1271/bbb.61.1434
   Stalmach A, 2010, MOL NUTR FOOD RES, V54, P323, DOI 10.1002/mnfr.200900194
   Venables MC, 2008, AM J CLIN NUTR, V87, P778, DOI 10.1093/ajcn/87.3.778
   Wang Y, 2009, J AGR FOOD CHEM, V57, P8109, DOI 10.1021/jf804025c
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   Yang CS, 2002, ANNU REV PHARMACOL, V42, P25, DOI 10.1146/annurev.pharmtox.42.082101.154309
   Yang DJ, 2007, J CHROMATOGR A, V1156, P312, DOI 10.1016/j.chroma.2006.11.088
   Zeeb DJ, 2000, ANAL CHEM, V72, P5020, DOI 10.1021/ac000418f
NR 43
TC 99
Z9 113
U1 7
U2 138
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0963-9969
EI 1873-7145
J9 FOOD RES INT
JI Food Res. Int.
PD JUN 15
PY 2010
VL 43
IS 5
BP 1537
EP 1544
DI 10.1016/j.foodres.2010.04.029
PG 8
WC Food Science & Technology
SC Food Science & Technology
GA 645CO
UT WOS:000281428700045
DA 2025-04-28
ER

PT J
AU Hostmark, AT
AF Hostmark, Arne Torbjorn
TI The Oslo Health Study: A Dietary Index estimating high intake of soft drinks and low intake of fruits and vegetables was positively associated with components of the metabolic syndrome
SO APPLIED PHYSIOLOGY NUTRITION AND METABOLISM-PHYSIOLOGIE APPLIQUEE NUTRITION ET METABOLISME
LA English
DT Article
DE metabolic syndrome; dietary acid load; men; women; cross-sectional study
ID stearoyl-coa desaturase; insulin-resistance; acid load; urine ph; consumption; population; risk; triglycerides; cholesterol; sucrose
AB A previous finding that soft drink intake is associated with increased serum triglycerides and decreased highdensity-lipoprotein (HDL) cholesterol, both components of the metabolic syndrome (MetS), raises the question of whether other aspects of an unhealthy diet might be associated with MetS. Main MetS requirements are central obesity and 2 of the following: increased triglycerides, low HDL, increased systolic or diastolic blood pressure, and elevated fasting blood glucose. Of the 18 770 participants in the Oslo Health Study, there were 13 170 respondents (5997 men and 7173 women) with data on MetS factors (except fasting glucose) and on the components used to determine the Dietary Index score (calculated as the intake estimate of soft drinks divided by the sum of intake estimates of fruits and vegetables). MetSRisk was calculated as the sum of arbitrarily weighted factors positively associated with MetS divided by HDL cholesterol. Using regression analyses, the association of the Dietary Index with MetSRisk, with the number of MetS requirements present, and with the complete MetS was studied. In young, middle-aged, and senior men and women, there was, in general, a positive association (p < 0.001) between the Dietary Index and the MetS estimates, which persisted in regression models adjusted for sex, age, time since the last meal, intake of cheese, intake of fatty fish, intake of coffee, intake of alcohol, smoking, physical activity, education, and birthplace. Thus, an index reflecting a high intake of soft drinks and a low intake of fruit and vegetables was positively and independently associated with aspects of MetS.
C1 Univ Oslo, Sect Prevent Med & Epidemiol, N-0318 Oslo, Norway.
C3 University of Oslo
RP Hostmark, AT (corresponding author), Univ Oslo, Sect Prevent Med & Epidemiol, Box 1130 Blindern, N-0318 Oslo, Norway.
EM a.t.hostmark@medisin.uio.no
CR Archer SL, 1998, ANN EPIDEMIOL, V8, P433, DOI 10.1016/S1047-2797(98)00007-6
   BARZEL US, 1995, J BONE MINER RES, V10, P1431, DOI 10.1002/jbmr.5650101002
   Brenner RR, 2003, LIPIDS, V38, P733, DOI 10.1007/s11745-003-1121-x
   Dargent-Molina P, 2008, J BONE MINER RES, V23, P1915, DOI 10.1359/JBMR.080712
   Dhingra R, 2007, CIRCULATION, V116, P480, DOI 10.1161/CIRCULATIONAHA.107.689935
   Dobrzyn A, 2005, PROSTAG LEUKOTR ESS, V73, P35, DOI 10.1016/j.plefa.2005.04.011
   Dobrzyn A, 2005, OBES REV, V6, P169, DOI 10.1111/j.1467-789X.2005.00177.x
   Dobrzyn P, 2008, EUR J LIPID SCI TECH, V110, P93, DOI 10.1002/ejlt.200700249
   Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356
   Heaney RP, 2008, AM J CLIN NUTR, V87, P1567S, DOI 10.1093/ajcn/87.5.1567S
   Hildrum B, 2007, BMC PUBLIC HEALTH, V7, P0, DOI 10.1186/1471-2458-7-220
   Hostmark AT, 2010, CLIN REV OPINIONS, V2, P8
   Hostmark AT, 2009, APPL PHYSIOL NUTR ME, V34, P901, DOI 10.1139/H09-094
   HOSTMARK AT, 1985, ACTA PHYSIOL SCAND, V125, P553, DOI 10.1111/j.1748-1716.1985.tb07755.x
   *INT DIAB FED, 2009, IDF CONS WORLDW DEF, V0, P0
   JENSDOTTIR T, 2006, PMID, V85, P226, DOI 10.1177/154405910608500304.PMID:16498068
   Kapicioglu S, 2000, DIS ESOPHAGUS, V13, P69, DOI 10.1046/j.1442-2050.2000.00082.x
   Merchant AT, 2007, AM J CLIN NUTR, V85, P225
   MOSTOL A, 2004, DIETARY ASSESSMENT W, V0, P0
   MURRAY RK, 2000, HARPERS BIOCH, V0, P281
   Nakamura MT, 2004, ANNU REV NUTR, V24, P345, DOI 10.1146/annurev.nutr.24.121803.063211
   NEWSHOLME EA, 1983, BIOCH MED SCI, V0, P509
   REMER T, 1995, J AM DIET ASSOC, V95, P791, DOI 10.1016/S0002-8223(95)00219-7
   SCHLIERF G, 1973, J CLIN INVEST, V52, P732, DOI 10.1172/JCI107235
   Sidorenkov O, 2010, BMC PUBLIC HEALTH, V10, P0, DOI 10.1186/1471-2458-10-23
   Sogaard AJ, 2004, INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH, V3, P3, DOI 10.1186/1475-9276-3-3
   Taylor EN, 2008, KIDNEY INT, V73, P207, DOI 10.1038/sj.ki.5002588
   van Hees AMJ, 2008, J NUTR, V138, P2399, DOI 10.3945/jn.108.094516
   Warensjö E, 2008, AM J CLIN NUTR, V88, P203, DOI 10.1093/ajcn/88.1.203
   Welch AA, 2008, BRIT J NUTR, V99, P1335, DOI 10.1017/S0007114507862350
NR 30
TC 14
Z9 18
U1 1
U2 7
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 1200 MONTREAL ROAD, BUILDING M-55, OTTAWA, ON K1A 0R6, CANADA
SN 1715-5312
EI 
J9 APPL PHYSIOL NUTR ME
JI Appl. Physiol. Nutr. Metab.
PD DEC 15
PY 2010
VL 35
IS 6
BP 816
EP 825
DI 10.1139/H10-080
PG 10
WC Nutrition & Dietetics; Physiology; Sport Sciences
SC Nutrition & Dietetics; Physiology; Sport Sciences
GA 697YJ
UT WOS:000285555400011
PM 21164553
DA 2025-04-28
ER

PT J
AU Tanaka, K
   Tamaru, S
   Nishizono, S
   Miyata, Y
   Tamaya, K
   Matsui, T
   Tanaka, T
   Echizen, Y
   Ikeda, I
AF Tanaka, Kazunari
   Tamaru, Shizuka
   Nishizono, Shoko
   Miyata, Yuji
   Tamaya, Kei
   Matsui, Toshiro
   Tanaka, Takashi
   Echizen, Yoshie
   Ikeda, Ikuo
TI Hypotriacylglycerolemic and Antiobesity Properties of a New Fermented Tea Product Obtained by Tea-Rolling Processing of Third-Crop Green Tea (Camellia sinensis) Leaves and Loquat (Eriobotrya japonica) Leaves
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE fermented tea; loquat leaves; hypotriacylglycerol; antiobesity; black tea polyphenol
ID fatty-acid synthase; black tea; catechin-polyphenols; lipid-accumulation; lipase; oxidation; caffeine; cultures; enzymes
AB We manufactured a new fermented tea by tea-rolling processing of third-crop green tea (Camellia sinensis) leaves and loquat (Eriobotrya japonica) leaves. The mixed fermented tea extract inhibited pancreatic lipase activity in vitro, and effectively suppressed postprandial hypertriacylglycerolemia in rats. Rats fed a diet containing 1% freeze-dried fermented tea extract for 4 weeks had a significantly lower liver triacylglycerol concentration and white adipose tissue weight than those fed the control diet lacking fermented tea extract. The activity of fatty acid synthase in hepatic cytosol markedly decreased in the fermented tea extract group as compared to the control group. The serum and liver triacylglycerol- and body fat-lowering effects of the mixed fermented tea extract were strong relative to the level of dietary supplementation. These results suggest that the new fermented tea product exhibited hypotriacylglycerolemic and antiobesity properties through suppression of both liver fatty acid synthesis and postprandial hypertriacylglycerolemia by inhibition of pancreatic lipase.
C1 [Tanaka, Kazunari; Tamaru, Shizuka; Nishizono, Shoko; Miyata, Yuji; Echizen, Yoshie] Nagasaki Univ, Grad Sch Human Hlth Sci, Nagoya, Nagasaki 8512195, Japan.
   [Nishizono, Shoko] Miyazaki Univ, Cooperat Res Ctr, Miyazaki 8892191, Japan.
   [Miyata, Yuji] Higashisonogi Tea Branch, Nagasaki Prefectural Agr & Forestry Expt Stn, Higashisonogi, Nagasaki 8593801, Japan.
   [Tamaya, Kei] Ind Technol Ctr Nagasaki, Nagasaki 8560026, Japan.
   [Matsui, Toshiro] Kyushu Univ, Grad Sch, Fac Agr, Higashi Ku, Fukuoka 8128581, Japan.
   [Tanaka, Takashi] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528521, Japan.
   [Echizen, Yoshie; Ikeda, Ikuo] Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi 9818555, Japan.
C3 Nagasaki University; University of Miyazaki; Kyushu University; Nagasaki University; Tohoku University
RP Tanaka, K (corresponding author), Nagasaki Univ, Grad Sch Human Hlth Sci, 1-1-1 Manabino, Nagoya, Nagasaki 8512195, Japan.
EM katanaka@sun.ac.jp
FU Nagasaki Prefecture, Japan
CR Du YT, 2005, J ENZYM INHIB MED CH, V20, P349, DOI 10.1080/14756360500148841
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   FLETCHER MJ, 1968, CLIN CHIM ACTA, V22, P393, DOI 10.1016/0009-8981(68)90041-7
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Fujiki H, 1998, MUTAT RES-FUND MOL M, V402, P307, DOI 10.1016/S0027-5107(97)00310-2
   Han LK, 1999, INT J OBESITY, V23, P174, DOI 10.1038/sj.ijo.0800806
   Han LK, 1999, INT J OBESITY, V23, P98, DOI 10.1038/sj.ijo.0800766
   Han LK, 2001, INT J OBESITY, V25, P1459, DOI 10.1038/sj.ijo.0801747
   Ikeda I, 2005, BIOSCI BIOTECH BIOCH, V69, P1049, DOI 10.1271/bbb.69.1049
   Ikeda I, 2005, J NUTR, V135, P155, DOI 10.1093/jn/135.2.155
   KADA T, 1985, MUTAT RES, V150, P127, DOI 10.1016/0027-5107(85)90109-5
   KELLEY DS, 1986, BIOCHEM J, V235, P87, DOI 10.1042/bj2350087
   KELLEY DS, 1984, BIOCHEM J, V217, P543, DOI 10.1042/bj2170543
   Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411
   Kusano R, 2008, CHEM PHARM BULL, V56, P266, DOI 10.1248/cpb.56.266
   Li RW, 2006, J ETHNOPHARMACOL, V104, P24, DOI 10.1016/j.jep.2005.08.045
   Lin CL, 2007, J LIPID RES, V48, P2334, DOI 10.1194/jlr.M700128-JLR200
   Lin JK, 2006, MOL NUTR FOOD RES, V50, P211, DOI 10.1002/mnfr.200500138
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MARKWELL MA, 1973, J BIOL CHEM, V248, P3426
   Matsui T, 2007, J AGR FOOD CHEM, V55, P99, DOI 10.1021/jf0627672
   Matsumoto N, 1998, J NUTR SCI VITAMINOL, V44, P337, DOI 10.3177/jnsv.44.337
   MIYATA Y, 2006, PATENT NO. 2006013866, V0, P0
   MIYATA Y, 2005, PATENT NO. 2005014129, V0, P0
   Miyata Y, 2010, J JPN SOC FOOD SCI, V57, P171, DOI 10.3136/nskkk.57.171
   Miyata Y, 2009, J JPN SOC FOOD SCI, V56, P647, DOI 10.3136/nskkk.56.647
   Moon HS, 2007, OBESITY, V15, P2571, DOI 10.1038/oby.2007.309
   Nakai M, 2005, J AGR FOOD CHEM, V53, P4593, DOI 10.1021/jf047814+
   OCHOA S, 1955, METHOD ENZYMOL, V1, P739, DOI 10.1016/0076-6879(55)01129-4
   Piccinelli AL, 2004, J AGR FOOD CHEM, V52, P5863, DOI 10.1021/jf040100e
   ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129
   Shishikura Y, 2006, J AGR FOOD CHEM, V54, P1906, DOI 10.1021/jf051988p
   SPERRY WM, 1950, J BIOL CHEM, V187, P97
   Tanaka T, 2002, J AGR FOOD CHEM, V50, P2142, DOI 10.1021/jf011301a
   Tokunaga S, 2002, ANN EPIDEMIOL, V12, P157, DOI 10.1016/S1047-2797(01)00307-6
   Venables MC, 2008, AM J CLIN NUTR, V87, P778, DOI 10.1093/ajcn/87.3.778
   WALTON PA, 1985, ANAL BIOCHEM, V151, P479, DOI 10.1016/0003-2697(85)90208-8
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   Yeh CW, 2003, PHARMACOGENOMICS J, V3, P267, DOI 10.1038/sj.tpj.6500192
   YOSHINO K, 1994, AGE, V17, P79, DOI 10.1007/BF02435010
NR 41
TC 30
Z9 32
U1 2
U2 38
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0916-8451
EI 1347-6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PD AUG 15
PY 2010
VL 74
IS 8
BP 1606
EP 1612
DI 10.1271/bbb.100197
PG 7
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry, Applied; Food Science & Technology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry; Food Science & Technology
GA 648VJ
UT WOS:000281722200015
PM 20699580
DA 2025-04-28
ER

PT J
AU Kent, LM
   Worsley, A
AF Kent, Lillian M.
   Worsley, Anthony
TI Breakfast size is related to body mass index for men, but not women
SO NUTRITION RESEARCH
LA English
DT Article
DE Breakfast; Survey; Dietary practice; BMI; Men; Prudent lifestyle; "Affluent lifestyle"
ID nutrition examination survey; 3rd national-health; weight-gain; consumption; patterns; adolescents; adequacy; children; energy; adults
AB The objective of this study was to examine the effect of self-reported breakfast size, daily eating, and other health habits on body mass index (BMI). We hypothesized that a consumption of a substantial breakfast compared with skipping or small breakfasts would be associated with lower BMI. Three independent, cross-sectional, screening surveys were conducted by Sydney Adventist Hospital in 1976, 1986, and 2005 in the surrounding community. The archived survey forms of 384 men and 338 women in 1976, 244 men and 229 women in 1986, and 270 men and 62 women in 2005 were randomly selected. Body mass index was determined from height and weight measured by hospital staff. The reported amount consumed at breakfast was one of several eating habits that predicted BMI for men but not women. It explained 5% to 6% of the variance in male BMI in all 3 years examined. As the reported breakfast amount increased, men's BMI decreased. Lifestyle confounders including vegetarianism and physical activity did not affect this relationship. However, the consumption of breakfast was significantly positively associated with consumption of cereals, bread, fruit, and spreads, while coffee consumption was significantly associated with smaller breakfasts or breakfast skipping. The consumption of relatively large breakfasts may influence BMI in men, and its promotion may help reduce the prevalence of obesity in Australia and elsewhere. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Kent, Lillian M.] Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia.
   [Worsley, Anthony] Univ Wollongong, Sch Hlth Sci, Wollongong, NSW 2522, Australia.
C3 Australian National University; University of Wollongong
RP Kent, LM (corresponding author), Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia.
EM u4783787@anu.edu.au
FU Deakin University, Melbourne, Australia; Sanitarium Health Food Company; Australian Research Council
CR Albertson AM, 2009, J AM DIET ASSOC, V109, P1557, DOI 10.1016/j.jada.2009.06.363
   Bazzano LA, 2005, OBES RES, V13, P1952, DOI 10.1038/oby.2005.240
   Berg C, 2009, APPETITE, V52, P21, DOI 10.1016/j.appet.2008.07.008
   Bjorntorp P, 2001, OBES REV, V2, P73, DOI 10.1046/j.1467-789x.2001.00027.x
   Cho S, 2003, J AM COLL NUTR, V22, P296, DOI 10.1080/07315724.2003.10719307
   Dubois L, 2009, PUBLIC HEALTH NUTR, V12, P19, DOI 10.1017/S1368980008001894
   EGGER G, 1996, FAT LOSS HDB GUIDE P, V0, P0
   Erlichman J, 2002, OBES REV, V3, P273, DOI 10.1046/j.1467-789X.2002.00078.x
   Fiore H, 2006, J AM DIET ASSOC, V106, P55, DOI 10.1016/j.jada.2005.09.046
   Fulton JE, 2009, ARCH INTERN MED, V169, P2124, DOI 10.1001/archinternmed.2009.413
   Grimes DA, 2002, LANCET, V359, P248, DOI 10.1016/S0140-6736(02)07451-2
   Haines PS, 2003, OBES RES, V11, P945, DOI 10.1038/oby.2003.130
   Isaksson Hanna, 2008, FOOD NUTR RES, V52, P0, DOI 10.3402/fnr.v52i0.1809
   Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364
   Kent LM, 2009, ASIA PAC J CLIN NUTR, V18, P453
   Keski-Rahkonen A, 2003, EUR J CLIN NUTR, V57, P842, DOI 10.1038/sj.ejcn.1601618
   Louie JCY, 2008, ASIA PAC J CLIN NUTR, V17, P657
   MARMOT M, 2001, B WORLD HEALTH ORGAN, V79, P906
   Nicklas TA, 1998, J AM DIET ASSOC, V98, P1432, DOI 10.1016/S0002-8223(98)00325-3
   Rampersaud GC, 2005, J AM DIET ASSOC, V105, P743, DOI 10.1016/j.jada.2005.02.007
   Ravussin E, 2002, J CLIN INVEST, V109, P1537, DOI 10.1172/JCI200216045
   Song WO, 2005, J AM DIET ASSOC, V105, P1373, DOI 10.1016/j.jada.2005.06.002
   Swinburn BA, 2004, PUBLIC HEALTH NUTR, V7, P123, DOI 10.1079/PHN2003585
   Szajewska H, 2010, CRIT REV FOOD SCI, V50, P113, DOI 10.1080/10408390903467514
   van der Heijden AAWA, 2007, OBESITY, V15, P2463, DOI 10.1038/oby.2007.292
   Willett WC, 1999, AM J CLIN NUTR, V70, P434S, DOI 10.1093/ajcn/70.3.434s
   Williams BM, 2009, PUBLIC HEALTH NUTR, V12, P489, DOI 10.1017/S1368980008002760
   Williams P, 2002, NUTRITION & DIETETICS, V59, P103
   Williams P, 2005, INT J FOOD SCI NUTR, V56, P65, DOI 10.1080/09637480500082108
   Wilson DM, 2010, OBESITY, V18, P402, DOI 10.1038/oby.2009.261
   Wing RR, 2005, AM J CLIN NUTR, V82, P222S, DOI 10.1093/ajcn/82.1.222S
   Worsley A, 2004, PUBLIC HEALTH NUTR, V7, P649, DOI 10.1079/PHN2003577
NR 32
TC 18
Z9 20
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
EI 
J9 NUTR RES
JI Nutr. Res.
PD APR 15
PY 2010
VL 30
IS 4
BP 240
EP 245
DI 10.1016/j.nutres.2010.03.006
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 610CD
UT WOS:000278706400003
PM 20534326
DA 2025-04-28
ER

PT J
AU Phung, OJ
   Baker, WL
   Matthews, LJ
   Lanosa, M
   Thorne, A
   Coleman, CI
AF Phung, Olivia J.
   Baker, William L.
   Matthews, Leslie J.
   Lanosa, Michael
   Thorne, Alicia
   Coleman, Craig I.
TI Effect of green tea catechins with or without caffeine on anthropometric measures: a systematic review and meta-analysis
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID randomized controlled-trial; energy-expenditure; body-fat; cardiovascular-disease; weight maintenance; abdominal fat; double-blind; obesity; extract; consumption
AB Background: Green tea catechins (GTCs) with or without caffeine have been studied in randomized controlled trials (RCTs) for their effect on anthropometric measures and have yielded conflicting results. Objective: The objective was to perform a systematic review and meta-analysis of RCTs of GTCs on anthropometric variables, including body mass index (BMI), body weight, waist circumference (WC), and waist-to-hip ratio (WHR). Design: A systematic literature search of MEDLINE, EMBASE, CENTRAL, and the Natural Medicines Comprehensive Database was conducted through April 2009. RCTs that evaluated GTCs with or without caffeine and that reported BMI, body weight, WC, or WHR were included. The weighted mean difference of change from baseline (with 95% CIs) was calculated by using a random-effects model. Results: Fifteen studies (n = 1243 patients) met the inclusion criteria. On meta-analysis, GTCs with caffeine decreased BMI (-0.55; 95% CI: -0.65, -0.40), body weight (-1.38 kg; 95% CI: -1.70, -1.06), and WC (-1.93 cm; 95% CI: -2.82, -1.04) but not WHR compared with caffeine alone. GTC ingestion with caffeine also significantly decreased body weight (-0.44 kg; 95% CI: -0.72, -0.15) when compared with a caffeine-free control. Studies that evaluated GTCs without concomitant caffeine administration did not show benefits on any of the assessed anthropometric endpoints. Conclusions: The administration of GTCs with caffeine is associated with statistically significant reductions in BMI, body weight, and WC; however, the clinical significance of these reductions is modest at best. Current data do not suggest that GTCs alone positively alter anthropometric measurements. Am J Clin Nutr 2010; 91: 73-81.
C1 [Phung, Olivia J.; Baker, William L.; Matthews, Leslie J.; Lanosa, Michael; Coleman, Craig I.] Univ Connecticut, Sch Pharm, Storrs, CT USA.
   [Phung, Olivia J.; Baker, William L.] Hartford Hosp, Dept Drug Informat, Hartford, CT 06115 USA.
   [Thorne, Alicia] Cleveland Clin, Cleveland, OH 44106 USA.
C3 University of Connecticut; Hartford Hospital; Cleveland Clinic Foundation
RP Coleman, CI (corresponding author), Univ Connecticut, Sch Pharm, Pharmacoecon & Outcomes Studies Grp, Hartford Hosp, 80 Seymour St, Hartford, CT 06102 USA.
EM ccolema@harthosp.org
CR Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643
   *AM DIET ASS, 2008, EV AN MAN AD DIET GU, V0, P0
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Auvichayapat P, 2008, PHYSIOL BEHAV, V93, P486, DOI 10.1016/j.physbeh.2007.10.009
   BAX L, 2008, MIX COMPREHENSIVE FR, V0, P0
   Bax L, 2007, BMC MED RES METHODOL, V7, P0, DOI 10.1186/1471-2288-7-40
   Burke GL, 2008, ARCH INTERN MED, V168, P928, DOI 10.1001/archinte.168.9.928
   Chan CCW, 2006, J SOC GYNECOL INVEST, V13, P63, DOI 10.1016/j.jsgi.2005.10.006
   Chow HHS, 2005, CLIN CANCER RES, V11, P4627, DOI 10.1158/1078-0432.CCR-04-2549
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Diepvens K, 2006, PHYSIOL BEHAV, V87, P185, DOI 10.1016/j.physbeh.2005.09.013
   Diepvens K, 2005, BRIT J NUTR, V94, P1026, DOI 10.1079/BJN20051580
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q
   Frank J, 2009, J NUTR, V139, P58, DOI 10.3945/jn.108.096412
   Fukino Y, 2008, EUR J CLIN NUTR, V62, P953, DOI 10.1038/sj.ejcn.1602806
   Fukino Y, 2005, J NUTR SCI VITAMINOL, V51, P335, DOI 10.3177/jnsv.51.335
   Goto T, 1996, J CHROMATOGR A, V749, P295, DOI 10.1016/0021-9673(96)00456-6
   Guh DP, 2009, BMC PUBLIC HEALTH, V9, P0, DOI 10.1186/1471-2458-9-88
   Higgins JP, 2011, COCHRANE HDB SYSTEMA, V5, P0
   Hill AM, 2007, J AM COLL NUTR, V26, P396S, DOI 10.1080/07315724.2007.10719628
   Hsu CH, 2008, CLIN NUTR, V27, P363, DOI 10.1016/j.clnu.2008.03.007
   Hursel R, 2009, AM J CLIN NUTR, V89, P822, DOI 10.3945/ajcn.2008.27043
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   Lloyd-Jones D, 2009, CIRCULATION, V119, PE21, DOI 10.1161/CIRCULATIONAHA.108.191261
   Maki KC, 2009, J NUTR, V139, P264, DOI 10.3945/jn.108.098293
   Maron DJ, 2003, ARCH INTERN MED, V163, P1448, DOI 10.1001/archinte.163.12.1448
   Matsuyama T, 2008, OBESITY, V16, P1338, DOI 10.1038/oby.2008.60
   McKay DL, 2007, J AM COLL NUTR, V26, P362S, DOI 10.1080/07315724.2007.10719624
   Nádas J, 2008, MED SCI MONITOR, V14, P0
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nagao T, 2007, OBESITY, V15, P1473, DOI 10.1038/oby.2007.176
   Nagao T, 2009, OBESITY, V17, P310, DOI 10.1038/oby.2008.505
   PISUNYER X, 1998, CLIN GUIDELINES IDEN, V0, P0
   Sarma DN, 2008, DRUG SAFETY, V31, P469, DOI 10.2165/00002018-200831060-00003
   Takeshita M, 2008, JPN PHARMACOL THER, V36, P767
   Thielecke F, 2009, PHYTOCHEMISTRY, V70, P11, DOI 10.1016/j.phytochem.2008.11.011
   TSUCHIDA T, 2002, PROGR MED, V22, P2189
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   Wu CH, 2003, OBES RES, V11, P1088, DOI 10.1038/oby.2003.149
NR 43
TC 133
Z9 150
U1 1
U2 38
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JAN 15
PY 2010
VL 91
IS 1
BP 73
EP 81
DI 10.3945/ajcn.2009.28157
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 534SM
UT WOS:000272917600011
PM 19906797
DA 2025-04-28
ER

PT J
AU Esfahani, FH
   Asghari, G
   Mirmiran, P
   Azizi, F
AF Esfahani, Firoozeh Hosseini
   Asghari, Golaleh
   Mirmiran, Parvin
   Azizi, Fereidoun
TI Reproducibility and Relative Validity of Food Group Intake in a Food Frequency Questionnaire Developed for the Tehran Lipid and Glucose Study
SO JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE food frequency questionnaire; validity and reproducibility; food group; Tehran
ID dietary questionnaire; noncommunicable disease; nutrient adequacy; pilot phase; validation; obesity; prevention; cohort; population; cancer
AB Objective: To examine the validity and reproducibility of food groups in the semi-quantitative food frequency questionnaire (FFQ) developed for the Tehran Lipid and Glucose Study (TLGS). Methods: To evaluate the reproducibility of food groups included in the FFQ, 132 Subjects (61 men and 71 women) aged 20 years or older twice completed a 168-item FFQ (FFQ1, FFQ2), with a 14-month interval between FFQ1 and FFQ2. Over the 1-year interval, 12 dietary recalls (DRs) were collected (1 each month) to assess the validity of the FFQ. Seventeen food groups were derived front the FFQ based on methods described in previous studies. Age-adjusted and deattenuated Spearman correlation coefficients were used to assess the validity of the FFQ. Results: The mean (SD) age and body mass index of subjects were 35.5 (16.8) years and 25.5 (5.2)kg/m(2), respectively. Validity correlation coefficients ranged from 0.03 (liquid oil) to 0.77 (simple Sugars) in men (median, 0.44), and from 0.12 (snacks) to 0.79 (simple Sugars) in women (median, 0.37). The energy-adjusted intraclass correlation coefficient, which reflects the reproducibility of the FFQ, was 0.51 in men and was highest for tea and coffee (0.91); in women it vas 0.59 and was highest for simple sugars (0.74). The highest percentage of complete agreement and disagreement was observed for snacks and desserts (60.6%) and potatoes and dairy products (12.8%), respectively, in men, and tea and coffee (62.9%) and legumes (15.7%) in women. Conclusions: The FFQ that was designed for the TLGS was found to be reliable and valid for assessing the intake of several food groups.
C1 [Esfahani, Firoozeh Hosseini; Asghari, Golaleh; Mirmiran, Parvin] Shahid Beheshti Univ Med Sci, Obes Res Ctr, Res Inst Endocrine Sci, Tehran 193954763, Iran.
   [Mirmiran, Parvin] Shahid Beheshti Univ Med Sci, Dept Human Nutr, Fac Nutr & Food Technol, Natl Nutr & Food Technol Inst, Tehran 193954763, Iran.
   [Azizi, Fereidoun] Shahid Beheshti Univ Med Sci, Endocrine Res Ctr, Res Inst Endocrine Sci, Tehran 193954763, Iran.
C3 Shahid Beheshti University Medical Sciences; Shahid Beheshti University Medical Sciences; Shahid Beheshti University Medical Sciences
RP Mirmiran, P (corresponding author), Shahid Beheshti Univ Med Sci, Obes Res Ctr, Res Inst Endocrine Sci, 24 Parvaneh St,Yemen Ave, Tehran 193954763, Iran.
EM mirmiran@endocrine.ac.ir
FU Research Institute or Endocrine Sciences, Shahid Beheshti University of Medical Sciences, I.R. Iran [098]
CR Unknown -, 1997, INT J EPIDEMIOL, V26 Suppl 1, P0
   Azadbakht L, 2005, EUR J CLIN NUTR, V59, P1233, DOI 10.1038/sj.ejcn.1602234
   Azizi F, 2002, SOZ PRAVENTIV MED, V47, P408, DOI 10.1007/s000380200008
   Azizi F, 2009, TRIALS, V10, P0, DOI 10.1186/1745-6215-10-5
   BohlscheidThomas S, 1997, INT J EPIDEMIOL, V26, PS59, DOI 10.1093/ije/26.suppl_1.S59
   Cade J, 2002, PUBLIC HEALTH NUTR, V5, P567, DOI 10.1079/PHN2001318
   Chiuve SE, 2008, CIRCULATION, V118, P947, DOI 10.1161/CIRCULATIONAHA.108.781062
   Date C, 2005, J EPIDEMIOL, V15, PS9, DOI 10.2188/jea.15.S9
   Ebrahimpour Pantea, 2006, METABOLIC SYNDROME AND RELATED DISORDERS, V4, P172, DOI 10.1089/met.2006.4.172
   Elwood PC, 2007, J EPIDEMIOL COMMUN H, V61, P695, DOI 10.1136/jech.2006.053157
   FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E
   Ghafarpour M, 1999, THE MANUAL FOR HOUSEHOLD MEASURES, V0, P0
   Gill Tim, 2006, ASIA PAC J CLIN NUTR, V15 Suppl, P3
   GOLDBOHM RA, 1994, EUR J CLIN NUTR, V48, P253
   Hu FB, 1999, AM J CLIN NUTR, V69, P243
   Johansson I, 2002, PUBLIC HEALTH NUTR, V5, P487, DOI 10.1079/PHN2001315
   Kaaks R, 1997, INT J EPIDEMIOL, V26, PS26, DOI 10.1093/ije/26.suppl_1.S26
   Kelishadi R, 2008, PUBLIC HEALTH NUTR, V11, P246, DOI 10.1017/S1368980007000262
   Kimiagar M, 1995, NATL FOOD CONSUMPTIO, V0, P0
   Kipnis V, 2003, AM J EPIDEMIOL, V158, P14, DOI 10.1093/aje/kwg091
   Larsen L, 2006, J AM ACAD NURSE PRAC, V18, P70, DOI 10.1111/j.1745-7599.2006.00105.x
   Malekshah AF, 2006, EUR J CLIN NUTR, V60, P971, DOI 10.1038/sj.ejcn.1602407
   Marks GC, 2006, J NUTR, V136, P459, DOI 10.1093/jn/136.2.459
   McCullough ML, 2003, CANCER CAUSE CONTROL, V14, P959, DOI 10.1023/B:CACO.0000007983.16045.a1
   Mirmiran P, 2006, J AM COLL NUTR, V25, P354, DOI 10.1080/07315724.2006.10719546
   Nagel G, 2007, BRIT J NUTR, V98, P194, DOI 10.1017/S0007114507691636
   Ocke MC, 1997, INT J EPIDEMIOL, V26, PS37, DOI 10.1093/ije/26.suppl_1.S37
   Ocke MC, 1997, AM J CLIN NUTR, V65, P1240
   Pisani P, 1997, INT J EPIDEMIOL, V26, PS152, DOI 10.1093/ije/26.suppl_1.S152
   ROSNER B, 1988, AM J EPIDEMIOL, V127, P377, DOI 10.1093/oxfordjournals.aje.a114811
   SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858
   Schatzkin A, 2003, INT J EPIDEMIOL, V32, P1054, DOI 10.1093/ije/dyg264
   Schröder H, 2004, J NUTR, V134, P3355, DOI 10.1093/jn/134.12.3355
   Sturm R, 2008, PUBLIC HEALTH, V122, P739, DOI 10.1016/j.puhe.2008.01.004
   Willett WC, 1998, NUTR EPIDEMIOLOGY, V0, P0
NR 36
TC 623
Z9 632
U1 0
U2 12
PU JAPAN EPIDEMIOLOGICAL ASSOC
PI FUKUOKA
PA FUKUOKA INST HEALTH & ENVIRONMENTAL SCIENCES, MUKAIZANO 39, DAZAIFU, FUKUOKA, 818-0135, JAPAN
SN 0917-5040
EI 
J9 J EPIDEMIOL
JI J. Epidemiol.
PD MAR 15
PY 2010
VL 20
IS 2
BP 150
EP 158
DI 10.2188/jea.JE20090083
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 568BR
UT WOS:000275497300010
PM 20154450
DA 2025-04-28
ER

PT J
AU Kao, CC
   Wu, BT
   Tsuei, YW
   Shih, LJ
   Kuo, YL
   Kao, YH
AF Kao, Chung-Cheng
   Wu, Bo-Tsung
   Tsuei, Yi-Wei
   Shih, Li-Jane
   Kuo, Yu-Liang
   Kao, Yung-Hsi
TI Green Tea Catechins: Inhibitors of Glycerol-3-Phosphate Dehydrogenase
SO PLANTA MEDICA
LA English
DT Article
DE green tea; Camellia sinensis; Theaceae; epigallocatechin-3-gallate
ID epigallocatechin gallate; polyphenols; (-)-epigallocatechin-3-gallate; accumulation; mechanisms; caffeine
AB Green tea catechins, especially (-)-epigallocatechin-3-gallate (EGCG), are known to regulate obesity and fat accumulation. We performed a kinetic analysis in a cell-free system to determine the mode of inhibition of glycerol-3-phosphate dehydrogenase (GPDH; EC 1.1.1.8) by EGCG. GPDH catalyzes the beta-nicotinamide adenine dinucleotide (NADH)-dependent reduction of dihydroxyacetone phosphate (DHAP) to yield glycerol-3-phosphate, which serves as one of the major precursors of triacylglycerols. We found that EGCG dose-dependently inhibited GPDH activity at a concentration of approximately 20 mu M for 50% inhibition. The IC50 values of other green tea catechins, such as (-)-epicatechin, (-)-epicatechin-3-gallate, and (-)-epigallocatechin, were all above 100 mu M. This suggests a catechin type-dependent effect. Based on double-reciprocal plots of the kinetic data, EGCG was a noncompetitive inhibitor of the GPDH substrates, NADH and DHAP, with respective inhibition constants (Ki) of 18 and 31 mu M. Results of this study possibly support previous studies that EGCG mediates fat content.
C1 [Wu, Bo-Tsung; Kao, Yung-Hsi] Natl Cent Univ, Dept Life Sci, Jhongli 32001, Taoyuan County, Taiwan.
   [Kao, Chung-Cheng; Tsuei, Yi-Wei] Armed Forces Taoyuan Gen Hosp, Dept Emergency, Tao Yuan, Taiwan.
   [Shih, Li-Jane] Armed Forces Taoyuan Gen Hosp, Dept Joint Lab, Tao Yuan, Taiwan.
   [Kuo, Yu-Liang] Armed Forces Taoyuan Gen Hosp, Dept Obstet & Gynecol, Natl Def Med Ctr, Tao Yuan, Taiwan.
C3 National Central University; National Defense Medical Center
RP Kao, YH (corresponding author), Natl Cent Univ, Dept Life Sci, 300 Jhongda Rd, Jhongli 32001, Taoyuan County, Taiwan.
EM ykao@cc.ncu.edu.tw
FU National Science Council, Taiwan [NSC95-2311-B-008-008-MY3/NSC98-2311-B-008-001-MY3]; Taoyuan Armed Forces General Hospital; CGH-NCU Joint Research Foundation [CNJRF-98CGH-NCU-B3]
CR Abe I, 2000, BIOCHEM BIOPH RES CO, V268, P767, DOI 10.1006/bbrc.2000.2217
   Abe I, 2000, FEBS LETT, V483, P131, DOI 10.1016/S0014-5793(00)02100-1
   Calixto Joao B, 2004, PLANTA MEDICA, V70, P93
   Chen D, 2005, BIOCHEM PHARMACOL, V69, P1523, DOI 10.1016/j.bcp.2005.01.024
   CHOSH KS, 2004, BIOCHEM BIOPH RES CO, V325, P807
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Furuyashiki T, 2004, BIOSCI BIOTECH BIOCH, V68, P2353, DOI 10.1271/bbb.68.2353
   Haslam E, 1996, J NAT PROD, V59, P205, DOI 10.1021/np960040+
   Hiipakka RA, 2002, BIOCHEM PHARMACOL, V63, P1165, DOI 10.1016/S0006-2952(02)00848-1
   Hwang JT, 2005, BIOCHEM BIOPH RES CO, V338, P694, DOI 10.1016/j.bbrc.2005.09.195
   IRELAND RC, 1986, J BIOL CHEM, V261, P1779
   Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109
   Koyama Y, 2004, PLANTA MED, V70, P1100, DOI 10.1055/s-2004-832659
   Ku HC, 2009, AM J PHYSIOL-CELL PH, V297, PC121, DOI 10.1152/ajpcell.00272.2008
   Lambert JD, 2003, J NUTR, V133, P3262S, DOI 10.1093/jn/133.10.3262S
   LEE MJ, 1995, CANCER EPIDEM BIOMAR, V4, P393
   Lee WJ, 2005, MOL PHARMACOL, V68, P1018, DOI 10.1124/mol.104.008367
   Liao SS, 2001, VITAM HORM, V62, P1, DOI 10.1016/S0083-6729(01)62001-6
   Lin JK, 2006, MOL NUTR FOOD RES, V50, P211, DOI 10.1002/mnfr.200500138
   Mandel S, 2004, J NEUROCHEM, V88, P1555, DOI 10.1046/j.1471-4159.2003.02291.x
   Mochizuki M, 2004, PHYTOTHER RES, V18, P449, DOI 10.1002/ptr.1437
   Moon HS, 2007, OBESITY, V15, P2571, DOI 10.1038/oby.2007.309
   Rejman J, 2004, J AGR FOOD CHEM, V52, P246, DOI 10.1021/jf034745a
   ROBERTS EAH, 1952, J SCI FOOD AGR, V3, P193, DOI 10.1002/jsfa.2740030501
   Ullmann U, 2003, J INT MED RES, V31, P88, DOI 10.1177/147323000303100205
   Wang CT, 2009, MOL NUTR FOOD RES, V53, P349, DOI 10.1002/mnfr.200800013
   Wang X, 2001, BIOCHEM BIOPH RES CO, V288, P1200, DOI 10.1006/bbrc.2001.5923
   WISE LS, 1979, J BIOL CHEM, V254, P273
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038
NR 31
TC 13
Z9 16
U1 0
U2 3
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0032-0943
EI 1439-0221
J9 PLANTA MED
JI Planta Med.
PD MAY 15
PY 2010
VL 76
IS 7
BP 694
EP 696
DI 10.1055/s-0029-1240623
PG 3
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine
GA 596BT
UT WOS:000277659000008
PM 19937554
DA 2025-04-28
ER

PT J
AU Savica, V
   Bellinghieri, G
   Kopple, JD
AF Savica, Vincenzo
   Bellinghieri, Guido
   Kopple, Joel D.
TI The Effect of Nutrition on Blood Pressure
SO ANNUAL REVIEW OF NUTRITION, VOL 30
LA English
DT Review; Book Chapter
DE diet; obesity; salt; hypertension; dietary compliance; public health
ID obstructive sleep-apnea; coffee bean extract; life-style modification; coronary-heart-disease; body-mass index; obesity-associated hypertension; cardiovascular risk-factors; randomized controlled-trial; atrial-natriuretic-peptide; sympathetic-nerve activity
AB The incidence and severity of hypertension are affected by nutritional status and intake of many nutrients. Excessive energy intake and obesity arc major causes of hypertension. Obesity is associated with increased activity of the renin-angiotensin-aldosterone and sympathetic nervous systems, possibly other mineralcorticoid activity, insulin resistance, salt-sensitive hypertension and excess salt intake, and reduced kidney function. High sodium chloride intake strongly predisposes to hypertension. Increased alcohol consumption may acutely elevate blood pressure. High intakes of potassium, polyunsaturated fatty acids, and protein, along with exercise and possibly vitamin D, may reduce blood pressure. Less-conclusive studies suggest that amino acids, tea, green coffee bean extract, dark chocolate, and foods high in nitrates may reduce blood pressure. Short-term studies indicate that specialized diets may prevent or ameliorate mild hypertension; most notable are the Dietary Approaches to Stop Hypertension (DASH) diet, which is high in fruits, vegetables, and low-fat dairy products, and the DASH low-sodium diet. Long-term compliance to these diets remains a major concern.
C1 [Savica, Vincenzo] Univ Messina, Nephrol Unit, I-98168 Messina, Italy.
   [Savica, Vincenzo] Univ Messina, Unit Dialysis, Papardo Hosp, I-98168 Messina, Italy.
   [Kopple, Joel D.] Univ Calif Los Angeles, Los Angeles Biomed Res Inst, Harbor UCLA Med Ctr, David Geffen Sch Med, Torrance, CA 90501 USA.
   [Kopple, Joel D.] Univ Calif Los Angeles, Sch Publ Hlth, Torrance, CA 90501 USA.
   [Savica, Vincenzo; Bellinghieri, Guido] Univ Messina, Polyclin, I-98168 Messina, Italy.
C3 University of Messina; University of Messina; Lundquist Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of Messina
RP Savica, V (corresponding author), Univ Messina, Nephrol Unit, I-98168 Messina, Italy.
EM jkopple@labiomed.org
CR Allender PS, 1996, ANN INTERN MED, V124, P825, DOI 10.7326/0003-4819-124-9-199605010-00007
   Almeida OP, 2009, AM J GERIAT PSYCHIAT, V17, P889, DOI 10.1097/JGP.0b013e3181b047e3
   ALTURA BM, 1984, SCIENCE, V223, P1315, DOI 10.1126/science.6701524
   Unknown -, 1990, ARCH INTERN MED, V150, P153, DOI 10.1001/archinte.150.1.153
   Unknown -, 2004, DIET REF INT WAT POT, V0, P0
   Unknown -, 2005, DIETARY GUIDELINES FOR AMERICANS, V0, P0
   Antonios TFT, 1996, LANCET, V348, P250, DOI 10.1016/S0140-6736(96)01463-8
   Appel LJ, 2006, HYPERTENSION, V47, P296, DOI 10.1161/01.HYP.0000202568.01167.B6
   APPEL LJ, 1993, ARCH INTERN MED, V153, P1429, DOI 10.1001/archinte.153.12.1429
   Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083
   Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601
   Azadbakht L, 2005, DIABETES CARE, V28, P2823, DOI 10.2337/diacare.28.12.2823
   Baguet JP, 2006, J HYPERTENS, V24, P205, DOI 10.1097/01.hjh.0000198039.39504.63
   BARKER DJP, 1995, EUR J CLIN INVEST, V25, P457, DOI 10.1111/j.1365-2362.1995.tb01730.x
   Barri YM, 1997, AM J MED SCI, V314, P37, DOI 10.1097/00000441-199707000-00008
   Beltowski J, 2006, J HYPERTENS, V24, P789
   Blaine B, 2008, J HEALTH PSYCHOL, V13, P1190, DOI 10.1177/1359105308095977
   Bouillon R, 2009, AM J HYPERTENS, V22, P816, DOI 10.1038/ajh.2009.105
   Brancati FL, 1996, ARCH INTERN MED, V156, P61, DOI 10.1001/archinte.156.1.61
   Brook RD, 2001, AM J CARDIOL, V88, P1264, DOI 10.1016/S0002-9149(01)02088-4
   Bucher HC, 1996, JAMA-J AM MED ASSOC, V275, P1016, DOI 10.1001/jama.275.13.1016
   Burke V, 2005, J HYPERTENS, V23, P1241, DOI 10.1097/01.hjh.0000170388.61579.4f
   Burke V, 2001, HYPERTENSION, V38, P821, DOI 10.1161/hy1001.092614
   Burke V, 2008, NUTR METAB CARDIOVAS, V18, P198, DOI 10.1016/j.numecd.2006.10.004
   Burke V, 2008, HEALTH EDUC RES, V23, P202, DOI 10.1093/her/cym017
   Cakir H, 2006, WESTERN J NURS RES, V28, P190, DOI 10.1177/0193945905283367
   Canoy D, 2004, J HYPERTENS, V22, P2067, DOI 10.1097/00004872-200411000-00007
   CAPPUCCIO FP, 1995, AM J EPIDEMIOL, V142, P935, DOI 10.1093/oxfordjournals.aje.a117741
   CAPPUCCIO FP, 1991, J HYPERTENS, V9, P465, DOI 10.1097/00004872-199105000-00011
   CAPPUCCIO FP, 1985, BMJ-BRIT MED J, V291, P235, DOI 10.1136/bmj.291.6490.235
   Chamarthi B, 2007, J CLIN ENDOCR METAB, V92, P1340, DOI 10.1210/jc.2006-2093
   Chen ZY, 2009, J AGR FOOD CHEM, V57, P4485, DOI 10.1021/jf900803r
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Collier SR, 2008, J HUM HYPERTENS, V22, P678, DOI 10.1038/jhh.2008.36
   Cooper R, 1997, J HUM HYPERTENS, V11, P107, DOI 10.1038/sj.jhh.1000391
   Corti R, 2002, CIRCULATION, V106, P2935, DOI 10.1161/01.CIR.0000046228.97025.3A
   Cottrell EC, 2007, P NUTR SOC, V66, P198, DOI 10.1017/S0029665107005447
   Curhan GC, 1998, J AM SOC NEPHROL, V9, P1645
   Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S
   CUTLER JA, 1991, HYPERTENSION, V17, PI27, DOI 10.1161/01.HYP.17.1_Suppl.I27
   Danoviz ME, 2006, CLIN EXP PHARMACOL P, V33, P248, DOI 10.1111/j.1440-1681.2006.04353.x
   Dauchet L, 2006, J NUTR, V136, P2588, DOI 10.1093/jn/136.10.2588
   de Brito-Ashurst I, 2009, J AM SOC NEPHROL, V20, P2075, DOI 10.1681/ASN.2008111205
   De Nicola L, 2005, SEMIN NEPHROL, V25, P425, DOI 10.1016/j.semnephrol.2005.05.014
   Dengel DR, 2007, PHYSIOL RES, V56, P393, DOI 10.33549/physiolres.931002
   DEPERGOLA G, 1994, INT J OBESITY, V18, P93
   Dessì-Fulgheri P, 1997, J HYPERTENS, V15, P1695, DOI 10.1097/00004872-199715120-00074
   DORNFELD LP, 1987, KIDNEY INT, V32, P0
   DORNFELD LP, 1985, INT J OBESITY, V9, P381
   Elmer PJ, 2006, ANN INTERN MED, V144, P485, DOI 10.7326/0003-4819-144-7-200604040-00007
   Engler MB, 2004, J AM COLL NUTR, V23, P197, DOI 10.1080/07315724.2004.10719361
   Eriksson J, 2000, HYPERTENSION, V36, P790, DOI 10.1161/01.HYP.36.5.790
   Esposito K, 2006, DIABETES CARE, V29, P954, DOI 10.2337/diacare.29.04.06.dc05-2541
   Feig DI, 2008, NEW ENGL J MED, V359, P1811, DOI 10.1056/NEJMra0800885
   Feig DI, 2008, JAMA-J AM MED ASSOC, V300, P924, DOI 10.1001/jama.300.8.924
   Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42
   Fisher NDL, 2003, J HYPERTENS, V21, P2281, DOI 10.1097/00004872-200312000-00016
   Folsom AR, 2007, AM J HYPERTENS, V20, P225, DOI 10.1016/j.amjhyper.2006.09.003
   Ford ES, 2008, AM J HYPERTENS, V21, P1124, DOI 10.1038/ajh.2008.246
   Forman JP, 2009, JAMA-J AM MED ASSOC, V302, P401, DOI 10.1001/jama.2009.1060
   Friedrich MJ, 2002, JAMA-J AM MED ASSOC, V287, P1382, DOI 10.1001/jama.287.11.1382
   Fuchs FD, 2001, HYPERTENSION, V37, P1242, DOI 10.1161/01.HYP.37.5.1242
   Fujita T, 2008, CURR HYPERTENS REP, V10, P421, DOI 10.1007/s11906-008-0078-y
   Fujita T, 2008, J MOL MED, V86, P729, DOI 10.1007/s00109-008-0343-1
   Funatsu K, 2005, HYPERTENS RES, V28, P521, DOI 10.1291/hypres.28.521
   Funk KL, 2008, HEALTH PROMOT PRACT, V9, P271, DOI 10.1177/1524839906289035
   Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI 10.1172/JCI20042162S
   Gallen IW, 1998, AM J KIDNEY DIS, V31, P19, DOI 10.1053/ajkd.1998.v31.pm9428447
   Gao SK, 2009, ARCH INTERN MED, V169, P702, DOI 10.1001/archinternmed.2009.17
   Govindarajan G, 2005, AM J MED SCI, V330, P311, DOI 10.1097/00000441-200512000-00009
   Grassi D, 2005, HYPERTENSION, V46, P398, DOI 10.1161/01.HYP.0000174990.46027.70
   Grassi D, 2005, AM J CLIN NUTR, V81, P611
   Grassi G, 2008, J NEUROENDOCRINOL, V20, P63, DOI 10.1111/j.1365-2826.2008.01688.x
   Grassi G, 2005, HYPERTENSION, V46, P321, DOI 10.1161/01.HYP.0000174243.39897.6c
   Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383
   Griffith LE, 1999, AM J HYPERTENS, V12, P84, DOI 10.1016/S0895-7061(98)00224-6
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   Hafidh S, 2005, AM J MED SCI, V330, P343, DOI 10.1097/00000441-200512000-00013
   Hamano S, 2005, INT J UROL, V12, P859, DOI 10.1111/j.1442-2042.2005.01160.x
   HARIHARAN S, 1991, J LAB CLIN MED, V117, P423
   Haynes WG, 1997, J CLIN INVEST, V100, P270, DOI 10.1172/JCI119532
   He F, 2002, J HUM HYPERTENS, V16, P761, DOI 10.1038/sj.jhh.1001459
   He FJ, 2006, LANCET, V367, P320, DOI 10.1016/S0140-6736(06)68069-0
   He J, 2005, ANN INTERN MED, V143, P1, DOI 10.7326/0003-4819-143-1-200507050-00004
   Hebert Patricia R, 1995, ANNALS OF EPIDEMIOLOGY, V5, P130, DOI 10.1016/1047-2797(94)00057-Z
   HENSON LC, 1987, AM J CLIN NUTR, V46, P893, DOI 10.1093/ajcn/46.6.893
   Higdon JV, 2006, CRIT REV FOOD SCI, V46, P101, DOI 10.1080/10408390500400009
   HISHIKAWA K, 1992, JPN HEART J, V33, P41
   Hodgson JM, 2006, CLIN EXP PHARMACOL P, V33, P838, DOI 10.1111/j.1440-1681.2006.04450.x
   Hodgson JM, 2005, J HYPERTENS, V23, P47, DOI 10.1097/00004872-200501000-00012
   Hodgson JM, 2002, CLIN SCI, V102, P195, DOI 10.1042/CS20010120
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Hord NG, 2009, AM J CLIN NUTR, V90, P1, DOI 10.3945/ajcn.2008.27131
   Horvath K, 2008, ARCH INTERN MED, V168, P571, DOI 10.1001/archinte.168.6.571
   Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P655, DOI 10.1001/jama.295.6.655
   Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102
   Huxley R, 2008, OBES REV, V9, P53, DOI 10.1111/j.1467-789X.2007.00439.x
   Ip MSM, 2002, AM J RESP CRIT CARE, V165, P670, DOI 10.1164/ajrccm.165.5.2103001
   Jafar TH, 2006, CAN MED ASSOC J, V175, P1071, DOI 10.1503/cmaj.060464
   Jee SH, 1999, HYPERTENSION, V33, P647, DOI 10.1161/01.HYP.33.2.647
   Jee SH, 2002, AM J HYPERTENS, V15, P691, DOI 10.1016/S0895-7061(02)02964-3
   Jeffery RW, 2000, HEALTH PSYCHOL, V19, P5, DOI 10.1037/0278-6133.19.Suppl1.5
   Johnson AG, 2001, J HYPERTENS, V19, P1053, DOI 10.1097/00004872-200106000-00009
   Johnson RJ, 2002, NEW ENGL J MED, V346, P913, DOI 10.1056/NEJMra011078
   Jones-Burton C, 2006, AM J NEPHROL, V26, P268, DOI 10.1159/000093833
   Kaaja RJ, 2006, J HYPERTENS, V24, P131, DOI 10.1097/01.hjh.0000194121.19851.e5
   Kabir AA, 2006, AM J HYPERTENS, V19, P639, DOI 10.1016/j.amjhyper.2005.10.026
   Kahn R, 2005, LANCET, V366, P1921, DOI 10.1016/S0140-6736(05)67778-1
   KATZEFF HL, 1990, P SOC EXP BIOL MED, V194, P198, DOI 10.3181/00379727-194-43078
   Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3
   Kelly T, 2008, INT J OBESITY, V32, P1431, DOI 10.1038/ijo.2008.102
   Kennedy RL, 2005, DIABETIC MED, V22, P821, DOI 10.1111/j.1464-5491.2005.01594.x
   Khan NA, 2006, CAN J CARDIOL, V22, P583, DOI 10.1016/S0828-282X(06)70280-X
   King DE, 2009, AM J MED, V122, P528, DOI 10.1016/j.amjmed.2008.11.013
   KIYOHARA Y, 1995, STROKE, V26, P368, DOI 10.1161/01.STR.26.3.368
   Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103
   Klag MJ, 2002, ARCH INTERN MED, V162, P657, DOI 10.1001/archinte.162.6.657
   Kojuri Javad, 2007, BMC CARDIOVASC DISORD, V7, P34
   Kotchen TA, 1998, CIRCULATION, V98, P613, DOI 10.1161/01.CIR.98.6.613
   Kotchen TA, 2009, AM J HYPERTENS, V22, P350, DOI 10.1038/ajh.2009.15
   Kozuma K, 2005, HYPERTENS RES, V28, P711, DOI 10.1291/hypres.28.711
   KRISHNA GG, 1987, J LAB CLIN MED, V109, P724
   Kuchel O, 1998, AM J PHYSIOL-REG I, V275, PR1164, DOI 10.1152/ajpregu.1998.275.4.R1164
   Kuhlmann A, 2004, AM J PHYSIOL-RENAL, V286, PF526, DOI 10.1152/ajprenal.00316.2003
   Kumanyika SK, 2005, J HUM HYPERTENS, V19, P33, DOI 10.1038/sj.jhh.1001774
   Kurukulasuriya LR, 2008, ENDOCRIN METAB CLIN, V37, P647, DOI 10.1016/j.ecl.2008.06.002
   Landsberg L, 2001, J HYPERTENS, V19, P523, DOI 10.1097/00004872-200103001-00001
   Lavigne C, 2000, AM J PHYSIOL-ENDOC M, V278, PE491, DOI 10.1152/ajpendo.2000.278.3.E491
   LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819
   Leuenberger V, 2006, REV MED SUISSE, V2, P2041
   LEUENBERGER V, 2006, REV MED SUISSE, V2, P2044
   Lien LF, 2007, HYPERTENSION, V50, P609, DOI 10.1161/HYPERTENSIONAHA.107.089458
   Logan AG, 2007, AM J HYPERTENS, V20, P223, DOI 10.1016/j.amjhyper.2006.10.006
   Lopez L, 2009, AM J HYPERTENS, V22, P325, DOI 10.1038/ajh.2008.348
   MacGregor G A, 1999, NUTR METAB CARDIOVASC DIS, V9, P6
   MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9
   Mann M, 2008, AM J CARDIOL, V101, P1518, DOI 10.1016/j.amjcard.2007.12.041
   Margolis KL, 2008, HYPERTENSION, V52, P847, DOI 10.1161/HYPERTENSIONAHA.108.114991
   Mark AL, 2007, CURR HYPERTENS REP, V9, P368, DOI 10.1007/s11906-007-0068-5
   McCall DO, 2009, CIRCULATION, V119, P2153, DOI 10.1161/CIRCULATIONAHA.108.831297
   MCCARRON DA, 1991, CONTRIB NEPHROL, V90, P2
   McCarron DA, 2001, AM J HYPERTENS, V14, P206S, DOI 10.1016/S0895-7061(01)02090-8
   MCCARRON DA, 1989, HOSP PRACT, V24, P229
   McCarron DA, 1998, AM J CLIN NUTR, V68, P517, DOI 10.1093/ajcn/68.3.517
   Melander O, 2007, J HYPERTENS, V25, P619, DOI 10.1097/HJH.0b013e328013cd50
   Mellen PB, 2008, ARCH INTERN MED, V168, P308, DOI 10.1001/archinternmed.2007.119
   Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590
   MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776
   Moreira LB, 1998, J HYPERTENS, V16, P175, DOI 10.1097/00004872-199816020-00007
   MORRIS MC, 1993, CIRCULATION, V88, P523, DOI 10.1161/01.CIR.88.2.523
   Morris RC, 1999, HYPERTENSION, V33, P18, DOI 10.1161/01.HYP.33.1.18
   Mu Jian-jun, 2003, ZHONGHUA YUFANG YIXUE ZAZHI, V37, P90
   Naismith DJ, 2003, BRIT J NUTR, V90, P53, DOI 10.1079/BJN2003861
   NAKAKI T, 1990, LANCET, V336, P696, DOI 10.1016/0140-6736(90)92196-O
   Narkiewicz K, 1999, CIRCULATION, V100, P2332, DOI 10.1161/01.CIR.100.23.2332
   Narkiewicz K, 2006, OBES REV, V7, P155, DOI 10.1111/j.1467-789X.2006.00226.x
   Nowson CA, 2003, J NUTR, V133, P4118, DOI 10.1093/jn/133.12.4118
   Nuttall FQ, 2006, AM J PHYSIOL-ENDOC M, V291, PE786, DOI 10.1152/ajpendo.00011.2006
   Obarzanek E, 1996, JAMA-J AM MED ASSOC, V275, P1598, DOI 10.1001/jama.275.20.1598
   Obligado SH, 2008, AM J HYPERTENS, V21, P257, DOI 10.1038/ajh.2007.62
   Ochiai R, 2004, HYPERTENS RES, V27, P731, DOI 10.1291/hypres.27.731
   Olsen MH, 2005, HYPERTENSION, V46, P660, DOI 10.1161/01.HYP.0000179575.13739.72
   Papaioannou TG, 2006, CLIN MED RES, V4, P114, DOI 10.3121/cmr.4.2.114
   Patel SB, 2008, CURR HYPERTENS REP, V10, P131, DOI 10.1007/s11906-008-0025-y
   Pausova Z, 2006, CURR OPIN NEPHROL HY, V15, P173, DOI 10.1097/01.mnh.0000214775.42103.a5
   Pausova Z, 2005, HYPERTENSION, V46, P1280, DOI 10.1161/01.HYP.0000188049.23233.fb
   Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901
   Pere AK, 2000, KIDNEY INT, V58, P2462, DOI 10.1046/j.1523-1755.2000.00429.x
   Pfeifer M, 2001, J CLIN ENDOCR METAB, V86, P1633, DOI 10.1210/jc.86.4.1633
   Phillips BG, 2000, AM J PHYSIOL-HEART C, V279, PH234, DOI 10.1152/ajpheart.2000.279.1.H234
   Pierce GL, 2008, HYPERTENSION, V52, P72, DOI 10.1161/HYPERTENSIONAHA.108.111427
   Pilz S, 2009, NAT REV CARDIOL, V6, P621, DOI 10.1038/nrcardio.2009.135
   Pinar R, 2006, WESTERN J NURS RES, V28, P214, DOI 10.1177/0193945905283413
   Pittas AG, 2007, J CLIN ENDOCR METAB, V92, P2017, DOI 10.1210/jc.2007-0298
   Power C, 2006, INT J EPIDEMIOL, V35, P34, DOI 10.1093/ije/dyi183
   REISIN E, 1978, NEW ENGL J MED, V298, P1, DOI 10.1056/NEJM197801052980101
   RESNICK LM, 1986, ANN INTERN MED, V105, P649, DOI 10.7326/0003-4819-105-5-649
   RICH GM, 1991, AM J HYPERTENS, V4, PS642, DOI 10.1093/ajh/4.11S.642S
   ROCCHINI AP, 1989, NEW ENGL J MED, V321, P580, DOI 10.1056/NEJM198908313210905
   Rohrer JE, 2007, BMC HEALTH SERV RES, V7, P0, DOI 10.1186/1472-6963-7-212
   Rossi GP, 2008, J CLIN ENDOCR METAB, V93, P2566, DOI 10.1210/jc.2008-0251
   Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101
   SAITO K, 1989, HYPERTENSION, V13, P219, DOI 10.1161/01.HYP.13.3.219
   Saito T, 2008, ADV EXP MED BIOL, V606, P295, DOI 10.1007/978-0-387-74087-4_12
   Sanders PW, 2007, SEMIN DIALYSIS, V20, P408, DOI 10.1111/j.1525-139X.2007.00316.x
   Sarzani R, 2008, J HYPERTENS, V26, P831, DOI 10.1097/HJH.0b013e3282f624a0
   Satterfield S, 1991, ANN EPIDEMIOL, V1, P455
   SCHERRER U, 1994, CIRCULATION, V89, P2634, DOI 10.1161/01.CIR.89.6.2634
   Schulz M, 2005, J HUM HYPERTENS, V19, P61, DOI 10.1038/sj.jhh.1001776
   SCIARRONE SEG, 1990, CLIN EXP PHARMACOL P, V17, P197, DOI 10.1111/j.1440-1681.1990.tb01305.x
   Shah M, 2007, AM J CLIN NUTR, V85, P1251, DOI 10.1093/ajcn/85.5.1251
   Shaldon S, 2006, CLIN NEPHROL, V66, P1
   Shaldon S, 2002, NEPHROL DIAL TRANSPL, V17, P1163, DOI 10.1093/ndt/17.7.1163
   Shamsuzzaman ASM, 2003, JAMA-J AM MED ASSOC, V290, P1906, DOI 10.1001/jama.290.14.1906
   Sharma A M, 2001, CURR HYPERTENS REP, V3, P152, DOI 10.1007/s11906-001-0030-x
   Sharma AM, 2002, INT J OBESITY, V26, PS5, DOI 10.1038/sj.ijo.0802210
   Siebenhofer A, 2013, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007654.pub3
   Sjöström L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622
   St Peter JV, 2006, CLIN CHEM, V52, P680, DOI 10.1373/clinchem.2005.062562
   STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598
   Stamler J, 1997, AM J CLIN NUTR, V65, P626, DOI 10.1093/ajcn/65.2.626S
   Stamler J, 2009, CIRCULATION, V120, P221, DOI 10.1161/CIRCULATIONAHA.108.839241
   Steffens AA, 2006, J HYPERTENS, V24, P1489, DOI 10.1097/01.hjh.0000239282.27938.0f
   Stein AD, 2006, EUR J EPIDEMIOL, V21, P759, DOI 10.1007/s10654-006-9065-2
   Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007
   Streppel MT, 2005, ARCH INTERN MED, V165, P150, DOI 10.1001/archinte.165.2.150
   Suzuki A, 2002, HYPERTENS RES, V25, P99, DOI 10.1291/hypres.25.99
   Talmor Y, 2008, EUR J CLIN INVEST, V38, P548, DOI 10.1111/j.1365-2362.2008.01977.x
   Taubert D, 2003, JAMA-J AM MED ASSOC, V290, P1029, DOI 10.1001/jama.290.8.1029
   Taylor EN, 2005, JAMA-J AM MED ASSOC, V293, P455, DOI 10.1001/jama.293.4.455
   Taylor EN, 2005, KIDNEY INT, V68, P1230, DOI 10.1111/j.1523-1755.2005.00516.x
   Taylor EN, 2006, AM J KIDNEY DIS, V48, P905, DOI 10.1053/j.ajkd.2006.09.004
   Touyz RM, 2004, HYPERTENSION, V44, P248, DOI 10.1161/01.HYP.0000138070.47616.9d
   Tuan NT, 2008, J NUTR, V138, P1377, DOI 10.1093/jn/138.7.1377
   Viera AJ, 2008, J CLIN HYPERTENS, V10, P105, DOI 10.1111/j.1751-7176.2008.07577.x
   Vollmer WM, 2001, ANN INTERN MED, V135, P1019, DOI 10.7326/0003-4819-135-12-200112180-00005
   Wang TJ, 2004, CIRCULATION, V109, P594, DOI 10.1161/01.CIR.0000112582.16683.EA
   Watanabe T, 2006, CLIN EXP HYPERTENS, V28, P439, DOI 10.1080/10641960600798655
   Webb AJ, 2008, HYPERTENSION, V51, P784, DOI 10.1161/HYPERTENSIONAHA.107.103523
   WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028
   Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657
   Whelton PK, 1997, JAMA-J AM MED ASSOC, V277, P1624, DOI 10.1001/jama.277.20.1624
   Whelton PK, 2002, JAMA-J AM MED ASSOC, V288, P1882, DOI 10.1001/jama.288.15.1882
   Whelton SP, 2005, J HYPERTENS, V23, P475, DOI 10.1097/01.hjh.0000160199.51158.cf
   Wildman RP, 2005, J HYPERTENS, V23, P737, DOI 10.1097/01.hjh.0000163141.82212.5f
   WILLIAMS M, 1986, J CLIN INVEST, V78, P1687, DOI 10.1172/JCI112763
   Winkelmayer WC, 2005, JAMA-J AM MED ASSOC, V294, P2330, DOI 10.1001/jama.294.18.2330
   WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320
   Wofford MR, 2004, CURR PHARM DESIGN, V10, P3621, DOI 10.2174/1381612043382855
   Wu GR, 2006, CLIN EXP HYPERTENS, V28, P489, DOI 10.1080/10641960600798705
   Xiang W, 2005, AM J PHYSIOL-ENDOC M, V288, PE125, DOI 10.1152/ajpendo.00224.2004
   Yang CS, 2004, J NUTR, V134, P3181S, DOI 10.1093/jn/134.11.3181S
   Yuan WH, 2007, J BIOL CHEM, V282, P29821, DOI 10.1074/jbc.M705495200
   Yung LM, 2008, INFLAMMOPHARMACOLOGY, V16, P230, DOI 10.1007/s10787-008-8022-y
   ZEMEL MB, 1986, J HYPERTENS, V4, P0
   Zheng YN, 2005, J AM SOC NEPHROL, V16, P2288, DOI 10.1681/ASN.2005020193
   Zhou CL, 2008, KIDNEY INT, V74, P170, DOI 10.1038/ki.2008.101
   Zilkens RR, 2005, HYPERTENSION, V45, P874, DOI 10.1161/01.HYP.0000164639.83623.76
   1947, 1900, V157, V0, P2413
   2003, 1900, V297, V0, P319
NR 240
TC 160
Z9 181
U1 2
U2 92
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA
SN 0199-9885
EI 1545-4312
J9 ANNU REV NUTR
JI Annu. Rev. Nutr.
PD JUN 15
PY 2010
VL 30
IS 
BP 365
EP 401
DI 10.1146/annurev-nutr-010510-103954
PG 37
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA BRN63
UT WOS:000283182500018
PM 20645853
DA 2025-04-28
ER

PT J
AU Myslobodsky, M
   Eldan, A
AF Myslobodsky, M.
   Eldan, A.
TI Winning a Won Game: Caffeine Panacea for Obesity Syndemic
SO CURRENT NEUROPHARMACOLOGY
LA English
DT Article
DE Caffeine targets; obesity; reactive oxygen species; networks; polypharmacy
ID obstructive sleep-apnea; endothelial growth-factor; blood-pressure rhythm; tnf-alpha production; body-mass index; adipose-tissue; substance-p; adenosine receptors; coffee consumption; circadian patterns
AB Over the past decades, chronic sleep reduction and a concurrent development of obesity have been recognized as a common problem in the industrialized world. Among its numerous untoward effects, there is a possibility that insomnia is also a major contributor to obesity. This attribution poses a problem for caffeine, an inexpensive, "natural" agent that is purported to improve a number of conditions and is often indicated in a long-term pharmacotherapy in the context of weight management. The present study used the "common target" approach by exploring the tentative shared molecular networks of insomnia and adiposity. It discusses caffeine targets beyond those associated with adenosine signaling machinery, phosphodiesterases, and calcium release channels. Here, we provide a view suggesting that caffeine could exert some of its effects by acting on several signaling complexes composed of HIF-1 alpha/VEGF/IL-8 along with NO, TNF-alpha, IL1, and GHRH, among others. Although the relevance of these targets to the reported therapeutic effects of caffeine has remained difficult to assess, the utilization of caffeine efficacies and potencies recommend its repurposing for development of novel therapeutic approaches. Among indications mentioned, are neuroprotective, nootropic, antioxidant, proliferative, anti-fibrotic, and anti-angiogenic that appear under a variety of dissimilar diagnostic labels comorbid with obesity. In the absence of safe and efficacious antiobesity agents, caffeine remains an attractive adjuvant.
C1 [Myslobodsky, M.] NIMH, Clin Brain Disorders Branch, NIH, Bethesda, MD 20892 USA.
   [Myslobodsky, M.] Howard Univ, Grad Sch, Washington, DC 20059 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Howard University
RP Myslobodsky, M (corresponding author), NIMH, Clin Brain Disorders Branch, NIH, Bethesda, MD 20892 USA.
EM myslobom@mail.nih.gov
CR Albensi BC, 2000, SYNAPSE, V35, P151
   Alonso-Vale MIC, 2005, AM J PHYSIOL-ENDOC M, V288, PE805, DOI 10.1152/ajpendo.00478.2004
   Arnardottir ES, 2009, SLEEP, V32, P447, DOI 10.1093/sleep/32.4.447
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   ASTRUP A, 1992, INT J OBESITY, V16, P269
   Astrup A, 2000, ENDOCRINE, V13, P207, DOI 10.1385/ENDO:13:2:207
   Avram MM, 2007, J AM ACAD DERMATOL, V56, P472, DOI 10.1016/j.jaad.2006.06.022
   Baethge C, 2009, BIPOLAR DISORD, V11, P494, DOI 10.1111/j.1399-5618.2009.00727.x
   Bass J, 2005, ARCH INTERN MED, V165, P15, DOI 10.1001/archinte.165.1.15
   Blanck HM, 2007, J AM DIET ASSOC, V107, P441, DOI 10.1016/j.jada.2006.12.009
   Blundell JE, 2006, OBESITY, V14, P160S, DOI 10.1038/oby.2006.298
   Bogdan A, 2001, LIFE SCI, V68, P1607, DOI 10.1016/S0024-3205(01)00966-3
   Bogdan A, 2005, BRIT J NUTR, V93, P515, DOI 10.1079/BJN20041380
   Bray GA, 2000, INT J OBESITY, V24, PS8, DOI 10.1038/sj.ijo.0801269
   Calabrese EJ, 2008, AGEING RES REV, V7, P8, DOI 10.1016/j.arr.2007.07.001
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Carley DW, 2005, IDRUGS, V8, P310
   Casadó V, 2009, PHARMACOL THERAPEUT, V124, P248, DOI 10.1016/j.pharmthera.2009.07.005
   Chaput JP, 2006, EUR J CLIN PHARMACOL, V62, P793, DOI 10.1007/s00228-006-0186-z
   Chavez-Valdez R, 2009, PEDIATR RES, V65, P203, DOI 10.1203/PDR.0b013e31818d66b1
   Cohen MV, 2008, BASIC RES CARDIOL, V103, P203, DOI 10.1007/s00395-007-0687-7
   COLAS C, 2009, INT J ANDROL, V0, P0
   COLLINS C, 1979, J PHARM PHARMACOL, V31, P611, DOI 10.1111/j.2042-7158.1979.tb13602.x
   CONNOR S, 2003, INDEPENDENT, V8, P1
   Cornelis MC, 2004, J MED GENET, V41, P758, DOI 10.1136/jmg.2004.022012
   Crawford C, 2000, ANN NY ACAD SCI, V907, P21
   Daly JW, 2007, CELL MOL LIFE SCI, V64, P2153, DOI 10.1007/s00018-007-7051-9
   Daly JW, 2000, J AUTONOM NERV SYST, V81, P44, DOI 10.1016/S0165-1838(00)00110-7
   Danforth E, 2000, NAT GENET, V26, P13, DOI 10.1038/79111
   Dray C, 2007, J PHYSIOL BIOCHEM, V63, P329, DOI 10.1007/BF03165764
   Dvorak HF, 2005, J THROMB HAEMOST, V3, P1835, DOI 10.1111/j.1538-7836.2005.01361.x
   Edwards JM, 2008, CORONARY ARTERY DIS, V19, P27, DOI 10.1097/MCA.0b013e3282f262b4
   Eichling PS, 2005, J CLIN SLEEP MED, V1, P291
   FEIHL F, 2008, CARDIOVASC RES, V22, P0
   Feihl F, 2006, HYPERTENSION, V48, P1012, DOI 10.1161/01.HYP.0000249510.20326.72
   Ferre S, 2008, FRONT BIOSCI-LANDMRK, V13, P2391, DOI 10.2741/2852
   Flier JS, 2004, ANN INTERN MED, V141, P885, DOI 10.7326/0003-4819-141-11-200412070-00014
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132
   Fredholm BB, 1999, PHARMACOL REV, V51, P83
   Garvey JF, 2009, EUR RESPIR J, V33, P1195, DOI 10.1183/09031936.00111208
   Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901
   Goel N, 2009, J BIOL RHYTHM, V24, P85, DOI 10.1177/0748730408328914
   GOMEZAMBROSI J, 2009, J NUTR BIOCH, V0, P0
   Greenway Frank L, 2008, ENDOCR PRACT, V14, P697
   Gross K, 2009, AM J PHYSIOL-GASTR L, V296, PG1012, DOI 10.1152/ajpgi.90351.2008
   Gunga HC, 2003, EUR J APPL PHYSIOL, V88, P497, DOI 10.1007/s00421-002-0734-x
   Gurevich F, 2009, AM J MED, V122, P322, DOI 10.1016/j.amjmed.2008.11.025
   Hackman RM, 2006, INT J OBESITY, V30, P1545, DOI 10.1038/sj.ijo.0803283
   Haguenauer D, 2000, OSTEOPOROSIS INT, V11, P727, DOI 10.1007/s001980070051
   Hammoud AO, 2008, FERTIL STERIL, V90, P2222, DOI 10.1016/j.fertnstert.2007.10.011
   Härtter S, 2003, BRIT J CLIN PHARMACO, V56, P679, DOI 10.1046/j.1365-2125.2003.01933.x
   Haslam D, 2006, BMJ-BRIT MED J, V333, P640, DOI 10.1136/bmj.333.7569.640
   Hasler G, 2004, SLEEP, V27, P661, DOI 10.1093/sleep/27.4.661
   Hayashi K, 2009, J ORTHOP SCI, V14, P253, DOI 10.1007/s00776-009-1336-9
   Hemmrich K, 2006, MOL PSYCHIATR, V11, P980, DOI 10.1038/sj.mp.4001892
   Hong BN, 2008, NEUROSCI LETT, V441, P302, DOI 10.1016/j.neulet.2008.06.049
   Hopkins AL, 2006, CURR OPIN STRUC BIOL, V16, P127, DOI 10.1016/j.sbi.2006.01.013
   Horrigan LA, 2004, INT IMMUNOPHARMACOL, V4, P1409, DOI 10.1016/j.intimp.2004.06.005
   Hu G, 2007, AM J CLIN NUTR, V86, P457, DOI 10.1093/ajcn/86.2.457
   Huang C, 2009, PREV CHRONIC DIS, V6, P0
   Huang QL, 2006, J ENDOCRINOL, V191, P179, DOI 10.1677/joe.1.06906
   Jacobson Kenneth A, 2009, HANDB EXP PHARMACOL, V0, PP1, DOI 10.1007/978-3-540-89615-9_1
   Janson C, 2001, SLEEP, V24, P425, DOI 10.1093/sleep/24.4.425
   Jessen A, 2005, DIABETES OBES METAB, V7, P327, DOI 10.1111/j.1463-1326.2004.00389.x
   Kamat JP, 2000, INT J RADIAT BIOL, V76, P1281
   Karagiannides I, 2008, GASTROENTEROLOGY, V134, P747, DOI 10.1053/j.gastro.2007.12.032
   Kawahara M, 2008, ANTICANCER RES, V28, P1681
   Kidd PM, 2008, ALTERN MED REV, V13, P85
   Kiefer FN, 2003, CURR PHARM DESIGN, V9, P1733, DOI 10.2174/1381612033454540
   KNOBLOVITS P, 2009, J ANDROL, V0, P0
   KOSTOPOULOS G, 1987, EPILEPSIA, V28, P415, DOI 10.1111/j.1528-1157.1987.tb03667.x
   Krueger JM, 2008, NAT REV NEUROSCI, V9, P910, DOI 10.1038/nrn2521
   Lacobellis G, 2008, HORM METAB RES, V40, P442, DOI 10.1055/s-2008-1062724
   LANDAW SA, 1990, CLIN LAB MED, V10, P857
   Landolt HP, 2008, BIOCHEM PHARMACOL, V75, P2070, DOI 10.1016/j.bcp.2008.02.024
   Laposky AD, 2006, AM J PHYSIOL-REG I, V290, PR894, DOI 10.1152/ajpregu.00304.2005
   Lauderdale DS, 2009, AM J EPIDEMIOL, V170, P805, DOI 10.1093/aje/kwp230
   Lavie L, 2009, PROG CARDIOVASC DIS, V51, P303, DOI 10.1016/j.pcad.2008.08.003
   Lavie P, 2009, J SLEEP RES, V18, P397, DOI 10.1111/j.1365-2869.2009.00754.x
   Ledoux S, 2008, DIABETES, V57, P3247, DOI 10.2337/db07-1812
   Lee SH, 2008, INT J GERONTOL, V2, P1, DOI 10.1016/S1873-9598(08)70001-2
   Liao J, 2004, NUTR CANCER, V48, P44, DOI 10.1207/s15327914nc4801_7
   Liu ZW, 2007, J NEUROPHYSIOL, V97, P837, DOI 10.1152/jn.00873.2006
   Martin-Schild S, 2009, J STROKE CEREBROVASC, V18, P86, DOI 10.1016/j.jstrokecerebrovasdis.2008.09.015
   Meier M, 2009, CURR PROBL DERMATOL, V38, P1, DOI 10.1159/000232301
   Merighi S, 2007, MOL PHARMACOL, V72, P395, DOI 10.1124/mol.106.032920
   Motivala SJ, 2009, PSYCHONEUROENDOCRINO, V34, P540, DOI 10.1016/j.psyneuen.2008.10.016
   Mourad JJ, 2008, ANN ONCOL, V19, P927, DOI 10.1093/annonc/mdm550
   Mutphy P, 2002, LEUKEMIA RES, V26, P1007, DOI 10.1016/S0145-2126(02)00053-X
   Myslobodsky M, 2010, REV NEUROSCIENCE, V21, P67
   Myslobodsky M, 2009, OBESITY FACTS, V2, P384, DOI 10.1159/000261422
   Myslobodsky M, 2009, CURR DRUG TARGETS, V10, P1009, DOI 10.2174/138945009789577927
   NABE B, 1995, J SLEEP RES, V4, P97, DOI 10.1111/j.1365-2869.1995.tb00196.x
   Naguib M, 2007, J PINEAL RES, V42, P12, DOI 10.1111/j.1600-079X.2006.00384.x
   Nagy JA, 2007, ANNU REV PATHOL-MECH, V2, P251, DOI 10.1146/annurev.pathol.2.010506.134925
   Nielsch U, 2007, DRUG DISCOV TODAY, V12, P1025, DOI 10.1016/j.drudis.2007.10.004
   Nilsson PM, 2004, DIABETES CARE, V27, P2464, DOI 10.2337/diacare.27.10.2464
   Nishimura S, 2007, DIABETES, V56, P1517, DOI 10.2337/db06-1749
   Norman D, 2008, SLEEP BREATH, V12, P199, DOI 10.1007/s11325-007-0153-7
   Obal F, 2003, FRONT BIOSCI-LANDMRK, V8, PD520, DOI 10.2741/1033
   Ohta M, 1999, ANN NUTR METAB, V43, P52, DOI 10.1159/000012767
   Pasarica M, 2009, DIABETES, V58, P718, DOI 10.2337/db08-1098
   Pastorino F, 2009, CURR DRUG TARGETS, V10, P1021, DOI 10.2174/138945009789577954
   Patel SR, 2008, INT J OBESITY, V32, P1825, DOI 10.1038/ijo.2008.198
   Penev Plamen D, 2007, CURR OPIN ENDOCRINOL DIABETES OBES, V14, P374, DOI 10.1097/MED.0b013e3282be9093
   Pietersen AN, 2009, NEUROPHARMACOLOGY, V56, P481, DOI 10.1016/j.neuropharm.2008.10.001
   Prunet-Marcassus B, 2003, ENDOCRINOLOGY, V144, P5347, DOI 10.1210/en.2003-0693
   Qin LQ, 2003, LIFE SCI, V73, P2467, DOI 10.1016/S0024-3205(03)00628-3
   Quinones MP, 2009, NEUROBIOL DIS, V35, P165, DOI 10.1016/j.nbd.2009.02.019
   Riksen NP, 2009, PHARMACOL THERAPEUT, V121, P185, DOI 10.1016/j.pharmthera.2008.10.006
   Ryzhov S, 2007, J PHARMACOL EXP THER, V320, P565, DOI 10.1124/jpet.106.114850
   Sabisz M, 2008, CURR PHARM BIOTECHNO, V9, P325, DOI 10.2174/138920108785161497
   SAWYNOK J, 1995, DRUGS, V49, P37, DOI 10.2165/00003495-199549010-00004
   Sawynok J, 1998, EUR J PHARMACOL, V347, P1, DOI 10.1016/S0014-2999(97)01605-1
   She MH, 2009, PHARMACOL RES, V59, P248, DOI 10.1016/j.phrs.2009.01.005
   Shi D, 2003, CELL MOL NEUROBIOL, V23, P331, DOI 10.1023/A:1023688604792
   SILVERMAN K, 1992, NEW ENGL J MED, V327, P1109, DOI 10.1056/NEJM199210153271601
   Simon C, 1998, J CLIN ENDOCR METAB, V83, P1893, DOI 10.1210/jc.83.6.1893
   Singer M, 2003, MED ANTHROPOL Q, V17, P423, DOI 10.1525/maq.2003.17.4.423
   Sinton CM, 1999, J SLEEP RES, V8, P197, DOI 10.1046/j.1365-2869.1999.00158.x
   Skurk T, 2007, J CLIN ENDOCR METAB, V92, P1023, DOI 10.1210/jc.2006-1055
   SNYDER SH, 1984, J PSYCHIAT RES, V18, P91, DOI 10.1016/0022-3956(84)90001-3
   Son TG, 2008, NEUROMOL MED, V10, P236, DOI 10.1007/s12017-008-8037-y
   Song YM, 2009, ACTA BIOL HUNG, V60, P399, DOI 10.1556/ABiol.60.2009.4.6
   Spinetta MJ, 2008, PSYCHOPHARMACOLOGY, V201, P361, DOI 10.1007/s00213-008-1294-5
   Stafford RS, 2008, NEW ENGL J MED, V358, P1427, DOI 10.1056/NEJMp0802107
   Stone Trevor W, 2009, HANDB EXP PHARMACOL, V0, PP535, DOI 10.1007/978-3-540-89615-9_17
   Strandberg L, 2008, OBESITY, V16, P710, DOI 10.1038/oby.2007.95
   Subauste AR, 2007, AM J PHYSIOL-ENDOC M, V293, PE159, DOI 10.1152/ajpendo.00629.2006
   Sullivan SS, 2009, EXPERT OPIN EMERG DR, V14, P411, DOI 10.1517/14728210903171948
   Suzawa M, 2003, NAT CELL BIOL, V5, P224, DOI 10.1038/ncb942
   Szentirmai E, 2007, AM J PHYSIOL-REG I, V293, PR922, DOI 10.1152/ajpregu.00237.2007
   Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x
   Taylor CT, 2008, BIOCHEM J, V409, P19, DOI 10.1042/BJ20071249
   Tchekalarova J, 2009, SEIZURE-EUR J EPILEP, V18, P463, DOI 10.1016/j.seizure.2009.04.002
   Terzano MG, 2003, DRUG SAFETY, V26, P261, DOI 10.2165/00002018-200326040-00004
   Tjepkema Michael, 2005, HEALTH REP, V17, P9
   Tobinick EL, 2009, DRUG NEWS PERSPECT, V22, P119, DOI 10.1358/dnp.2009.22.2.1303818
   Tsioufis C, 2008, J HUM HYPERTENS, V22, P501, DOI 10.1038/jhh.2008.20
   Ursing C, 2003, J ENDOCRINOL INVEST, V26, P403, DOI 10.1007/BF03345194
   Vali A, 2005, J DERMATOL TREAT, V16, P234, DOI 10.1080/09546630510011801
   Vondracek SF, 2009, PHARMACOTHERAPY, V29, P305, DOI 10.1592/phco.29.3.305
   Vorona RD, 2005, ARCH INTERN MED, V165, P25, DOI 10.1001/archinte.165.1.25
   Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102
   Widberg CH, 2009, AM J PHYSIOL-ENDOC M, V296, PE121, DOI 10.1152/ajpendo.90602.2008
   Williams CJ, 2008, DIABETES CARE, V31, P504, DOI 10.2337/dc07-1952
   Wolden-Hanson T, 2000, ENDOCRINOLOGY, V141, P487, DOI 10.1210/en.141.2.487
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yang HY, 2004, CLIN EXP METASTAS, V21, P719, DOI 10.1007/s10585-004-8251-4
   Yang R, 2008, J ANDROL, V29, P586, DOI 10.2164/jandrol.107.004721
   Yeomans MR, 2007, PHYSIOL BEHAV, V92, P831, DOI 10.1016/j.physbeh.2007.06.006
   Yoshimura Hiroshi, 2005, CURRENT NEUROPHARMACOLOGY, V3, P309, DOI 10.2174/157015905774322543
   Yu LQ, 2006, NEUROSCI LETT, V393, P31, DOI 10.1016/j.neulet.2005.09.036
   Zhang GL, 2004, BRAIN RES, V1028, P225, DOI 10.1016/j.brainres.2004.09.017
   Zhang QX, 1997, J SURG RES, V67, P147, DOI 10.1006/jsre.1996.4983
   Zhao J, 2003, BRIT J PHARMACOL, V140, P1399, DOI 10.1038/sj.bjp.0705573
NR 157
TC 1
Z9 2
U1 0
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES
SN 1570-159X
EI 1875-6190
J9 CURR NEUROPHARMACOL
JI Curr. Neuropharmacol.
PD JUN 15
PY 2010
VL 8
IS 2
BP 149
EP 160
DI 10.2174/157015910791233213
PG 12
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 599KE
UT WOS:000277910000010
PM 21119886
DA 2025-04-28
ER

PT J
AU Celi, FS
   Brychta, RJ
   Linderman, JD
   Butler, PW
   Alberobello, AT
   Smith, S
   Courville, AB
   Lai, EW
   Costello, R
   Skarulis, MC
   Csako, G
   Remaley, A
   Pacak, K
   Chen, KY
AF Celi, Francesco S.
   Brychta, Robert J.
   Linderman, Joyce D.
   Butler, Peter W.
   Alberobello, Anna Teresa
   Smith, Sheila
   Courville, Amber B.
   Lai, Edwin W.
   Costello, Rene
   Skarulis, Monica C.
   Csako, Gyorgy
   Remaley, Alan
   Pacak, Karel
   Chen, Kong Y.
TI Minimal changes in environmental temperature result in a significant increase in energy expenditure and changes in the hormonal homeostasis in healthy adults
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY
LA English
DT Article
ID brown adipose-tissue; mild cold; obesity; deiodinase; metabolism; caffeine; protein; plasma; diet; fat
AB Objective: Resting energy expenditure (EE) is a major contributor to the total EE and thus plays an important role in body weight regulation. Adaptive thermogenesis is a major component of EE in rodents, but little is known on the effects of exposure of humans to mild and sustainable reduction in environmental temperature. Design: To characterize the dynamic changes in continuously measured resting EE, substrate utilization, and hormonal axes simultaneously in response to mild reduction in environmental temperature, we performed a cross-over intervention. Methods: Twenty-five volunteers underwent two 12-h recordings of EE in whole room indirect calorimeters at 24 and 19 degrees C with simultaneous measurement of spontaneous movements and hormonal axes. Results: Exposure to 19 degrees C resulted in an increase in plasma and urine norepinephrine levels (P < 0.0001), and a 5.96% (P < 0.001) increase in EE without significant changes in spontaneous physical activity. Exposure to the lower temperature resulted in a significant increase in free fatty acid levels (P < 0.01), fasting insulin levels (P < 0.05), and a marginal decrease in postprandial glucose levels. A small but significant (P < 0.002) increase in serum free thyroxine and urinary free cortisol (P < 0.05) was observed at 19 degrees C. Conclusions: Our observations indicate that exposure to 19 degrees C, a mild and tolerable cold temperature, results in a predictable increase in EE driven by a sustained rise in catecholamine and the activation of counter-regulatory mechanisms.
C1 [Celi, Francesco S.; Brychta, Robert J.; Linderman, Joyce D.; Butler, Peter W.; Alberobello, Anna Teresa; Smith, Sheila; Skarulis, Monica C.; Chen, Kong Y.] NIDDK, Clin Endocrinol Branch, Bethesda, MD 20892 USA.
   [Butler, Peter W.; Lai, Edwin W.; Pacak, Karel] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Reprod & Adult Endocrinol Branch, Bethesda, MD 20892 USA.
   [Courville, Amber B.; Costello, Rene; Csako, Gyorgy; Remaley, Alan] NIH, Dept Lab Med, Ctr Clin, CRC, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)
RP Celi, FS (corresponding author), NIDDK, Clin Endocrinol Branch, Bldg 10,RM 6-3940,10 Ctr Dr,MSC 1613, Bethesda, MD 20892 USA.
EM fc93a@nih.gov
FU NIDDK [Z01-DK047057-02, Z01-DK071013-02]; Clinical Center, NIH
CR Unknown -, 2000, NIH PUBL, V0, P0
   Astrup A, 2000, ENDOCRINE, V13, P207, DOI 10.1385/ENDO:13:2:207
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   Camm AJ, 1996, CIRCULATION, V93, P1043
   Canettieri G, 2000, ENDOCRINOLOGY, V141, P1804, DOI 10.1210/en.141.5.1804
   CSAKO G, 1990, CLIN CHEM, V36, P645
   Cypess AM, 2009, NEW ENGL J MED, V360, P1509, DOI 10.1056/NEJMoa0810780
   DAUNCEY MJ, 1981, BRIT J NUTR, V45, P257, DOI 10.1079/BJN19810102
   de Jonge L, 2001, INT J OBESITY, V25, P929, DOI 10.1038/sj.ijo.0801656
   EISENHOFER G, 1986, CLIN CHEM, V32, P2030
   FAGIUS J, 1991, ACTA PHYSIOL SCAND, V142, P201, DOI 10.1111/j.1748-1716.1991.tb09148.x
   Hansen DL, 1998, AM J CLIN NUTR, V68, P1180, DOI 10.1093/ajcn/68.6.1180
   Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857
   Hull H, 2009, J CLIN DENSITOM, V12, P95, DOI 10.1016/j.jocd.2008.09.004
   HUTTUNEN P, 1981, EUR J APPL PHYSIOL, V46, P339, DOI 10.1007/BF00422121
   JENNIFER JPH, 2006, DIETARY REFERENCE IN, V0, P84
   Kinugasa H, 1999, EXP PHYSIOL, V84, P369, DOI 10.1111/j.1469-445X.1999.01839.x
   Lichtenbelt WDV, 2002, AM J PHYSIOL-ENDOC M, V282, PE1077, DOI 10.1152/ajpendo.00020.2001
   Lichtenbelt WDV, 2009, NEW ENGL J MED, V360, P1500, DOI 10.1056/NEJMoa0808718
   Magnus-Levy A, 1895, BERLIN KLIN. WOCHSCHR, V32, P650
   Maia AL, 2005, J CLIN INVEST, V115, P2524, DOI 10.1172/JCI25083
   McAllister EJ, 2009, CRIT REV FOOD SCI, V49, P868, DOI 10.1080/10408390903372599
   MIFFLIN MD, 1990, AM J CLIN NUTR, V51, P241, DOI 10.1093/ajcn/51.2.241
   Popkin BM, 2006, OBES REV, V7, P271, DOI 10.1111/j.1467-789X.2006.00230.x
   RAVUSSIN E, 1986, J CLIN INVEST, V78, P1568, DOI 10.1172/JCI112749
   RIZZA RA, 1980, J CLIN INVEST, V65, P682, DOI 10.1172/JCI109714
   Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748
   SCHEIDEGGER K, 1984, J CLIN ENDOCR METAB, V58, P895, DOI 10.1210/jcem-58-5-895
   Schrauwen P, 2002, INT J OBESITY, V26, P450, DOI 10.1038/sj.ijo.0801943
   Shannon JR, 1999, CLIN SCI, V96, P483, DOI 10.1042/CS19980206
   Skarulis MC, 2010, J CLIN ENDOCR METAB, V95, P256, DOI 10.1210/jc.2009-0543
   Smith SR, 2000, AM J CLIN NUTR, V71, P450
   VANDER A, 1998, HUMAN PHYSL MECH BOD, V0, P625
   Virtanen KA, 2009, NEW ENGL J MED, V360, P1518, DOI 10.1056/NEJMoa0808949
   Westerterp KR, 2002, CURR OPIN CLIN NUTR, V5, P489, DOI 10.1097/00075197-200209000-00006
   WESTERTERPPLANTM, 2002, CLIN NUTR, V56, P288, DOI 10.1038/SJ.EJCN.1601308)
   Wijers SLJ, 2010, OBESITY, V18, P1092, DOI 10.1038/oby.2010.74
   Yoshioka M, 2001, BRIT J NUTR, V85, P203, DOI 10.1079/BJN2000224
NR 38
TC 71
Z9 79
U1 0
U2 14
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0804-4643
EI 1479-683X
J9 EUR J ENDOCRINOL
JI Eur. J. Endocrinol.
PD DEC 15
PY 2010
VL 163
IS 6
BP 863
EP 872
DI 10.1530/EJE-10-0627
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 678RR
UT WOS:000284098400003
PM 20826525
DA 2025-04-28
ER

PT J
AU Wan, CJ
   Lin, LY
   Yu, TH
   Sheu, WHH
AF Wan, Chu-Jen
   Lin, Li-Yun
   Yu, Tung-Hsi
   Sheu, Wayne H-H
TI Metabolic syndrome associated with habitual indulgence and dietary behavior in middle-aged health-care professionals
SO JOURNAL OF DIABETES INVESTIGATION
LA English
DT Article
DE Health-care professionals; Habitual indulgence; Metabolic syndrome
ID alcohol-consumption; coffee consumption; insulin-resistance; dairy consumption; tea consumption; blood-pressure; risk-factors; green tea; prevalence; obesity
AB Aims/Introduction: Few studies, especially in Asia, have examined the relevance between metabolic syndrome (MetS), habitual indulgence and dietary behaviors in health-care professionals. The present study evaluates metabolic syndrome rate and its association with habitual indulgence (coffee, tea, alcohol and cigarette smoking) and diet behavior in health-care professionals. Materials and Methods: Information was collected from 514 health-care professionals (147 men, 367 women) who underwent routine physical examinations at a medical center in central Taiwan. Results: Mean age was 48 +/- 5 years for men and 45 +/- 4 years for women. Mean body mass index was 25.2 +/- 4.0 kg/m(2) for men and 22.5 +/- 3.4 kg/m(2) for women. The age-adjusted MetS rate among subjects was 24.8-11.7% in men and 7.8-5.4% in women, using two different definitions, respectively. The MetS rate among those who occasionally or frequently consumed tea was higher than among those who never consumed tea (P < 0.05). Although the proportion of subjects who had MetS differed among those with differing alcohol drinking habits (never, quit and current; P < 0.05), a posteriori comparisons showed no significant differences between the two groups. Compared with those who had never smoked, the rate was higher in former smokers and current smokers (P < 0.001). No significant association with coffee consumption was found. People with MetS often consumed sweetened beverages (P < 0.05), rarely read nutrition labels and seldom consumed dairy products. Conclusions: Health-care professionals who regularly consume tea, smoke, frequently have sweetened drinks, rarely read nutrition labels or rarely consume dairy products are at higher risk of suffering from MetS. (J Diabetes Invest, doi:10.1111/j.2040-1124.2010.00055.x, 2010)
C1 [Sheu, Wayne H-H] Taichung Vet Gen Hosp, Dept Internal Med, Div Endocrinol & Metab, Taichung, Taiwan.
   [Wan, Chu-Jen] Taichung Vet Gen Hosp, Dept Dietet, Taichung, Taiwan.
   [Wan, Chu-Jen; Lin, Li-Yun] Hungkuang Univ, Dept Food Sci & Appl Biotechnol, Taichung, Taiwan.
   [Yu, Tung-Hsi] Hungkuang Univ, Dept Hotel & Restaurant Management, Taichung, Taiwan.
   [Sheu, Wayne H-H] Natl Chung Hsing Univ, Inst Med Technol, Taichung 40227, Taiwan.
   [Sheu, Wayne H-H] Natl Yang Ming Univ, Coll Med, Taipei 112, Taiwan.
C3 Taichung Veterans General Hospital; Taichung Veterans General Hospital; Hungkuang University; Hungkuang University; National Chung Hsing University; National Yang Ming Chiao Tung University
RP Sheu, WHH (corresponding author), Taichung Vet Gen Hosp, Dept Internal Med, Div Endocrinol & Metab, Taichung, Taiwan.
EM whhsheu@vghtc.gov.tw
CR Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8
   Azadbakht L, 2005, AM J CLIN NUTR, V82, P523, DOI 10.1093/ajcn/82.3.523
   Boisaubin EV, 2001, AM J MED SCI, V322, P31, DOI 10.1097/00000441-200107000-00006
   Brooke D, 1996, ADDICTION, V91, P317, DOI 10.1111/j.1360-0443.1996.tb02281.x
   CAPLAN RP, 1994, BRIT MED J, V309, P1261, DOI 10.1136/bmj.309.6964.1261
   Després JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488
   Djoussé L, 2004, OBES RES, V12, P1375, DOI 10.1038/oby.2004.174
   Driessen MT, 2009, EUR J CLIN NUTR, V63, P536, DOI 10.1038/ejcn.2008.6
   Ford ES, 2005, DIABETES CARE, V28, P2745, DOI 10.2337/diacare.28.11.2745
   Fraser ML, 2007, COMPLEMENT THER MED, V15, P46, DOI 10.1016/j.ctim.2006.07.002
   Galassi A, 2006, AM J MED, V119, P812, DOI 10.1016/j.amjmed.2006.02.031
   Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
   Harris A, 2007, PSYCHONEUROENDOCRINO, V32, P322, DOI 10.1016/j.psyneuen.2007.01.003
   Hino A, 2007, DIABETES RES CLIN PR, V76, P383, DOI 10.1016/j.diabres.2006.09.033
   Hodgson JM, 2006, CLIN EXP PHARMACOL P, V33, P838, DOI 10.1111/j.1440-1681.2006.04450.x
   Huxley R, 2009, ARCH INTERN MED, V169, P2053, DOI 10.1001/archinternmed.2009.439
   Hwang LC, 2006, J FORMOS MED ASSOC, V105, P626, DOI 10.1016/S0929-6646(09)60161-3
   Ishizaka N, 2005, ATHEROSCLEROSIS, V181, P381, DOI 10.1016/j.atherosclerosis.2005.01.026
   Jee SH, 1999, HYPERTENSION, V33, P647, DOI 10.1161/01.HYP.33.2.647
   Jee SH, 2001, AM J EPIDEMIOL, V153, P353, DOI 10.1093/aje/153.4.353
   John U, 2005, OBES RES, V13, P101, DOI 10.1038/oby.2005.13
   Kim SY, 2000, J AGR RESOUR ECON, V25, P215
   Kreuter MW, 1997, AM J PREV MED, V13, P277, DOI 10.1016/S0749-3797(18)30175-2
   Lee WY, 2005, DIABETES RES CLIN PR, V67, P70, DOI 10.1016/j.diabres.2004.05.006
   Lin CC, 2007, BMC PSYCHIATRY, V7, P0, DOI 10.1186/1471-244X-7-12
   Marmot MG, 1997, LANCET, V350, P235, DOI 10.1016/S0140-6736(97)04244-X
   McKeown NM, 2004, DIABETES CARE, V27, P538, DOI 10.2337/diacare.27.2.538
   Mennen LI, 2000, NUTR RES, V20, P335, DOI 10.1016/S0271-5317(00)00127-5
   Neuhouser ML, 1999, J AM DIET ASSOC, V99, P45, DOI 10.1016/S0002-8223(99)00013-9
   Pereira MA, 2002, JAMA-J AM MED ASSOC, V287, P2081, DOI 10.1001/jama.287.16.2081
   ROMELSJO A, 1992, BRIT J ADDICT, V87, P1173
   Rosengren A, 2004, LANCET, V364, P953, DOI 10.1016/S0140-6736(04)17019-0
   Shimada K, 2004, DIABETES RES CLIN PR, V65, P227, DOI 10.1016/j.diabres.2004.01.003
   Smith DR, 2007, BMC PUBLIC HEALTH, V7, P0, DOI 10.1186/1471-2458-7-115
NR 34
TC 9
Z9 9
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2040-1116
EI 2040-1124
J9 J DIABETES INVEST
JI J. Diabetes Investig.
PD DEC 15
PY 2010
VL 1
IS 6
BP 259
EP 265
DI 10.1111/j.2040-1124.2010.00055.x
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 755DR
UT WOS:000289907400006
PM 24843441
DA 2025-04-28
ER

PT J
AU Grove, KA
   Lambert, JD
AF Grove, Kimberly A.
   Lambert, Joshua D.
TI Laboratory, Epidemiological, and Human Intervention Studies Show That Tea (Camellia sinensis) May Be Useful in the Prevention of Obesity
SO JOURNAL OF NUTRITION
LA English
DT Review
ID diet-induced obesity; green tea; epigallocatechin gallate; body-fat; (-)-epigallocatechin gallate; weight-loss; 3t3-l1 preadipocytes; metabolic syndrome; galloyl moiety; glucose-uptake
AB Tea (Camellia sinensis, Theaceae) and tea polyphenols have been studied for the prevention of chronic diseases, including obesity. Obesity currently affects >20% of adults in the United States and is a risk factor for chronic diseases such as type II diabetes, cardiovascular disease, and cancer. Given this increasing public health concern, the use of dietary agents for the prevention of obesity would be of tremendous benefit. Whereas many laboratory studies have demonstrated the potential efficacy of green or black tea for the prevention of obesity, the underlying mechanisms remain unclear. The results of human intervention studies are mixed and the role of caffeine has not been clearly established. Finally, there is emerging evidence that high doses of tea polyphenols may have adverse side effects. Given that the results of scientific studies on dietary components, including tea polyphenols, are often translated into dietary supplements, understanding the potential toxicities of the tea polyphenols is critical to understanding their potential usefulness in preventing obesity. In this review, we will critically evaluate the evidence for the prevention of obesity by tea, discuss the relevance of proposed mechanisms in light of tea polyphenol bioavailability, and review the reports concerning the toxic effects of high doses of tea polyphenols and the implication that this has for the potential use of tea for the prevention of obesity. We hope that this review will expose areas for further study and encourage research on this important public health issue. J. Nutr. 140: 446-453,2010.
C1 [Grove, Kimberly A.; Lambert, Joshua D.] Penn State Univ, Dept Food Sci, University Pk, PA 16802 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Penn State Behrend
RP Lambert, JD (corresponding author), Penn State Univ, Dept Food Sci, University Pk, PA 16802 USA.
EM jdl134@psu.edu
FU NIH [AT004678]
CR Unknown -, 2008, STATE-SPECIFIC PREVALENCE AND TRENDS IN ADULT CIGARETTE SMOKING --- UNITED STATES, V0, P0
   Ashida H, 2004, BIOFACTORS, V22, P135, DOI 10.1002/biof.5520220126
   Auvichayapat P, 2008, PHYSIOL BEHAV, V93, P486, DOI 10.1016/j.physbeh.2007.10.009
   Balentine DA, 1997, CRIT REV FOOD SCI, V37, P693, DOI 10.1080/10408399709527797
   Bernert CP, 2007, DIABETES METAB, V33, P13, DOI 10.1016/j.diabet.2006.11.004
   Blumenthal TC, 2006, HERB GRAM, V0, P64
   Bose M, 2008, J NUTR, V138, P1677, DOI 10.1093/jn/138.9.1677
   Bruno RS, 2008, J NUTR, V138, P323, DOI 10.1093/jn/138.2.323
   Cao H, 2007, J AGR FOOD CHEM, V55, P6372, DOI 10.1021/jf070695o
   Cho SY, 2007, AM J PHYSIOL-ENDOC M, V292, PE1166, DOI 10.1152/ajpendo.00436.2006
   Chow HHS, 2005, CLIN CANCER RES, V11, P4627, DOI 10.1158/1078-0432.CCR-04-2549
   Chow HHS, 2003, CLIN CANCER RES, V9, P3312
   Chow HHS, 2001, CANCER EPIDEM BIOMAR, V10, P53
   Diepvens K, 2005, BRIT J NUTR, V94, P1026, DOI 10.1079/BJN20051580
   Du YT, 2005, J ENZYM INHIB MED CH, V20, P349, DOI 10.1080/14756360500148841
   Filippatos TD, 2008, DRUG SAFETY, V31, P53, DOI 10.2165/00002018-200831010-00005
   Finkelstein EA, 2009, HEALTH AFFAIR, V28, PW822, DOI 10.1377/hlthaff.28.5.w822
   Galati G, 2006, FREE RADICAL BIO MED, V40, P570, DOI 10.1016/j.freeradbiomed.2005.09.014
   Guh DP, 2009, BMC PUBLIC HEALTH, V9, P0, DOI 10.1186/1471-2458-9-88
   Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464
   Hossain SJ, 2002, J AGR FOOD CHEM, V50, P5215, DOI 10.1021/jf020252e
   Hughes LAE, 2008, AM J CLIN NUTR, V88, P1341, DOI 10.3945/ajcn.2008.26058
   Hursel R, 2009, INT J OBESITY, V33, P956, DOI 10.1038/ijo.2009.135
   Ikeda I, 2005, J NUTR, V135, P155, DOI 10.1093/jn/135.2.155
   Isbrucker RA, 2006, FOOD CHEM TOXICOL, V44, P636, DOI 10.1016/j.fct.2005.11.003
   Ito Y, 2008, BIOMED RES-TOKYO, V29, P27, DOI 10.2220/biomedres.29.27
   Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109
   Kim HJ, 2009, PHYTOTHER RES, V23, P467, DOI 10.1002/ptr.2647
   Kohri T, 2001, J AGR FOOD CHEM, V49, P1042, DOI 10.1021/jf0011236
   Ku HC, 2009, AM J PHYSIOL-CELL PH, V297, PC121, DOI 10.1152/ajpcell.00272.2008
   Lambert JD, 2005, AM J CLIN NUTR, V81, P284S, DOI 10.1093/ajcn/81.1.284S
   Lambert JD, 2006, DRUG METAB DISPOS, V34, P8, DOI 10.1124/dmd.104.003434
   Lambert JD, 2003, MUTAT RES-FUND MOL M, V523, P201, DOI 10.1016/S0027-5107(02)00336-6
   Lambert JD, 2007, MOL PHARMACEUT, V4, P819, DOI 10.1021/mp700075m
   Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025
   Liu HS, 2006, AM J PHYSIOL-ENDOC M, V290, PE273, DOI 10.1152/ajpendo.00325.2005
   Maki KC, 2009, J NUTR, V139, P264, DOI 10.3945/jn.108.098293
   Mazzanti G, 2009, EUR J CLIN PHARMACOL, V65, P331, DOI 10.1007/s00228-008-0610-7
   Menet MC, 2004, J AGR FOOD CHEM, V52, P2455, DOI 10.1021/jf035427e
   Moon HS, 2007, CHEM-BIOL INTERACT, V167, P85, DOI 10.1016/j.cbi.2007.02.008
   Mulder TPJ, 2001, J CHROMATOGR B, V760, P271, DOI 10.1016/S0378-4347(01)00285-7
   Murase T, 2006, INT J OBESITY, V30, P561, DOI 10.1038/sj.ijo.0803135
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Murase T, 2005, AM J PHYSIOL-REG I, V288, PR708, DOI 10.1152/ajpregu.00693.2004
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nagao T, 2007, OBESITY, V15, P1473, DOI 10.1038/oby.2007.176
   Nagao T, 2009, OBESITY, V17, P310, DOI 10.1038/oby.2008.505
   Nakai M, 2005, J AGR FOOD CHEM, V53, P4593, DOI 10.1021/jf047814+
   Newmark HL, 2001, CARCINOGENESIS, V22, P1871, DOI 10.1093/carcin/22.11.1871
   Pischon T, 2006, J NATL CANCER I, V98, P920, DOI 10.1093/jnci/djj246
   Poirier P, 2006, ARTERIOSCL THROM VAS, V26, P968, DOI 10.1161/01.ATV.0000216787.85457.f3
   Pories WJ, 2008, J CLIN ENDOCR METAB, V93, PS89, DOI 10.1210/jc.2008-1641
   Sang SM, 2004, BIOORGAN MED CHEM, V12, P3009, DOI 10.1016/j.bmc.2004.03.027
   Sang SM, 2002, TETRAHEDRON LETT, V43, P7129, DOI 10.1016/S0040-4039(02)01707-0
   Shimizu M, 2000, BIOFACTORS, V13, P61, DOI 10.1002/biof.5520130111
   Thielecke F, 2009, PHYTOCHEMISTRY, V70, P11, DOI 10.1016/j.phytochem.2008.11.011
   Wang CT, 2009, MOL NUTR FOOD RES, V53, P349, DOI 10.1002/mnfr.200800013
   Wang S, 2006, J NUTR BIOCHEM, V17, P492, DOI 10.1016/j.jnutbio.2006.03.004
   Wang X, 2003, BIOCHEM PHARMACOL, V66, P2039, DOI 10.1016/S0006-2952(03)00585-9
   Wang X, 2001, BIOCHEM BIOPH RES CO, V288, P1200, DOI 10.1006/bbrc.2001.5923
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Wolfram S, 2005, ANN NUTR METAB, V49, P54, DOI 10.1159/000084178
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   Wu BT, 2005, J AGR FOOD CHEM, V53, P5695, DOI 10.1021/jf050045p
   Wu CH, 2003, OBES RES, V11, P1088, DOI 10.1038/oby.2003.149
   Yang CS, 2007, TOXICOL APPL PHARM, V224, P265, DOI 10.1016/j.taap.2006.11.024
   Yang CS, 2002, ANNU REV PHARMACOL, V42, P25, DOI 10.1146/annurev.pharmtox.42.082101.154309
   Yang MH, 2001, J NUTR BIOCHEM, V12, P14, DOI 10.1016/S0955-2863(00)00140-6
   Yang TTC, 1999, LIFE SCI, V66, P411, DOI 10.1016/S0024-3205(99)00607-4
NR 69
TC 127
Z9 144
U1 0
U2 48
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD MAR 15
PY 2010
VL 140
IS 3
BP 446
EP 453
DI 10.3945/jn.109.115972
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 559FJ
UT WOS:000274807800002
PM 20089791
DA 2025-04-28
ER

PT J
AU Ikeda, M
   Maki, T
   Yin, G
   Kawate, H
   Adachi, M
   Ohnaka, K
   Takayanagi, R
   Kono, S
AF Ikeda, Mizuko
   Maki, Takako
   Yin, Guang
   Kawate, Hisaya
   Adachi, Masahiro
   Ohnaka, Keizo
   Takayanagi, Ryoichi
   Kono, Suminori
TI Relation of coffee consumption and serum liver enzymes in Japanese men and women with reference to effect modification of alcohol use and body mass index
SO SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
LA English
DT Article
ID gamma-glutamyl-transferase; food frequency questionnaire; self-defense officials; drinking; risk; caffeine; determinants; validity; records; obesity
AB Objective. Previous studies have shown that coffee consumption is inversely related to serum levels of liver enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT), but few have addressed the relation in women and effect modifications of alcohol use and obesity. We examined the association of coffee and green tea consumption with serum activities of liver enzymes in free-living Japanese men and women, focusing on sex difference and effect modifications of alcohol and obesity. Material and methods. The data were derived from the baseline survey of the Kyushu University Fukuoka Cohort Study, and included 12,020 Japanese men and women aged 49-76 years who were free of chronic liver diseases. Results. There was an inverse association between coffee consumption and elevated ALT in men, and the association between the two was weaker in women. In the analyses stratified by aminotransferases category, inverse associations of coffee consumption with serum activities of liver enzymes were observed in both men and women within the whole range and among those with aminotransferases within the reference range (ALT/AST < 40 IU/L for men and ALT/AST < 30 IU/L for women). Inverse associations of coffee with liver enzymes were more evident in those with high alcohol consumption and in those with low body mass index. Conclusions. Coffee drinking probably confers protection against alcohol-related increase in liver enzymes.
C1 [Ikeda, Mizuko] Kyushu Univ, Grad Sch Med Sci, Dept Prevent Med, Higashi Ku, Fukuoka 8128582, Japan.
   [Kawate, Hisaya; Adachi, Masahiro; Takayanagi, Ryoichi] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka 8128582, Japan.
   [Ohnaka, Keizo] Kyushu Univ, Grad Sch Med Sci, Dept Geriatr Med, Fukuoka 8128582, Japan.
C3 Kyushu University; Kyushu University; Kyushu University
RP Ikeda, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Prevent Med, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.
EM miz1976@phealth.med.kyushu-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
CR Adams LA, 2008, J GASTROEN HEPATOL, V23, P1089, DOI 10.1111/j.1440-1746.2008.05451.x
   Unknown -, 2000, STAND TABL FOOD COMP, V0, P0
   Anuurad E, 2003, J OCCUP HEALTH, V45, P335, DOI 10.1539/joh.45.335
   Aubin HJ, 1998, BIOL PSYCHIAT, V44, P638, DOI 10.1016/S0006-3223(97)00438-1
   Bravi F, 2007, HEPATOLOGY, V46, P430, DOI 10.1002/hep.21708
   CASIGLIA E, 1993, EUR J EPIDEMIOL, V9, P293, DOI 10.1007/BF00146266
   Corrao G, 2001, ANN EPIDEMIOL, V11, P458, DOI 10.1016/S1047-2797(01)00223-X
   HASEGAWA M, 1989, HEPATOLOGY, V10, P973, DOI 10.1002/hep.1840100614
   Hicks MB, 1996, FOOD RES INT, V29, P325, DOI 10.1016/0963-9969(96)00038-5
   Honjo S, 2001, J CLIN EPIDEMIOL, V54, P823, DOI 10.1016/S0895-4356(01)00344-4
   Honjo S, 1999, ANN EPIDEMIOL, V9, P325, DOI 10.1016/S1047-2797(99)00013-7
   Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899
   Kendrick SFW, 2007, J HEPATOL, V46, PS271, DOI 10.1016/S0168-8278(07)62317-4
   Kinoshita S, 2001, CLIN CHEM LAB MED, V39, P256, DOI 10.1515/CCLM.2001.040
   KLATSKY AL, 1992, AM J EPIDEMIOL, V136, P1248, DOI 10.1093/oxfordjournals.aje.a116433
   Klatsky AL, 2006, ARCH INTERN MED, V166, P1190, DOI 10.1001/archinte.166.11.1190
   Kobayashi M, 1994, RINSHO KENSA, V38, P844
   KONO S, 1994, AM J EPIDEMIOL, V139, P723, DOI 10.1093/oxfordjournals.aje.a117062
   Kotani K, 1994, NIHON SHOKAKIBYO GAKKAI ZASSHI, V91, P154
   Larsson SC, 2007, GASTROENTEROLOGY, V132, P1740, DOI 10.1053/j.gastro.2007.03.044
   Lee KY, 2002, J NUTR SCI VITAMINOL, V48, P467, DOI 10.3177/jnsv.48.467
   Marchesini G, 2008, J CLIN ENDOCR METAB, V93, PS74, DOI 10.1210/jc.2008-1399
   Nakanishi N, 2000, EUR J EPIDEMIOL, V16, P419, DOI 10.1023/A:1007683626665
   Nanri A, 2008, AM J CLIN NUTR, V87, P1488, DOI 10.1093/ajcn/87.5.1488
   NILSSEN O, 1990, AM J EPIDEMIOL, V132, P318, DOI 10.1093/oxfordjournals.aje.a115661
   Poikolainen K, 1997, AM J EPIDEMIOL, V146, P1019, DOI 10.1093/oxfordjournals.aje.a009230
   Puukka K, 2006, AM J CLIN NUTR, V83, P1351, DOI 10.1093/ajcn/83.6.1351
   Ruhl CE, 2005, GASTROENTEROLOGY, V128, P24, DOI 10.1053/j.gastro.2004.09.075
   STUART K, 2008, ENHANCED INFLAMMATOR, V0, P0
   Tanaka K, 1998, INT J EPIDEMIOL, V27, P438, DOI 10.1093/ije/27.3.438
   Tokudome Shinkan, 2004, ASIAN PAC J CANCER PREV, V5, P40
   Tokudome Y, 2005, J EPIDEMIOL, V15, P135, DOI 10.2188/jea.15.135
   Tsukamoto H, 2001, ALCOHOL CLIN EXP RES, V25, P171S, DOI 10.1097/00000374-200105051-00029
   Tverdal A, 2003, ANN EPIDEMIOL, V13, P419, DOI 10.1016/S1047-2797(02)00462-3
   Yoshida D, 2009, DIABETES METAB SYND, V3, P7, DOI 10.1016/j.dsx.2008.10.002
NR 35
TC 22
Z9 24
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0036-5513
EI 1502-7686
J9 SCAND J CLIN LAB INV
JI Scand. J. Clin. Lab. Invest.
PD APR 15
PY 2010
VL 70
IS 3
BP 171
EP 179
DI 10.3109/00365511003650165
PG 9
WC Medical Laboratory Technology; Medicine, Research & Experimental
SC Medical Laboratory Technology; Research & Experimental Medicine
GA 585HA
UT WOS:000276814500005
PM 20205615
DA 2025-04-28
ER

PT J
AU Thielecke, F
   Rahn, G
   Böhnke, J
   Adams, F
   Birkenfeld, A
   Jordan, J
   Boschmann, M
AF Thielecke, F.
   Rahn, G.
   Boehnke, J.
   Adams, F.
   Birkenfeld, Al
   Jordan, J.
   Boschmann, M.
TI Epigallocatechin-3-gallate and postprandial fat oxidation in overweight/obese male volunteers: a pilot study
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE EGCG; caffeine; energy expenditure; fat oxidation; calorimetry
ID green tea; energy-expenditure; substrate utilization; metabolic-rate; body-fat; caffeine; thermogenesis; obesity; ephedrine; gallate
AB Objectives: Drinking green tea is associated with many health benefits, including increased fat oxidation. We tested the hypothesis that epigallocatechin-3-gallate (EGCG), the main green tea catechin, increases fat oxidation in obese men. Methods: Ten healthy overweight/obese males (body mass index 31.3 +/- 0.8 kg/m(2)) were studied in a randomized, placebo-controlled, double-blind crossover trial. Study supplements were low EGCG (300 mg), high EGCG (600 mg), caffeine (200 mg), EGCG/caffeine (300 mg/200 mg) or placebo and were taken orally for 3 days. At the third day of supplementation, O-2 consumption and CO2 production was measured by indirect calorimetry to assess energy expenditure and fat oxidation over 4 h each after overnight fasting and after a standardized test meal. Results: Energy expenditure was not affected by any supplementation, neither after overnight fasting nor after the test meal. During the first 2 h after overnight fasting, fat oxidation increased by 7.7 (not significant, NS), 15.2 (NS), 26.3 (P<0.05 vs placebo) and 35.4% (P<0.01 vs placebo and low EGCG), for low EGCG, high EGCG, caffeine and EGCG/caffeine, respectively. During the first 2 h after the meal, the mean increase in fat oxidation was 33.3 (P<0.05 vs placebo), 20.2 (NS), 34.5 (P<0.05 vs placebo) and 49.4% (P<0.05 vs placebo) for low EGCG, high EGCG, caffeine and EGCG/caffeine, respectively. Conclusions: Low EGCG increases postprandial fat oxidation in obese men and this to the same extent as 200 mg caffeine, whereas high EGCG does not exert this effect. Fasting fat oxidation is increased only by caffeine (with or without EGCG). There is no synergism of low EGCG and 200 mg caffeine. Energy expenditure is not affected by EGCG. European Journal of Clinical Nutrition (2010) 64, 704-713; doi:10.1038/ejcn.2010.47; published online 7 April 2010
C1 [Boschmann, M.] Univ Med Berlin, Franz Volhard Clin Res Ctr, Expt & Clin Res Ctr, D-13125 Berlin, Germany.
   [Thielecke, F.] DSM Nutrit Prod, Basel, Switzerland.
   [Rahn, G.; Boehnke, J.; Adams, F.; Birkenfeld, Al; Jordan, J.; Boschmann, M.] HELIOS Clin Berlin Buch, Berlin, Germany.
C3 Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; DSM NV
RP Boschmann, M (corresponding author), Univ Med Berlin, Franz Volhard Clin Res Ctr, Expt & Clin Res Ctr, Charite Campus Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.
EM michael.boschmann@charite.de
FU DSM Nutritional Products
CR ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   Arch JRS, 1996, INT J OBESITY, V20, P191
   Arciero PJ, 2000, METABOLISM, V49, P101, DOI 10.1016/S0026-0495(00)90888-6
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Belza A, 2009, EUR J CLIN NUTR, V63, P57, DOI 10.1038/sj.ejcn.1602901
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   Blaak EE, 2000, ANN MED, V32, P380, DOI 10.3109/07853890008995942
   BORCHARDT RT, 1975, J MED CHEM, V18, P120, DOI 10.1021/jm00235a030
   Boschmann M, 2003, J CLIN ENDOCR METAB, V88, P6015, DOI 10.1210/jc.2003-030780
   Boschmann M, 2007, J CLIN ENDOCR METAB, V92, P3334, DOI 10.1210/jc.2006-1438
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   Brown CM, 2006, J CLIN ENDOCR METAB, V91, P3598, DOI 10.1210/jc.2006-0407
   Chan CCW, 2006, J SOC GYNECOL INVEST, V13, P63, DOI 10.1016/j.jsgi.2005.10.006
   Chantre P, 2002, PHYTOMEDICINE, V9, P3, DOI 10.1078/0944-7113-00078
   DULLOO AG, 1993, INT J OBESITY, V17, P0
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Dulloo AG, 1998, BRIT J NUTR, V80, P493, DOI 10.1017/S0007114598001573
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   DULLOO AG, 1993, NUTRITION, V9, P366
   FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   HENRY CJK, 1986, HUM NUTR-CLIN NUTR, V40C, P165
   Horton TJ, 1996, INT J OBESITY, V20, P91
   Hung PF, 2005, AM J PHYSIOL-CELL PH, V288, PC1094, DOI 10.1152/ajpcell.00569.2004
   Jordan J, 2004, CIRCULATION, V109, P1823, DOI 10.1161/01.CIR.0000126283.99195.37
   Juhel C, 2000, J NUTR BIOCHEM, V11, P45, DOI 10.1016/S0955-2863(99)00070-4
   KAJIMOTO O, 2006, J HEALTH SCI, V1, P161
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   LANDSBERG L, 1993, INT J OBESITY S1, V17, P29
   Liles JT, 2007, BRIT J PHARMACOL, V150, P29, DOI 10.1038/sj.bjp.0706942
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nagao T, 2007, OBESITY, V15, P1473, DOI 10.1038/oby.2007.176
   Ota N, 2005, J HEALTH SCI, V51, P233, DOI 10.1248/jhs.51.233
   Raederstorff DG, 2003, J NUTR BIOCHEM, V14, P326, DOI 10.1016/S0955-2863(03)00054-8
   Rhodes MJC, 1996, P NUTR SOC, V55, P371, DOI 10.1079/PNS19960036
   Rudelle S, 2007, OBESITY, V15, P349, DOI 10.1038/oby.2007.529
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   TSUCHIDA T, 2002, PROGR MED, V22, P2189
   Ullmann U, 2003, J INT MED RES, V31, P88, DOI 10.1177/147323000303100205
   Venables MC, 2008, AM J CLIN NUTR, V87, P778, DOI 10.1093/ajcn/87.3.778
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Wolfram S, 2005, ANN NUTR METAB, V49, P54, DOI 10.1159/000084178
   Yang CS, 2000, J NUTR, V130, P2409, DOI 10.1093/jn/130.10.2409
   Yang MH, 2001, J NUTR BIOCHEM, V12, P14, DOI 10.1016/S0955-2863(00)00140-6
   Yoshioka M, 1998, BRIT J NUTR, V80, P503, DOI 10.1017/S0007114598001597
NR 48
TC 53
Z9 53
U1 0
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
EI 1476-5640
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD JUL 15
PY 2010
VL 64
IS 7
BP 704
EP 713
DI 10.1038/ejcn.2010.47
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 621YP
UT WOS:000279623300008
PM 20372175
DA 2025-04-28
ER

